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Purpose: The aim of this thesis was to investigate the stability of penethamate 
(PNT), an ester prodrug of benzylpenicillin (BP), used intramuscularly (i.m.) in the 
treatment of bovine mastitis. The specific objectives were to understand the chemical 
stability of PNT in aqueous and oily vehicles; to develop some understanding of the 
effect of absorption rate from the i.m. site on milk levels of BP; to formulate a stable 
ready-to-use (RTU) product and to test this product in a pilot study in the target 
species ( cow). 
Methods: A reversed phase HPLC assay was developed to study the 
degradation kinetics of PNT in aqueous vehicles. Several formulation approaches 
such as cosolvents, cyclodextrins, common ion and oily vehicles to enhance the 
chemical stability of PNT were assessed. A simulation model was constructed for the 
prediction of absorption rate from i.m. injection site and concentration of BP, the 
hydrolytic product of PNT, in milk. A pilot animal study in cows was conducted to 
compare milk levels of BP after i.m. injection of a stable oily formulation of PNT 
with a marketed aqueous reconstituted suspension formulation. 
Results: A reversed phase HPLC assay for simultaneous determination of PNT 
and its hydrolytic product BP using an isocratic system with photo diode array 
detection was developed and validated. The assay was linear over the concentration 
range 1-100 µg mr1 for both analytes (r > 0.99) with satisfactory inter-day and intra-
day precision (RSD :Sl %) and accuracy (98-99%) for PNT. 
The degradation of PNT in aqueous solutions followed pseudo-first-order 
kinetics over the pH range 2 - 9.3 with a V- shaped pH-rate profile with a sigmoid 
portion in the pH range 7.5 - 9.3 corresponding to the pKa (8.4) of PNT. The 
minimum degradation rate of PNT was at pH 4.5 (half-life (t112) = 44 hat 30 °C). The 
impact of buffer concentration and ionic strength on PNT stability was small but at 
pH 6 the type of buffer salt had some influence with solutions in acetate being about 
twice as stable as those in phosphate. The Arrhenius activation energies determined at 
pH 3.01, 6.01 and 8.04 were 62.1, 74.1 and 98.8 kJ mor1 respectively. 
In aqueous solutions, propylene glycol (PG) increased the t112 of PNT from 1.8 
days to 4.3 days at 30 °C, whereas hydroxypropyl- ~-cyclodextrin (HP-~-CD) and~-




to 1.1 days. The estimated shelf-life (t90) of PNT in solution of about 0.3 days (5% 
PG) and 0.7 days (60% PG) increased to 15 days (5% PG) and 11 days (60% PG) in a 
50% PNT suspension. With increasing concentration of HP-B-CD, the solubility of 
PNT increased linearly and resulted in a decrease in the estimated t90 of aqueous 
suspensions. The decrease in solubility of PNT due to the common ion effect resulted 
in an increase in the t90 (26 days) in aqueous suspension. 
PNT stability (% drug remaining) in oily suspensions after 105 days was in the 
order LP (light liquid paraffin) (96.2%) > MIG (miglyol 812) (95.4%) > EO (ethyl 
oleate) (94.1%) > SO (sunflower oil) (86.4%). PNT degradation was rapid in oily 
solutions of LP, MIG, EO and SO and less than 10 % remained after 7-15 days. 
The simulation model provided insights into the absorption rate of PNT from 
the i.m. injection site. Sensitivity analysis suggested that absorption rate constants 
(ka), clearance from plasma to milk (PA) and volume of distribution (V d) are critical 
parameters for predicting concentrations of BP in milk. The developed oily 
suspension formulation of PNT in EO with 0.15 % Polysorbate 80 showed good 
physical and chemical stability. A pilot animal study in cow suggested that the oily 
formulation achieves concentrations of BP in milk similar to those obtained from a 
marketed aqueous suspension formulation of PNT. The AUC0_48 and t112e1 of BP in 
milk after i.m. administration of the marketed aqueous suspension formulation of PNT 
were 3.56 ± 0.17 mg.h L-1 and 4.9 ± 0.3 h respectively, while the corresponding data 
for Formulation B were 4.9 ± 1.4 mg.h L-1 and 4.6 ± 1.2 h respectively. 
Conclusion: The chemical stability of PNT was greatly enhanced in oily 
suspensions with around 95% PNT remaining for over 3 months under intermediate 
storage conditions (30 °C). PNT can be formulated as a physically and chemically 
stable ready-to-use suspension. This suspension probably gives milk levels of BP 
comparable with the existing marketed aqueous suspension formulation and a larger 
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The literature reviewed in this chapter summarises the pharmacokinetic 
considerations of drugs to treat mastitis along with chemical instability of 
penethamate, an antibiotic used in the treatment of mastitis in cows. Formulation 
strategies to minimise the chemical instability of penethamate are also discussed. 
Penethamate (PNT) (Figure 1-1) is a diethylaminoethyl ester prodrug of 
benzylpenicillin (BP) used for the treatment of mastitis which is an inflammatory 
reaction of the mammary gland (udder) usually due to a microbial infection. 
(a) (b) 
Figure 1-1. Structure of (a) protonated form of PNT in acidic medium and (b) BP 
Bovine mastitis is characterized by inflammation (Figure 1-2) due to an influx 
of somatic cells, primarily polymorphonuclear neutrophils into the mammary gland 




























Figure 1-2. (a) Healthy udder (b) mastitic udder. Note the reddening of the infected 
quarter . 
In UK and US approximately 40-50 cases per 100 cows per year (Blowey and 
Edmondson, 2000) and in NZ - 14.5 cases per 100 cows (McDougall and Compton, 
2002) has been reported for clinical mastitis and up to 30% for sub-clinical mastitis. It 
is a major economic cost to the dairy industry because of decreased milk production, 
the need to discard infected milk and the labour costs for treatment (Hortet and 
Seegers, 1998; Zhao and Lacasse, 2008). Total world-wide costs from this disease 
may reach as high as USD35 billion (Wellenberg et al. , 2002). 
1.1.1. Etiology of mastitis 
Bacteria are the most common cause of mastitis in dairy cows and are 
commonly referred to as Mastitis Causing Organisms (MCOs). It has been reported 
that about 137 microbial species and subspecies are incriminated as etiological agents 
of mastitis (Watts, 1988) including aerobic and anaerobic bacteria, mycoplasmas, 
yeasts and fungi, out of which Streptococci, Staphylococci, Escherichia coli and other 
coliforms are the most important micro-organisms for causing bovine mastitis (Watts, 
1988; Mason, 2006). 
From an epidemiological viewpoint there are two main sources of mastitis 
namely, contagious and environmental pathogens. Infected udder quarters are the 
main source of contagious pathogens such as S. aureus and S. agalactiae which 
spread from diseased to healthy udder quarters in cattle. S. aureus is a non-motile, 
non-spore forming, facultative anaerobe, Gram-positive bacterium. It is responsible 




considered a problematic and significant bovine mastitis pathogen (Sandholm, et al., 
1990). S. agalactiae is a cytochrome-negative, facultative anaerobic Gram-positive 
bacterium. It is an obligate udder pathogen, highly contagious and usually transmitted 
during milking (Radostits et al., 2000). 
Environmental mastitis is caused by pathogens such as S. uberis and S. 
dysgalactiae that are transferred from the environment to the cow. Despite significant 
progress in the control of contagious pathogens it continues to be a major cause of 
financial loss (Bradley and Green, 2001). S. uberis is an opportunistic Gram-positive 
bacterium. It is one of the most common pathogens identified in the United Kingdom 
(Biggs, 2002) and gives rise to clinical and sub-clinical infections in lactating cows 
where it accounts for high cell counts and poor milk quality. S. dysgalactiae is a 
Gram-positive bacterium which mostly causes acute mastitis at the beginning of 
lactation. It is usually carried in the tonsils and vagina of carrier animals and 
infections often occur in dry cows and heifers, demonstrating its independence of the 
milking process (Bramley and Dodd, 1984). 
Apart from MCOs, mastitis can occur due to treatment failure and 
ineffectiveness of route of administration. Failure in treatment occurs as a result of 
insufficient concentrations of the antibiotic at the site of infection and short duration 
of standard treatments (Pyorala and Pyorala, 1998; Sol et al., 2000). The effectiveness 
of the route of administration of drugs depends on the location of the bacteria in the 
udder and physicochemical characteristics of the drug. 
1.1.2. Treatment prerequisites 
Antibiotics have been used for over 50 years to treat bovine mastitis in dairy 
herds (Grave et al., 1999). Although antibiotic therapy alone is not a magic potion for 
acute clinical mastitis, it remains an important part of the solution to mastitis (Ziv, 
1980c ). Mastitis treatment in cattle should result in disappearance of clinical 
symptoms such as abnormalities of milk, swelling of the udder, anorexia, reduced 
milk production, fever and disappearance of the causal organism. Given that mastitis 
is an inflammatory response to infection or injury, it is valuable to measure other 
factors, such as rise in somatic cell counts, in the laboratory so as to assess the 





milk correlates with the cellular response to infection in the udder and can be used to 
define the severity of the inflammatory response and to measure 'cytological' 
recovery (Funke, 1982). 
An ideal drug for intramuscular (i.m.) administration for mastitis therapy 
should have the following characteristics (Ziv, 1980b; Funke, 1982). 
• The pathogen concerned is susceptible to it. 
• It has a low minimum inhibitory concentration (MIC) against the majority of 
udder pathogens. 
• It has a high bio-availability from the i.m. injection site. 
• It has a low serum protein binding. 
• It is chemically a weak base or otherwise highly non-ionized in serum. 
• It is sufficiently lipid-soluble to readily diffuse through membranes. 
• It has an extended half-life in the body. 
• It distributes into the targeted tissue (udder) and milk. 
• It achieves concentration above the MIC90 value in the udder and milk. 
1.1.3. Pharmacokinetic considerations for mastitis therapy 
Pharmacokinetic information is needed as various drugs and dosage forms take 
different routes and time-course profiles within the body. There are several factors 
that control drug transfer from blood into milk: mammary gland physiology, buffer 
systems, proteins and lipids. The most important aspect of mammary gland 
physiology are the mammary alveoli, where milk is formed and stored until milking. 
The presence of milk in the highly vascularised mammary alveoli, which have a high 
surface area to volume ratio, allows for rapid bidirectional transfer between milk and 
plasma. An equilibrium model can be used to describe drug transfer across the 
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Figure 1-3. Partition of unbound drug in plasma and milk across the membrane where 
D is the non-ionised and Dir is the ionised form of drug. 
Drugs mostly pass across the blood-milk barrier by passive diffusion 
(Rasmussen, 1959; Miller et al.,1967a, Miller et al., 1967b; Rasmussen, 1971; 
Fleishaker, 2003) however some active transport has been reported (Syversen and 
Ratkje, 1985; Schadewinkel-Scherkl et al., 1993; Ito and Alcorn, 2003). Passive 
transfer of drugs from the blood into the milk is directly proportional to the 
concentration-gradient across the membrane and inversely proportional to the extent 
to which the drug is ionized, since ionized molecules pass through biological 
membranes only with difficulty. The degree of ionization of the drug is dependent on 
the ionisation constant (pKa) of the drug and the pH of the medium. The pKa is the pH 
value at which 50% of the drug molecules exist in ionized form. Most antibiotics in 
common use have pKa values between 3 and 10 as they are either weak organic acids 
or bases. Hence, most antibiotics exist in both ionized and non-ionized forms at 
physiological pH values. 
When a drug is partially ionized, it may be distributed in unequal concentrations 
on either side of a biological membrane, especially when a pH difference exists 
between the solutions on either side of the membrane. As the biological membrane is 
readily penetrated only by the unbound, unionized, lipid-soluble fraction, even a small 





exert a profound effect on the distribution of drugs (Miller et al., 1967a; Miller et al., 
1967b; McManaman and Neville, 2003). This is the reason why basic drugs such as 
PNT tend to accumulate in milk in the ionized form (Figure 1-3) often attaining 
concentrations higher than those in plasma (Miller et al., 1967a; Miller et al., 1967b; 
Ziv, 1980b; McManaman and Neville, 2003). 
Assuming that only the unbound, unionized form of a drug partitions between 
milk (M) and plasma (P), Rasmussen (1959) proposed Eq.1-1 and Eq.1-2 by using a 
rearranged form of the Henderson-Hasselbalch equation, to calculate the ratio of 
unbound drug in milk and plasma (M / P ratio). 
For acidic drugs 
For basic drugs 
Munbound _ I+IQ(PHm-PKa) 
~nbound - I+IO(pHP-pKa) 
Munbound _I+ IQ(PKa-PHm) 
punbound - I+IO(pKa-PHp) 
Eq.1-1 
Eq.1-2 
where Munbound and P unbound are the fractions of drug available for 
distribution, elimination, and pharmacodynamic action in milk and plasma 
respectively. pHm and pHp are pH values for milk and plasma respectively. Assuming 
that only the unionized, unbound form of the drug may traverse the membranes in the 
mammary alveoli, Fleishaker (2003) suggested that unbound drug may also bind to 
proteins in milk and plasma and drug may also partition into fat globules in the milk 
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Figure 1-4. Binding of unionised drug with proteins in plasma and proteins and fat 
globules in milk on either side of membrane. D is unionised and Dir is the ionised form 
of drug, DP is the binding of drug to protein and DFG is binding of drug to fat globules 
in milk. 
Eq. 1-1 and 1-2 assume that passive diffusion is the only process that controls 
the movement of drug between milk and plasma. However, the accumulation of drugs 
such as cimetidine, acyclovir, and nitrofurantoin in human milk at levels significantly 
higher than expected from passive diffusion suggests the presence of carrier mediated 
transport processes in the mammary gland (Ito and Alcorn, 2003). 
Syversen (1985) suggested that in addition to plasma membrane proteins, other 
mammary gland transport processes such as transcytosis, vesicular transport, 
exocytosis and milk fat secretion may contribute to drug transfer into milk. An in vivo 
animal study showed that the transport of BP across the mammary gland of goats and 
cows is reduced by concomitant probenecid administration and concluded that the 
mammary epithelium possesses a probenecid-sensitive organic anion transporter for 
BP (Schadewinkel-Scherkl et al., 1993; Ito and Alcorn, 2003). 
Additionally, molecular characterization studies indicate the expression of 
various transporters including: organic cation transporter, organic anion transporter, 
organic anion polypeptide transporter, oligopeptide transporter, nucleoside and 




protein transporter families at the lactating mammary epithelium (Ito and Alcorn, 
2003). Thus along with passive diffusion, it is apparent that transporters expressed in 
the mammary gland may transfer some drugs into milk. However the contribution of 
the active transport into and out of the mammary gland was reported (Schadewinkel-
Scherkl, et al., 1993) to be small in comparison with passive diffusion and is therefore 
more of theoretical rather than therapeutic interest in the treatment of mastitis. 
1.1.4. Choice of treatment 
In veterinary practice, for the treatment of mastitis, intramarnrnary and 
parenteral routes are important and extensively used by practitioners. However there 
is an ongoing debate over their comparative efficacy. 
The parenteral (systemic) route of administration has been introduced into 
mastitis therapy more than 50 years ago (Ziv, 1980b). It was suggested that systemic 
treatment would allow drug to penetrate throughout the udder better and be more 
efficient to treat mastitis (Pyorala, 2002). The advantage of systemic treatment may be 
partly explained by its effect on sub-clinical infections present in the untreated 
quarters of the cow. Hence, in addition to pharmacological issues and infection 
patterns, the number of quarters per cow affected by clinical or sub-clinical mastitis 
should be considered in the best choice of the antibiotic and its route of administration 
(Serieys et al., 2005). 
The intramarnrnary (IMM) route is considered to be a more convenient route of 
administration of antimicrobials in mastitis, as farmers can administer the drugs by 
themselves without assistance from a veterinarian (Gruet et al., 2001). The advantages 
of this route could be that antibiotics achieve high concentrations in the milk 
compartment of the mammary gland (Gruet et al., 2001) and a lower dose is required 
as the drug is administered straight to the infection site. 
However the IMM route suffers several disadvantages such as uneven 
distribution of drugs throughout the udder and risk of contamination from milking 
devices. Poor distribution in the udder means that sometimes drugs administered may 
not be able to make contact with MCOs (Pyorala and Pyorala, 1998; Almeida et al., 
2007). Additionally, there are very few reports demonstrating efficacy of this route for 
mastitis caused by environmental pathogens (Deluyker et al., 1999). 
9 
Commonly used antibiotics for the treatment of mastitis both by IMM and 
parenteral route are listed in Table 1-1. 
Table 1-1. Antibiotics commonly used for treatment oflactating cow mastitis 













Procaine benzylpenicillin Tiarnulin 
Procaine benzylpenicillin/Neomycin T rimethoprim 
Quinolones Tylosin 
1.2. Penethamate (PNT) - a chemically unstable drug 
Amongst the available parenteral treatments for mastitis, PNT, a prodrug of BP 
is found to be promising. It is a weakly basic, hydrolysable ester prodrug of BP with 
pKa 8.4 (Ziv, 1980a; Almeida et al., 2007). Following i.m injection, because of the pH 
difference between plasma and milk, an old report suggested that it achieves a 
concentration in the milk five to seven times higher than the concentration in plasma 
(Rasmussen, 1959). PNT is used as the hydriodide and available as a white, odourless 





soluble in water (-1 % at 20 °C), soluble in methanol, propylene glycol, polyethylene 
glycol, and acetone; insoluble in ether (The Merck Index, 2006). 
1.2.1. Spectrum of activity and MI Cs of BP after hydrolysis from PNT 
The antimicrobial activity of PNT is due to BP. Hallas-Moller et al. (1952) 
showed by microbiological assays that the antibacterial activity of PNT is due to 
hydrolysis to BP and PNT itself has no such activity. BP acts by directly interfering 
with the glycopeptides cross-linking reaction and thus inhibits the synthesis of the 
bacterial cell wall. BP is a time-dependent bactericidal antibiotic with a spectrum of 
activity primarily against non-penicillinase producing cocci. BP is particularly active 
against Streptococci such as S. uberis, S. dysgalactiae and S. agalactiae and 
penicillin- sensitive Staphylococci such as S. aureus. 










* S. uberis, S. dysgalactiae and S. agalactiae 













PNT after hydrolysis to BP has MIC90 values :S0.06µg mrI for penicillin 
sensitive Streptococci (Table 1-2). The Cmax of BP in the milk following doses of 7 .5 
mg kg-I and 15 mg kg-I of PNT after i.m injection rises to approximately 0.4 µg mrI 
and 0.8 µg mrI respectively which represents approximately 6 and 12 times the 
maximum MIC9o for susceptible mastitis pathogen (S. uberis) and the concentrations 






Researchers have shown that several MCOs adhere to and internalize into 
bovine mammary epithelial cells (Matthews et al., 1994). Adherence and 
internalization are important virulence attributes of bovine mastitis pathogens. 
Adherence is important for MCOs once they gain entry into the udder to protect them 
from flushing during milking. Once internalized, mastitis pathogens could infect 
deeper regions of the affected mammary gland resulting in the development of 
chronic intramammary infections. Following internalization, components of the 
immune system such as polymorphonuclear neutrophils, macrophages and antibodies, 
nonspecific antibacterial factors present in milk and antibiotics that do not cross 
mammary epithelial cell membranes are essentially ineffective. Therefore, it would 
appear that central to the control of several mastitis pathogens is the ability of 
antibiotic to penetrate into host cells and kill intracellular bacteria within the 
cytoplasm of mammary epithelial cells (Almeida et al., 2007). 
In vitro studies have shown that PNT is highly effective in killing S. uberis, S. 
dysgalactiae, S. agalactiae and S. aureus that were internalized in mammary 
epithelial cells. At high concentrations (32 µg mr1 to 32 mg mr1) killing rates ranged 
from 85% to 100%. At low concentrations (0.032 µg mr1 to 3.2 µg mr1) killing rates 
ranged from Oto 80% (Almeida et al., 2007). 
1.2.2. Pharmacokinetics of PNT 
Due to rapid hydrolysis of PNT in physiological conditions, BP is used as a 
residue marker in milk and plasma (EMEA, 2004). From the molecular weights, 1 g 
of PNT HI would produce 0.6 g of BP. Friton et al., (2003) reported that after i.m. 
injection of a marketed aqueous suspension of PNT (Mamyzin) in cows at a dose of 
15 mg kg-1 day 1 (first injection) and 7.5 mg kt1 day 2 and 3 (third injection), the 
AUCs for milk were two times higher than those for plasma (Table 1-3). Also 
administration of PNT at the recommended dose (10 g or 5 g) provided levels of BP 
in the milk above the MIC of a susceptible pathogen for almost 24 hours following 
each dose. It can be interpreted from the data of Friton et al., (2003) that initially the 
concentration of BP in plasma increases due to absorption of PNT and its conversion 
into BP. Later on, the drop in the plasma level of BP is influenced by the 





Table 1-3. Pharmacokinetic (PK) parameters for BP in plasma and milk following i.m. 
injection of Mamyzin ( Friton et al., 2003). Data are mean (n = 8). 
Cmax (µg mr1) 
tmax (h) 
t112 (h) 
AUCo-t (µg.h mr1) 
Cmax (µg mr1) 
tmax (h) 
t112 (h)* 
AUCo-t (µg.h mr1) 
Plasma PK after first 
injection 
(mean± SD) 
0.73 ± 0.20 
3.76 ± 1.26 
4.27 ± 1.48 
4.16 ± 0.44 
Milk PK after first injection 
(mean± SD) 
0.81 ± 0.19 
5.91 ± 2.58 
4.00 ± 0.68 
8.55 ± 1.73 
Plasma PK after third 
injection (mean ± SD) 
0.35 ± 0.13 
5.49 ± 1.42 
4.32 ± 2.79 
2.52 ± 0.50 
Milk PK after third 
injection (mean± SD) 
0.43 ± 0.10 
4.65 ± 2.63 
4.59 ± 1.12 
5.13 ± 1.08 
*Half-life of elimination in milk was determined from the slope of the decending 
curve using ~ln [Concentration]/~t from 8 to 24 h. 
1.2.2.1. Transfer of PNT from plasma to milk 
The mechanisms of drug absorption include diffusion, facilitated diffusion, 
active transport and pinocytosis. Diffusion is a passive process in which a 
concentration gradient of the diffusing substance must exist across the membrane. 
This spontaneous movement is also dependent on the physicochemical properties of 
the membrane and the diffusing substance. Diffusion is described by Ficks First Law 
of diffusion 
J=-DAdC 
dx Eq. 1-3 
where J is the flux of drug molecules across an area A per unit time, dC /dx is 
the concentration gradient, and D is the diffusion coefficient. 
On intramuscular administration (Figure 1-5), PNT (lipophilic weak base) 
circulates in the blood with 10% in the non-ionized form (BP only <0.001 %) and 




Ziv, 1980c) and is trapped in the milk (pH 6.5-6.8) where the majority of PNT is 
ionised (-98%). In addition, PNT is hydrolysed to BP (pKa 2.8) which is highly 
ionised in the milk thereby limiting its return to the circulation and resulting in 
accumulation of BP in the udder (Rasmussen, 1959). This phenomenon is known as 
ion trapping as shown in Figure 1-5. PNT is therefore "trapped" in the udder resulting 
in increased concentrations of BP in the udder. 
Membrane 
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Figure 1-5. Passage of PNT across the blood-milk barrier. P and Pir are the non-ionised 
and ionised forms of PNT respectively; BH and ff are the unionised and ionised form of 
BP respectively. 
The milk/plasma ratios for BP and PNT are shown in Table 1-4 (Rasmussen, 
1959; Ziv and Sulman, 1975; Ziv, 1980a; Friton et al., 2003). However, there is some 
ambiguity in the literature since the reported milk/plasma ratios varied from 2 based 
on recent studies using LC-MS (Friton et al., 2003) to 6.1 based on old reports using 









pKa Degree of lipid solubility Milk/Plasma ratio 
nature 
BP Acid 2.8 Moderate 0.2 
PNT Base 8.4 High 2-6.1 
1.2.3. Metabolism and excretion of PNT 
After i.m. injection all the PNT is hydrolysed to BP prior to excretion. It is 
eliminated as BP (40 to 70%) in the urine. A weak elimination may also take place via 
bile. The remaining, which is not excreted in the milk, is partially metabolised (30-
60%) by hydrolysis of the ~-lactam nucleus in the liver to biologically inactive other 
derivatives such as penicilloic acid and penicillenic acid and finally eliminated in the 
urine (Mamyzin injection technical monograph). 
1.2.4. Clinical studies of PNT in the treatment of mastitis 
Clinical studies in New Zealand (McDougall, 1998; McDougall, et al., 2007a; 
McDougall et al., 2007b) and in France (Serieys et al., 2005; Beggs and Wraight, 
2006; Salat et al., 2008) on clinical and sub-clinical mastitis conclude that (1) PNT is 
not only useful in treating clinical mastitis, but also gives additional value by treating 
the sub-clinical infections which may occur concurrently in adjacent quarters. (2) BP 
is still considered to be the treatment of choice in the presence of clinical mastitis 
caused by S. uberis or other Streptococci as well as penicillin-sensitive Staphylococci. 
' -
St Rose et al., (2003) in The Netherlands concluded that antibacterial treatment of 
sub-clinical infections during lactation prevents the spread of mastitis in the dairy 
herds and also reduces somatic cell counts in the bulk milk. 
Clinical study on sub-clinical mastitis in New Zealand (McDougall, 1998) 
found S. uberis as the predominant pathogen and concluded that there is significantly 




value of systemic treatment of clinical mastitis, which permits the treatment of both 
and often unrecognised clinically and sub clinically affected quarters. 
Another study in France examined the effect of PNT on clinical mastitis and 
concluded that treatment of clinically effected quarters brought about a significant 
benefit in adjacent sub-clinically, concurrently effected, quarters (Serieys et al., 2005). 
1.3. Stability aspects of PNT 
PNT is a prodrug of BP and like other P-lactam antibiotics has a fused P-lactam-
thiazolidine ring system, which is susceptible to cleavage by a variety of reagents as 
well as some enzymes (Deshpande et al., 2004). There are only a few old reports in 
the literature on the chemical stability of PNT in aqueous vehicles (Jensen et al., 
1951; Dinsmore and Bailey, 1952; Hallas-Moller et al., 1952; Keller, 1952) and 
suggesting that the degradation pathway of PNT involves its conversion to BP and 
diethylaminoethanol by hydrolysis (Figure 1-6). 
Jensen (1951) reported the half-life (t112) of PNT as 23 min and 220 min at pH 
7.3 and pH 6.2 respectively, at 37 °C in aqueous solutions. Similarly, Dinsmore 
(1952) determined the rates of hydrolysis of PNT in solutions at pH 2-7.5 and 
reported that PNT is most stable at pH 4.9 with <10% hydrolysed after 3 h at 25 °C. 
Improved stability of PNT was reported in suspension with 7% PNT hydrolysed at pH 
6 after 7 days at 25 °C (Keller, 1952). Hallas-Moller et al., (1952) studied the 
degradation of PNT in plasma samples at different pH and temperatures and reported 
that more than 85% of PNT degraded within 1 hat 37 °C. 
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PNT is an ester that undergoes hydrolysis and degrades rapidly in aqueous 
solutions; therefore in order to understand stability aspects of PNT, it is necessary to 
understand the factors such as, pH of the medium, buffers, buffer types, solvents, and 
temperature (Connors et al., 1986a) that may affect the stability of PNT. 
The study of pH dependence of reaction rates can give insight into the 
mechanism of catalysis (specific and general acid base catalysis) and practical 
information about drug stability (Connors et al., 1986a). Effect of pH on stability is 
determined by studying the acid and base catalysed hydrolysis of an ester at various 
concentrations of hydrogen and hydroxyl ion, by hydrolysing the ester in buffer 
solution of different pHs. The pH-rate profile obtained by plotting log k versus pH 
indicates the pH of maximum stability or minimum degradation (Connors et al., 
1986a). 
Often in addition to the effect of pH on the reaction rates, there may be 
catalysis by one or more species of the buffer components. The reaction is then said to 
be subject to general acid or general base catalysis depending on whether the catalytic 
components are acidic or basic. Finholt et al., (1965) investigated the effect of buffer 
on the degradation of BP. They found that dihydrogen citrate ion, the monohydrogen 
phosphate ion, and the borate ion imposed significant catalytic effects on the 
penicillin ion, while acetic acid, the acetate ion, the monohydrogen citrate ion, the 
unprotonated citrate ion, the dihydrogen phosphate ion, and borate ion were non 
catalytic. The log k - pH profile at zero buffer concentration gave a pH of minimum 
degradation at 6.75 (60 °C). They also found that increase in buffer concentration 
increased the rate of BP degradation. 
The labile ~-lactam ring of penicillins such as PNT and BP is characterized by 
its pronounced susceptibility to various nucleophiles, acid base reagents, metal ions, 
oxidizing agents and even solvents. Unlike PNT, degradation of BP has been 
extensively studied and several pathways have been proposed. It is very likely that 
PNT may undergo similar degradation pathway as that of BP and may result in similar 
degradation products. 
The major routes of degradation of BP are shown in Figure 1-7 (Blaha et al., 
1976; Deshpande et al., 2004). In alkaline conditions of pH 7.5-9.0, BP undergoes 
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rapid degradation (Hou and Poole, 1971; Deshpande et al., 2004) wherein the amide 
bond gets opened to give penicilloic acid. 
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Figure 1-7. Pathways of degradation of BP in enzymatic, acidic and alkaline conditions 
(Blaha et al., 1976; Deshpande et al., 2004). 
The carboxyl group present on penicilloic acid after bond opening undergoes 
decarboxylation giving rise to penilloic acid. However in strongly alkaline solution, 
BP is probably hydrolyzed directly to penicilloic acid. Formation of these degradation 
products of BP leads to the total loss of activity. 
In neutral medium, BP is hydrolyzed at the ~-lactam group to penicilloic acid. 
This reaction at constant temperature and pH is first order with respect to penicillin 
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and is directly proportional to hydroxyl ion concentration (Levine, 1960; Hou and 
Poole, 1971; Connors et al., 1986a; Deshpande et al., 2004). The mechanism of this 
reaction in neutral solution is not completely understood, but evidence from 
ultraviolet absorption data suggests that it proceeds through penicillenic acid (Hou 
and Poole, 1971; Connors et al., 1986a; Deshpande et al., 2004 ). It is rapidly 
converted to penicilloic acid with half-life, at pH 7.5 and 37°C of 6.5 minutes. The 
overall half-life of BP under these conditions is about 60 hours. 
In acidic medium the highly strained P-lactam ring and its amide bond breaks 
down (Brodersen, 1947; Schwartz, 1962; Hou and Poole, 1971; Blaha et al., 1976; 
Connors et al., 1986a; Deshpande et al., 2004) giving large number of complex 
products, including penilloic acid, penicillamine and penilloaldehyde through the 
highly unstable intermediates such as penillic acid, penicilloic acid and penicillenic 
acid. 
1.4. Methods of analysis of PNT 
Analytical measurements are necessary to investigate reaction mechanism, to 
understand stability and to determine of reaction rates. Therefore for stability 
assessments it is important to develop a method that will quantitatively determine the 
drug in the presence of degradation products. Study of chemical stability of PNT 
requires a suitable analytical technique like HPLC for assay and identification of 
degradation products of PNT. 
In the literature the reports on the stability (Jensen et al., 1951; Dinsmore and 
Bailey, 1952; Keller, 1952) or pharmacokinetics (Milthers and Roholt, 1953; Friton et 
al., 2003; EMEA, 2004) of PNT were based on the analysis of BP, the hydrolytic 
product, rather than PNT itself, by ultraviolet (UV) spectroscopy (Jensen et al. 1951; 
Dinsmore and Bailey 1952; Keller 1952; Milthers and Roholt, 1953), biological 
assays (Hallas-Moller et al., 1952) and a liquid chromatographic mass spectrometry 
(LC-MS) assay (EMEA, 2004). For understanding chemical stability under various 
conditions of temperature, pH and solvents and for formulation development of PNT 
it is important to analyse PNT and its degradation product but, there is no stability-
indicating high performance liquid chromatographic (HPLC) assay specific for the 
determination of PNT reported in the literature. 
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However there are several HPLC and LC-MS assays for the detection of BP in 
the presence of its degradation products or for other ~-lactam antibiotics (Ghebre-
Sellassie et al., 1982; Jehl et al., 1987; Yongxin et al., 1998; Daeseleire et al., 2000; 
Furusawa, 2001; Horimoto et al., 2002; Gabora, 2003; Mufioz et al., 2005). A 
knowledge and understanding of these methods can give an insight for the 
development of a validated HPLC method for PNT which will be useful in carrying 
out stability studies. 
1.5. Formulation strategies for the chemical stability of PNT 
1.5.1. Formulation limitations 
As discussed earlier the high instability of PNT prevents its formulation in an 
aqueous vehicle. At present, PNT is available as dry powder ready for reconstitution 
with diluents for i.m. injection (products: Mamyzin®-Boehringer Ingelheim, United 
Kingdom or Penethaject™-Bomac Laboratories Ltd., New Zealand). This is a 
formulation limitation as this suspension formulation (-333 mg mr1) has a shelf life 
of just 2 days at 15-20 °C and 7 days at 2-8 °C. This leads to discarding of unused 
product, making it unsuitable for use in farm conditions and is practically and 
economically not suitable for treatment of a large group of animals. Also from the 
veterinarian perspective, the reconstitution step is inconvenient in the field so that a 
ready-to-use liquid PNT product is sought as a preferred formulation type if available. 
This can be overcome by developing ready-to-use (no mixing required) stable liquid 
formulation with long shelf-life. Table 1-5 compares the advantages and formulation 
limitations of PNT with other marketed products. 
Since PNT offers advantageous physicochemical properties over BP and other 
~-lactam antibiotics, a ready-to-use chemically stable suspension formulation of PNT 
would be an important addition to the existing product range of antibiotics for the 
treatment of bovine mastitis. 
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i.m. injection and Strepcin HP MC 
Properties Injection (Penethaject™ or injection 
(Micronised BP) Mamyzin®) (BP and Streptomycin) 
Ready-to-use: no mixing required Yes No Yes 
One treatment treats all four quarters Yes Yes No 
No potential to introduce bacteria to teat 
Yes Yes No 
canal 
Treats subclinical & other quarters Yes Yes No 





Methods for stabilisation of drugs depends on storage or environmental factors 
such as temperature, light, moisture etc. and formulation factors such as pH of the 
solution, cosolvents, formulation in the form of a suspension, complexation, common 
ion and use of oily vehicles. To date, little effort has been made to stabilise PNT in 
liquid formulations. However there are several approaches that can protect PNT from 
degrading in liquid formulations. Some of these approaches are discussed below. 
1.5.2. Control of pH, buffer and ionic strength of aqueous environments 
For drug stabilisation in aqueous vehicles the most important factor is pH 
control. The rates of reactions in aqueous solutions are often markedly dependent on 
the solution pH, usually as a consequence of catalytic processes mediated by hydroxyl 
and hydronium ions (Connors et al., 1986a). An effective control of pH and buffer 
concentration along with determination of pH of maximum stability can be useful in 
formulating a stable aqueous formulation of PNT. Study of various factors such as 
buffer type, buffer strength, temperature and ionic strength provides an insight on the 
stability of drugs in aqueous solutions. The stability of BP in aqueous solutions has 
been studied earlier (Pulvertaft and Yudkin, 1946; Hahn, 1947; Connors et al., 1986a). 
There are reports which show that the degradation of BP in solution can be retarded in 
a particular type of buffer system (Hou and Poole, 1971; Deshpande et al., 2004). For 
example, Finholt et al., (1965) found that citric acid-citrate buffer has less catalyzing 
effect than phosphate buffer of similar buffer concentration on the degradation of BP. 
Lindsay (1972) reported the effect of ionic strength on the stability of BP and 
suggested that ionic strength effect is pH dependent with highest effect at pH 4.0. 
Since there are no reports on the degradation kinetics of PNT, a comprehensive study 
of the effect of various factors such as pH, ionic strength, buffer concentrations and 
type and temperature is warranted. 
1.5.3. Suspensions 
Stabilisation can be achieved by formulating the drug in a suitable suspension 
form. A suspension consists of insoluble solid particles dispersed in a liquid medium, 
with the solid particles accounting for 0.5-50% of the suspension. The vehicle may be 
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aqueous, oil, or both. These systems afford enhanced stability to active ingredients 
( e.g. PNT) that are prone to hydrolysis in aqueous solutions. Since the rate of 
degradation of a drug is related to the concentration of drug in solution, the chemical 
stability of a drug can be improved by formulating in suspension. In suspensions, drug 
degradation follows zero-order kinetics with the rate constant being dependent on the 
equilibrium solubility of the drug (Nash, 1996). Drugs such as procaine penicillin, 
ampicillin, chloramphenicol and aspirin have been formulated in suspensions and 
follow zero order kinetics (Nash, 1996). However the present reconstituted PNT 
aqueous suspension formulation has a short shelf life and further improvement is 
warranted. 
1.5.4. Cosolvents 
Many chemical degradation processes are mediated by water which plays a 
major role as a medium for the movement of molecules, as an environment fostering 
conformational changes, and as a reactant for hydrolysis (Martin and Bushmante, 
1993). Therefore, many degradation reactions of drugs can be either suppressed or 
completely eliminated by simply removing water. Cosolvents such as ethanol and 
propylene glycol have significant effect on the reaction rate (Zhao and Yalkowski, 
2001). In a cosolvent medium where both the reactants are ions, the absolute rate 
theory gives the following equation: 





where ln k is the rate constant at the dielectric constant f-, ln k0 is the rate constant in 
the medium of infinite dielectric constant, N is Avogadro's number, ZA is the charge 
on ion A, ZB is the charge on ion B, e is the electronic charge, T is absolute 
temperature, R is the gas constant and y is proportional to the interatomic distance in 
the activated complex. Using this equation a linear relationship can be predicted 
between ln k and 1/c. Thus the addition of cosolvent decreases the polarity of the 
reaction medium which in tum will not favour the formation of the charged species. It 
will stabilize a solute against any reaction that produces charged products or proceeds 
through a charged transition state (Zhao and Y alkowski, 2001 ). The concentration of 
the organic solvents such as alcohol that are generally used to enhance solubility, can 
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affect the dielectric constant of the solvent and thus influence the degradation rate of 
the active ingredients (Woodward et al., 1949; Hou and Poole, 1971; Deshpande et 
al., 2004) 
Also cosolvents reduce the collision probability between a water molecule and a 
drug molecule which is necessary for hydrolysis. Using cosolvents such as methanol, 
propylene glycol, and polyethylene glycol may have a stabilising effect by minimising 
hydrolysis of PNT. Zhao (2001) reported an increased stability of eptifibatide, an ester 
prodrug, in a semi-aqueous vehicle containing 10% ethanol and 40% propylene glycol 
in comparison with an aqueous vehicle and concluded that enhanced stability is a 
result of reduced hydrolysis-related degradation in the presence of cosolvents. 
However, cosolvents can also result in enhancement of solubility of drugs which 
can have potentially undesirable effects on the drug stability (Rubino, 2006). 
1.5.5. Complexation with cyclodextrins 
There are several reports in the literature involving complexation with 
cyclodextrins to enhance the stability of drugs (Loftsson et al., 1989; Loftsson 1995; 
Loftsson and Brewster, 1996; Masson et al., 1998). Complexing PNT with 
cyclodextrins (CDs) can be a useful approach for protection from hydrolysis. 
Cyclodextrins act as host molecules to form inclusion complexes with a wide variety 
of drug molecules (Loftsson and Brewster, 1996). CDs are water-soluble, naturally 
occurring cyclic glucose oligomers which have the ability to include selectively a 
range of drug/guest species in their hydrophobic cavity. The formation of an inclusion 
complex potentially alters the physicochemical properties of the drug molecule. 
The study of inclusion complexation (Figure 1-8) involves the phase solubility 
method described by Higuchi and Connors (1965), which examines the effect of a CD 
on the solubility of the drug. Phase solubility diagrams are divided into A and B 
types; A type curves indicate soluble inclusion complexes while B type suggest the 
formation of inclusion complexes with poor solubility. A-type curves are further 
subdivided into AL which depicts the linear increase in drug solubility as a function of 
CD concentration, Ap (positively deviating isotherms), and AN (negatively deviating 
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isotherms) subtypes. On the other hand a Bs type response represents complexes of 







Figure 1-8. Theoretical phase solubility diagram (Higuchi and Connors, 1965) 
~-CD often gives rise to B-type curves due to their poor water solubility 
whereas the chemically modified CDs like HP-~-CD and SBE-~-CD usually produce 
soluble complexes and thus give A-type systems (Rajeswari et al., 2005). 
Cyclodextrin interaction with drugs susceptible to degradation can result in 
several outcomes: cyclodextrins can retard degradation, can have no effect on 
reactivity, or can accelerate drug degradation. Drug-cyclodextrin complexation can 
shield, at least partly, the drug species from attack by various reactive molecules. That 
is, cyclodextrin can prevent hydrolysis, oxidation, and even enzymatic decomposition 
of drugs (Loftsson and Brewster, 1996). For example, aspirin (acetylsalicylic acid) is 
a phenolic acetate ester, and thus, it is unstable in aqueous solutions. The unionized 
aspirin forms stable (1: 1) inclusion complexes with the various ~-cyclodextrins in 
which aspirin undergoes 4-6 times slower hydrolysis than free aspirin (Loftsson et al., 
1993; Shehatta, 2002). 
On the other hand, as only the drug in solution can undergo degradation, 
enhancement of solubility by cyclodextrin can enhance the degradation of the drugs if 
25 
the labile groups are not protected. Encapsulation of PNT in the cycodextrin cavity 
can result in partial or complete protection of the ester group. Two schemes are shown 
which can be involved in the interaction of PNT with cyclodextrins (Figure 1-9). 
Scheme I is preferred as it will protect the ester group and prevent hydrolysis of PNT, 
in turn the stability can be improved. Also, the formation of insoluble cyclodextrin-
drug complexes (Br type solubility curve) can result in less drug in solution available 
for degradation and thus stability can be improved. However, if the interaction 
proceeds through Scheme II (Figure 1-9), may result in no or more enhanced 
hydrolytic degradation of PNT. 











Figure 1-9. Possible interactions of PNT with cyclodextrins 
1.5.6. Common ion 
Common ion effect is another approach to stabilise drug molecules by 
decreasing solubility (Serajuddin et al., 1987; Serajuddin, 2007; Zannou et al., 2007). 
PNT is in the form of hydroiodide salt. In aqueous solutions, addition of hydroiodide 
(HI) or potassium iodide (KI) should result in decreased solubility of PNT (Eq. 1-5). 
[PNTirr] solid ~ .., [PNTH+] s + [rJ Eq. 1-5 
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where [PNTH+rJsolid denotes undissolved solid salt that is in equilibrium with 
solution, [PNTH+]s is the salt solubility, and [r] is the counter-ion concentration. A 
similar effect is observed in the hydrochloride salts of drugs which often exhibit less 
than desirable solubility in gastric juice because of the abundance of chloride ions. 
This decrease in solubility may result in an increase in stability of PNT in aqueous 
suspensions. The apparent solubility product K'sp can be derived from Eq. 1-6: 
K\P = [PNTH+]Jr] Eq. 1-6 
When the excess counter-ions are absent, i.e. [PNTH+]s= [r], then the 
solubility = -VK' sp and thus the solubility remains unchanged. However, in presence of 
excess counter-ions, a decrease in solubility may be observed, according to Eq. 1-7. 
K'sp 
[PNTH+Js = [r] Eq. 1-7 
This decrease in solubility or formation of an insoluble salt may result in 
increase in stability of PNT in aqueous suspensions. 
1.5.7. Oily vehicles 
Drugs can be stabilised in oily vehicles as oils do not provide a favourable 
aqueous environment necessary for the hydrolytic reactions (Ni et al., 2002). Oily 
vehicles such as ethyl oleate, medium chain triglycerides and vegetable oils have been 
used to stabilise drugs from hydrolytic degradation reactions (Timmins et al., 1986; 
Knepp et al., 1998). There are reports of improved stability of diclofenac in 
ophthalmic solution in oils such as sunflower oil, arachis oil, safflower oil and sesame 
oil (Ahuja et al., 2009). Guyon et al., (1992) reported enhanced shelf-life (3 years) of 
cloxacillin in oily suspension formulation at room temperature. 
1.6. Simulation modeling 
Given the very limited data on PNT in animal studies, and given the difficulties 
of analysing such a rapidly hydrolysing drug, it could be of value to attempt to model 
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its pharmacokinetics and make predictions of milk levels of both PNT and BP, in 
order to guide formulation studies and the design of animal studies. 
Simulation models are in silica tools that provide useful insight into the 
pharmacokinetics of drugs by predicting drug concentrations in plasma and milk. 
Model predictions also offer the advantage of saving time and effort involved in 
conducting expensive animal studies. They require drug properties (pKa, t112 as a 
function of pH) along with pharmacokinetic parameters such as volume of distribution 
and clearance to make the predictions. 
Software such as PK solutions, Win Nonlin, SAAM II and Boomer is available 
for pharmacokinetic modeling; however, this software requires knowledge of 
programming languages (Charles and Duffull, 2001). On the other hand software 
packages such as ModelMaker and STELLA are user friendly and do not require 
knowledge of specific programming languages for pharmacokinetic predictions 
(Charles and Duffull, 2001). 
STELLA is general modeling software which can be adapted to 
pharmacokinetic applications. It is a completely graphical driven interface and has 
been utilised for generating a variety of pharmaceutically related simulation models 
(Grass and Morehead, 1989; Mikulecky, 1990; Ramsay et al., 1991; Grass and Lee, 
1993; Grass et al., 1994; Ranta et al., 2003; Shono et al., 2009). 
Such simulation models are useful in designing formulations (aqueous or oily 
suspensions) with different absorption rates, and in determining the dose and dosing 
frequency required to achieve preferred concentration versus time profiles of drugs in 
plasma and milk. 
1.7. Summary of the review ofliterature 
Mastitis is an infectious disease of dairy cattle and results in loss of milk 
production, discard of infected milk and premature culling of cows making it one of 
the most costly disease in dairy farming. Antibiotics are available to treat mastitis and 
parenteral formulations are preferred over intramammary for the treatment of mastitis. 
PNT due to its favourable pharmacokinetic properties provides an effective 
treatment for mastitis caused by penicillin sensitive MCOs and provides persistent and 
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high levels of bactericidal BP to all quarters following intramuscular injections 
maintaining antibacterial effects over the course of treatment. It effectively treats 
clinical and subclinical mastitis caused by MCOs whether occurring alone or 
concurrently in adjacent quarters to those affected clinically. 
The limitation of the current PNT formulations is that they are dry powders 
which have to be reconstituted with buffer prior to use. The storage life of the 
reconstituted products is short and any unused product has to be discarded. This is 
because of the chemical instability of PNT in the aqueous environment. It is an old 
drug however very little information is available on its chemical stability except that it 
hydrolyses to BP in aqueous vehicles. Also there are no reports in the literature on the 
analysis of PNT, and so BP has been used as a marker residue for PNT. 
Before applying various formulation strategies to improve the chemical 
stability of PNT, a thorough investigation on the chemical stability of PNT is 
warranted. This also requires development of stability indicating HPLC assay to 
determine the concentration of PNT in stability samples and formulations. 
Prediction of absorption rates from i.m sites and concentrations of BP after i.m 
injections of PNT in cows by using simulation model could provide valuable insight 
in the design of formulations and animal trials. 
Finally a chemically and physically stable formulation of PNT with longer 
shelf- life for the treatment of bovine mastitis is desirable. 
The overarching hypothesis for the research in this thesis was "A ready-to-use 
product containing PNT for the treatment of bovine mastitis by i.m. injection will be 
superior to the reconstituted products currently on the market." This initially required 
the development of a stability-indicating HPLC assay for PNT as described in Chapter 
2. Chapter 3 investigated a PNT product in aqueous vehicles whereas Chapter 4 
investigated a PNT product in an oily vehicle. 
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1.8. Aims of the thesis 
The aims of the experimental work in this thesis were to investigate the 
chemical stability of PNT, and to apply formulation strategies to minimise the 
hydrolytic degradation of PNT so that a chemically stable formulation can be 
prepared for the i.m treatment of bovine mastitis. Specifically the objectives were: 
• to develop and validate a stability-indicating HPLC assay for the 
determination of PNT in presence BP and other degradation products. 
• to carry out pre-formulation studies for PNT with respect to 
physicochemical properties, solubility, ionization and chemical stability 
in aqueous-based solutions and to apply formulation strategies to 
stabilise PNT in presence of cosolvents, cyclodextrins, common ion and 
oily vehicles . 
• to use the results from the kinetic studies to formulate a stable ready-to-
use i.m. PNT product. 
• to construct a STELLA simulation model to predict the absorption rates 
of PNT from i.m site and to predict concentrations of BP, the hydrolytic 
product of PNT in milk. 
• to carry out an animal study using a selected i.m. formulation of PNT in 
the target species (cow) to determine the concentration of BP in milk. 
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Chapter 2. Characterisation and 
HPLC method development of PNT1 
1 Parts of this chapter have been published: Jain et al., (2009). A stability-
indicating HPLC assay with diode array detection for the determination of a 
benzylpenicillin prodrug in aqueous solutions. Journal of Pharmaceutical and 
Biomedical Analysis 50(5): 841-846. 
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2.1. Introduction 
In the literature there are no reports on the analysis of PNT. The reports on the 
stability or pharmacokinetics of PNT were based on the analysis of BP, the hydrolytic 
product, rather than PNT itself, by ultraviolet (UV) spectroscopy, biological assays 
and a liquid chromatographic mass spectrometry (LC-MS) assay (Chapter 1). The 
current EMEA guidance (EMEA, 2009) prefers analyses of parent drug as well as the 
active metabolite. 
The stability of PNT as a function of pH is an important consideration in the 
formulation development particularly with regard to the formation of BP. The drug 
stability test guideline QIA (R2) issued by the International Conference on 
Harmonization (ICH, 2003) requires that analytical test procedures should be 
stability-indicating and that they should be fully validated. Therefore, in this study, a 
stability-indicating high performance liquid chromatographic (HPLC) assay specific 
for the determination of PNT was developed and validated. 
2.2. Chapter aims 
The aim of the work in this Chapter was to characterise the PNT samples 
received from the manufacturer and to develop a stability-indicating HPLC assay. The 
characterisation involved thermal analysis of PNT by differential scannmg 
calorimetry (DSC) and thermogravimetric analysis (TGA) and fourier transform 
infrared spectroscopic (FT-IR) analysis of PNT and BP. HPLC method development 
involved determination of the stability of PNT under a variety of I CH-recommended 
stress-testing conditions to develop and validate a stability-indicating HPLC assay 
capable of separating PNT and BP from the degradation products. 
2.3. Material and Methods 
2.3.1. Materials 
PNT (batch no. PE-0808001, purity 98.5%) was kindly donated by Bioquim, 
SA, Barcelona, Spain. Benzylpenicillin potassium (BP) (batch no. 054K27561) was 
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TGA analysis 
PNT powder samples were analysed by TGA (TGA Q 50 V6.7 Build 203 TA 
Instruments, New Castle, USA) under a nitrogen gas flow. The TGA equipment was 
calibrated by scanning nickel and iron before analysing the samples. Sample powders 
(5-10 mg) were placed in an open platinum pan, heated at 10 °C min-1 within the 
range of 20-250 °C under the dynamic nitrogen gas flow (50 ml min-1) and the loss of 
mass recorded. The data were analysed using TA Universal Analysis software, 
version 4.0C. 
FT-IR analysis of PNTand BP 
FT-IR spectra were obtained on a Varian 3100 FT-IR Excalibur sen es 
instrument under a nitrogen gas environment. Samples were prepared by placing the 
mixture of PNT or BP and KBr on the ZnSe crystal in the attenuated total reflectance 
(ATR) assembly of FT-IR instrument. FT-IR spectra of PNT or BP were analysed in 
the scanning range 4000-370 cm-1. The resolution used was 4 cm-1 (16 scans spectrum-
1). Data were analysed using the Varian Resolutions Pro 4.0 (version 4.0.5.009) 
software. 
2.3.2.2. Stability-indicating HPLC assay 
2.3.2.2.1. Instrumentation and chromatographic conditions 
The HPLC instrument employed was a Shimadzu LC-20 Prominence series 
(Shimadzu, Kyoto, Japan) LC system equipped with a LC-20AD quaternary pump, a 
DGU-20A5 degasser unit, a SPD-M20A diode array detector, a SIL-20AC auto-
injector (set at 4 °C) and a CT0-20A column oven (set at 40 °C). The output signal 
was monitored and processed using Class VP 7.4 software (Shimadzu, Kyoto, Japan). 
The injection volume was 100 µl and chromatographic separation was achieved on a 
Luna C18, 150 mm x 4.6 mm i.d., 5 µm particle size column (Phenomenex, New 
Zealand), using methanol acetonitrile-acetate buffer (pH 5; 50 mM)(35:5:60, v/v/v) as 
mobile phase at a flow rate of 1 ml min-1• PNT and BP were determined by UV 




2.3.2.2.2. Development of quenching solution 
For method validation, it was necessary to develop a diluent (quenching 
solution) in which PNT was stable for at least 24 h to limit the degradation in samples 
to negligible levels before and during the analysis. In the preliminary studies, buffer 
solutions of phosphate (pH 2.0 - 3.0 and 6.5 - 8.0), acetate (pH 4.0 - 6.0) and borate 
(pH 9.0 - 10) (50 mM) containing PNT (100 ug mr1) were stored at O and 25 °C and 
analysed for PNT content by the developed HPLC assay. Similarly combinations of 
solvents in different ratios (50-80%, v/v PG or ethanol) with acetate buffers (50mM to 
lM) containing PNT (100 ug ml-1) were also investigated at temperatures -80, 0, 4 
and 25 °C and analysed with the HPLC assay. 
2.3.2.2.3. Stress degradation of PNT 
Stress degradation studies of PNT were performed in accordance with ICH 
guidelines (ICH, 2003) in order to demonstrate the stability-indicating (Bakshi and 
Singh, 2002) feature of the assay. The degradation products were induced in acidic, 
alkaline, water and oxidation conditions. 
The experiments were carried out as follows: to 4 mL of a 1 mg mr1 solution of 
PNT in PG, 21 mL of HCl or NaOH or water or hydrogen peroxide (H20 2) solutions 
of different concentrations (0.03% and 0.3% v/v) were added. These samples, 
prepared in duplicate, were protected from light and stored at 25 °C. pH was measured 
at the beginning and end of the experiment and no pH change in the samples was 
observed except in water where pH was changed from 6.98 to 6.28. Aliquots were 
taken at appropriate time intervals depending on decomposition rate (until 0-60% of 
PNT remained), diluted with the quenching solution and analysed immediately for the 
determination of PNT and degradation products. 
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2.3.2.2.4. Stock solutions of PNT and BP 
For method validation a stock solution of PNT (1 mg mr1) was prepared in the 
quenching solution. Working solutions of 200 µg mr1 were prepared from the stock 
solution for the assay. A 1 mg mr1 stock solution of BP was also prepared in 
quenching solution. Stock solutions were stored at -80 °C. 
2.3.2.2.5. Validation ofmetlwd 
Method validation was carried out in accordance to ICH (1996) and Australian 
Pesticides & Veterinary Medicines Authority (APVMA) guidelines (APVMA, 2004). 
Specificity 
The specificity of the assay was determined by the complete separation of PNT 
in the presence of its degradation products generated under stress conditions. The 
asymmetry factors of the peaks were calculated from freshly prepared samples of 
PNT and BP. The peak purity test was carried out on stressed samples using the diode 
array detector. The PNT chromatographic peaks were corrected for background, and 
the wavelength range 215-340 nm was used to calculate peak-purity and similarity 
index. 
Linearity 
The assay was validated over the PNT concentration range of 1-100 µg mr1• 
Triplicate stock solutions of PNT were prepared in the quenching solution (200 µg mr 
1
) and diluted with quenching solution to give analytical standards at six concentration 
levels (1, 5, 10, 25, 50 and 100 µg mr1). Standard curves were constructed using 
standard regression techniques. All the standard solutions were stored in slushy-ice 
bath (0 °C) protected from light and analysed within 4 h of preparation. 
Precision 
The intra-day and inter-day variabilities were determined by repeated injections 
of quality control (QC) standards of PNT at concentrations of 3, 20 and 80 µg mr1 in 
quenching solution prepared from a different stock following the same procedure as 
for analytical standards. QC standards were protected from light at -80 °C (until 
analysed), thawed at O °C and then analysed. This was repeated on 5 consecutive days. 
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Accuracy 
Accuracy was accessed by comparing the predicted concentrations of the QC 
standards, using the standard curve, with the theoretical concentrations (3, 20 and 80 
µg mr1). 
Limit of detection (LOD) and limit of quantitation (LOQ) 
LOD and LOQ were determined on the basis of standard deviation ( o) of the 
response and slope (S) of the calibration curve using 3.3 cr /Sand 10 cr /S respectively. 
Linearity for BP 
The linearity for BP was investigated in the concentration range 1-100 µg mr1 
in triplicate following a similar procedure to that used for PNT. 
2.4. Results 
2.4.1. Characterisation of PNT 
DSC analysis showed a sharp endotherm and PNT started melting at 1 78 °C 
(onset) with melting peak at 179.8 °C (Figure 2-1) which is in accordance with the 
literature (The Merck Index, 2006). Further increase in temperature resulted in 
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Figure 2-1. DSC thermogram of PNT as received. 
As PNT is prone to hydrolysis, it was important to determine the moisture 
content in the powder samples. Using TGA, the recorded losses of masses of the 
samples heated under the dynamic flow of nitrogen were negligible (:'.S 0.03 %) up to 
100 °C indicating negligible moisture content (Figure 2-2). PNT samples showed a 
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Figure 2-2. TGA trace of PNT as received. 
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FT- IR analysis of PNT and BP 
The spectra of the standards of PNT and BP show a number of prominent peaks, 
especially in the region of 1800 cm-1 to 1500 cm-1 (Figure 2-3). Characteristic peaks 
for BP reported in the literature are 1777 cm-1, 1620 cm-1 and 1500 cm-1 (Moffat, et 
al., 2004) which corresponds to ~-lactam, carboxylate and amide II respectively. 
Table 2-1 shows the wave numbers and peak assignment for PNT and BP from this 
study. 
Interpretation of the spectra (Table 2-1) confirmed that the PNT spectra differ 
from BP in the ester (1750 cm-1) and carboxylate region (1615 cm-1)_ Various peak 
assignments are shown in Table 2-1. 
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Figure 2-3. FT-IR spectra of PNT and BP showing similarity in characteristic peaks. 
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Table 2-1. FT-IR peak assignment for PNT and BP 
PNT 
Wavenumber 
Peak Assignment (cm-1) 
1506 Amide II 
1680 Amide I 
1750 Ester 
1787 ~-lactam 
2.4.2. Stability-indicating HPLC assay 




1492 Amide II 
1672 Amide I 
1615 Carboxylate 
1776 ~-lactam 
In a preliminary study and later confirmed by the validated reversed phase 
HPLC method, PNT was found to degrade most rapidly in borate buffer (pH 1 O; 50 
mM) (20% remained after 1 h at O °C) and to be most stable in acetate buffer at pH 
4.8 (88% remained after 24 h at O °C) compared to solutions prepared in different 
buffers (phosphate, acetate) at pH 2 to 10. Combinations of solvents (50-80%, v/v PG 
or ethanol) with acetate buffers (50 mM to IM) were investigated as an appropriate 
diluent of PNT samples at temperatures -80, 0, 4 and 25 °C in an effort to develop a 
quenching solution in which PNT was stable for at least 24 h. Finally, a quenching 
solution containing PG-acetate buffer (IM) (50:50, v/v) (pH 4.8) was selected for 
method validation. At a ratio of quenching solution to sample solution of 9: 1 (v/v), the 
quenching solution was able to stabilise a PNT sample solution in borate buffer (pH 
1 O; 50 mM). That is, 98 ± 1 % PNT remained after 24 h at O °C and 99 ± 1 % after 3 
months at -80 °C (Figure 2-4 and 2-5). 
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Figure 2-4. Effect of quenching solution on the stability of PNT at O °C after 24 h. PNT 
was initially in borate buffer (pH 10; 50 mM) and this solution was mixed with 
quenching solution in the ratio 1 part PNT solution to 9 parts quenching solution. Data 
points are means (n =2). 
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Figure 2-5. Effect of quenching solution on the stability of PNT at -80 °C after 90 days. 
PNT was initially in borate buffer (pH 10; 50 mM) and this solution was mixed with 
quenching solution in the ratio 1 part PNT solution to 9 parts quenching solution. Data 
points are means (n =2). 
Similarly 98.2 ± 1 % of BP was detected after 24 h in the quenching solution at 0 
°C. For the preparation of stock solutions, the stability of PNT was determined in 
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various cosolvent systems (water, PG, PEG 400 or ethanol or their combinations) at 
different temperatures. The stability of PNT was in order PG > PEG > ethanol > 
water. Therefore, PG was selected and in it 98.5 ± 1 % PNT remained after 24 hat 0 
~C and 48 hat -20 °C. 
2.4.2.2. Development and optimisation of stability-indicating method 
For mobile phase development, initially only methanol and buffer in different 
ratios and pH were tried. A mobile phase consisting of methanol-acetate buffer (pH 5; 
50 mM) (40:60, v/v) gave symmetrical peaks and satisfactory resolution between PNT 
and BP. Acetate buffer (pH 5; 50 mM) was selected as both PNT (pKa 8.4) and BP 
(pKa 2.8) are ionised at this pH and the buffer provided good buffer capacity resulting 
in stable retention times (tR). However, the resolution between BP and degradation 
products was poor. The method was optimised by addition of 5% acetonitrile to the 
mobile phase, which resulted in shorter retention times and improved resolution with 
degradation products for both PNT and BP. Ultimately a mobile phase consisting of 
methanol-acetonitrile-acetate buffer (pH 5; 50 mM) (35:5:60, v/vlv) was selected. This 
mobile phase gave good resolution between PNT (tR = 10.3 min) and its major 
hydrolysis product BP (tR = 7.3) with no interference from other degradation products 
formed in the stress conditions. 
2.4.2.3. Stress degradation of PNT 
Under stress conditions the PNT peak reduced over time (Table 2-2) with 
appearance of different unknown degradation product peaks (I- IX) (Figure 2-6 to 2-
9). 
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Table 2-2. Effect of stress conditions on degradation of PNT at 25 °C in dark 
Stress condition Time (h) PNT remaining (%) 
Acidic 
1 mMHCl 22 53.6 
lOmMHCl 22 0.04 
Water 480 14.2 
0.1 mMNaOH 22 59.0 
Alkaline 
1 mMNaOH 22 44.3 
lOmMNaOH 2 2.0 
Oxidation 
0.3 % vlv H202 2 24.2 
3 % v/v H202 1 10.5 
Acidic conditions 
PNT degraded in acidic conditions (Table 2-2) with appearance of degradation 



























Figure 2-6. Overlay chromatograms showing degradation of PNT and formation of 
unknown degradation products at various times (solid line represents samples at time 0) 
in 10 mMHCI. 
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The absence of BP in the samples suggests that either any BP formed degraded 
rapidly or the hydrolysis of PNT to BP is negligible and degradation of PNT occurred 
predominantly by alternative pathways in the acidic solutions. These results were 
confirmed in the kinetic study and are discussed in Chapter 3. 
Alkaline conditions 
PNT was found to degrade more rapidly in the alkaline solutions than in the 
acidic solutions (Table 2-2). In 1 mM NaOH solutions degradation occurred even 
during sample preparation with rapid appearance of peaks I, II, III, IV, VI, VII, BP 
and IX (Figure 2-7). A significant amount of BP was observed indicating hydrolysis 
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Figure 2-7. Overlay chromatograms showing degradation of PNT and formation and of 
BP and unknown degradation products at various times (solid lines represent samples at 
time 0) in 1 mM NaOH. 
Water conditions 
In water, degradation occurred at a slower rate compared to acidic and alkaline 
conditions with appearance of I, IV, V, BP and IX. However, in the later stages 
another peak (VI) emerged which was also present in basic conditions but absent in 
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Figure 2-8. Overlay chromatograms showing degradation of PNT and formation and 
sequential degradation of BP and unknown degradation products at various times (solid 
lines represent samples at time 0) in water. 
Oxidative conditions 
PNT degraded most rapidly in the presence of H20 2 (Table 2-2) with a rapid 
formation of degradation peak III. In addition, a new degradation peak VIII was also 
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Figure 2-9. Overlay chromatograms showing degradation of PNT and formation of BP 
and unknown degradation products at various times (solid lines represent samples at 
time 0) in 0.3% (v/v) H20 2 solution. 
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2.4.2.4. Validation of stability-indicating HPLC method of PNT 
Specificity 
The HPLC method was found to be specific with complete separation of PNT 
(tR 10.3 ± 0.1 min) from its degradation products under all degradation conditions. 
The asymmetry factor was 1.1 and 1.0 for PNT and BP respectively. The peaks 
obtained were sharp with clear baseline separation. The peak purity and similarity 
indexes of PNT (Figure 2-10) and BP under all degradation conditions were> 0.999, 
confirming the absence of other substances co-eluting with PNT and BP. The assay of 
PNT was unaffected by the presence of BP and unidentified degradation products 














Total peak purity: 
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Figure 2-10. Typical diode array peak purity profile showing peak purity and similarity 
index for PNT 
Linearity, Precision, Accuracy, LOD and LOQfor PNT 
The assay for PNT was found to be linear in the range 1-100 µg mr1 with an 
equation y = 25964x + 780.16, intercept not significantly different from zero (p 2: 
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0.05) and a high correlation coefficient (r > 0.999) (Figure 2-11 ). Intra-day and inter-
day variabilities were low and accuracy was high (Table 2-3). The LOD and LOQ of 
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Figure 2-11. Standard curve for PNT in quenching solution using the stability-indicating 
HPLC method. 
Table 2-3. Intra-day, inter-day precision and accuracy(%) of QC standards at 3, 20 and 
80 µg mr1 (PNT) 
Theoretical 
Intra-day (n = 3) Inter-day (n = 5) 
cone. 
(µg mf1) Mean cone.± RSD1 Accuracy Mean cone.± RSD1 Accuracy 
SD (µg mr1) (%) (%) SD (µgmr1) (%) (%) 
3 2.30 ± 0.02 0.7 99.4 ± 0.7 2.90 ± 0.02 0.9 99.2 ± 0.7 
20 19.8 ± 0.1 0.4 98.8 ± 0.4 19.8±0.1 1.0 99.0 ± 0.8 
80 78.7 ± 0.3 0.4 98.4 ± 0.4 78.5 ± 0.1 0.2 98.2 ± 0.9 
1RSD % =SD/ mean x 100 
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Linearity, LOD and LOQfor BP 
The assay for BP was found to be linear in the range 1-100 µg mr1 with an 
equation y = 3175 lx + 625.98, intercept not significantly different from zero (p 2: 
0.05) and a high correlation coefficient (r > 0.999) (Figure 2-12). The LOD and LOQ 
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Figure 2-12. Standard curve for BP in quenching solution using the stability-indicating 
HPLC method. 
2.5. Discussion 
DSC, FT-IR and HPLC are well known tools for the characterisation and 
identification of drug samples. Since limited literature (The Merck Index, 2006) is 
available for the characterisation of PNT, an effort was made to characterise and 
identify the PNT sample received from the manufacturer before proceeding for further 
studies. Results from DSC a..11d FT-IR suggested that the sample were indeed PNT and 
FT-IR spectra were helpful in identifying the prodrug PNT from the active BP. 
PNT is widely used in treatment of bovine mastitis with favourable 
pharmacokinetics over BP. Although the hydriodide is soluble in aqueous solution, 
the high instability prevents its injectable formulation in an aqueous vehicle. In an 
effort to develop a more stable formulation it is important to develop a stability-
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indicating HPLC method to understand the stability behaviour of PNT in aqueous 
solutions. Also, there are no pharmacokinetic studies (Milthers and Roholt 1953; 
Friton et al., 2003) in which the PNT parent compound has been analysed. 
Due to its extreme instability in aqueous solutions particularly at high pH, there 
was a need to prepare a quenching solution in which degradation of PNT was limited 
to a negligible level so that the HPLC assay and validation could be performed. A 
quenching solution was also required for the degradation studies (Chapter 3). In this 
study, PNT was found to be relatively stable in pure PG; however, with addition of an 
alkaline solution of PNT to PG, the drug continued to degrade at an unacceptable rate 
such that only 50% remained after 24 h at O °C.However, the presence of 50% 1 M 
acetate buffer (pH 4.8) in PG conferred satisfactory stability to PNT at low 
temperatures. This indicates that the pH and buffer capacity are necessary features of 
the quenching solution. These results also provide useful information for formulation 
development. 
In the stress degradation studies, overlaid chromatograms (Figure 2-6 to 2-9) 
explained the disappearance of PNT and formation of degradation products under 
various conditions: acidic, water, alkaline hydrolysis and oxidation, and suggested 
that the assay was stability-indicating and capable of separating PNT in the presence 
of potential degradation products. The peak purity of PNT and BP under all these 
degradation conditions was greater than 0.999, confirming the absence of co-eluting 
substances. The assay was linear in the concentration range 1-100 µg mr1 (r > 0.999). 
Both intra-day variability (n = 3) and inter-day variability (n = 5) at 3.0, 20.0 and 80.0 
µg mr1 were satisfactory (RSD :S 1 %). The mean percentage accuracy at above 
concentration levels was 98-99%. 
The degradation pathways of BP as elucidated in earlier studies are complex 
(Brodersen 1947; Hallas-Moller et al. 1952; Levine 1960; Finholt et al. 1965; Blaha et 
al. 1976; Deshpan.de et al., 2004). In the current study, some effort was made to relate 
the results with these studies. PNT, being an ester prodrug of BP, may follow similar 
degradation pathways to BP in addition to hydrolysis to BP; however, there are 
limited data in the literature that discuss the fate of PNT in different pH conditions 
and the assays were based on spectrophotometric determination of BP (Jensen et al., 
1951; Dinsmore and Bailey, 1952; Keller, 1952). 
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In the acidic solutions of PNT, no BP was observed. Instead, four other 
degradation products were seen. This may be due to the high instability of BP in 
acidic solutions (Brodersen, 1947; Schwartz and Buckwalter, 1962; Finholt et al., 
1965; Schwartz, 1965; Blaha et al., 1976; Deshpande et al., 2004) or because the ester 
hydrolysis of PNT to BP is negligible and PNT degraded predominantly by alternative 
pathways. In either case, this result emphasises the futility of monitoring BP to assess 
the stability of PNT, and the need for a stability-indicating assay for PNT. Formation 
of BP in water and alkaline solutions is attributed to the hydrolysis of the ester group 
of PNT. The BP so formed may have resulted in formation of penicilloic and 
penicillenic acid, which are known to be formed in alkaline conditions (Brodersen, 
1947; Schwartz and Buckwalter, 1962; Schwartz, 1965; Finholt et al., 1965; Hou and 
Poole, 1971; Deshpande et al., 2004) and again emphasizing the need for a stability-
indicating assay for PNT. Similar conclusions apply to oxidative conditions. In the 
presence of H20 2, degradation peaks III and VIII were observed. These degradation 
products may be attributed to the oxidation of the sulphur and/or the tertiary amine 
present in the structures of PNT and BP. 
The stability-indicating assay developed for PNT is an important addition in the 
scarce scientific literature on PNT, since this prodrug is a useful molecule and yet 
there is no stability-indicating assay for it in the literature. The method is particularly 
valuable due to its ability to separate PNT and BP simultaneously in the presence of 
the other degradation products, and hence in combination with the quenching solution 




PNT was characterised and identified by DSC and FT-IR. TGA analysis 
confirmed that the moisture level was negligible in the PNT powder received from the 
manufacturer. A stability-indicating HPLC assay method was developed for the 
quantification of PNT and its major degradation product BP. The method is specific, 
accurate and precise. The procedure permits an accurate and quantitative 
determination of PNT and its major degradation product BP. All the degradation 
products formed during forced degradation studies are well separated from PNT 
demonstrating that the method is specific and stability-indicating. This method was 




Chapter 3. Chemical stability studies 
of PNT in aqueous solutions2 
2 Parts of this chapter have been published: Jain et al., (2011). Pre-formulation and 
chemical stability studies of penethamate, a benzylpenicillin ester prodrug in aqueous 




In the literature reports on the stability and pharmacokinetic studies on PNT 
(Chapter 1, Section 1.3), the investigators assumed, firstly, that the PNT was 
converted only to BP, which is not the case given that PNT can follow alternative 
degradation pathways (Chapter 2), secondly, that the BP was stable over the period of 
the kinetic studies and thirdly that the PNT did not interfere with the 
spectrophotometric analysis of BP. If the PNT degrades via additional pathways, 
rather than just to BP, the chemical stability will have been underestimated by studies 
based on BP analysis. In addition, if BP degrades during a kinetic study, the stability 
assessment based on the spectrophotometric assay of BP will again underestimate the 
stability of PNT. Given these uncertainties, an investigation of the stability of PNT, 
using a stability-indicating assay (Chapter 2) for PNT itself and for BP, was needed as 
a basis for possible development of a novel ready-to-use aqueous-based PNT 
formulation. 
In this study various stabilisation approaches such as use of cosolvents, 
complexation with cyclodextrins and suppression of solubility with the common ion 
iodide were also applied and their influence on the stability of PNT was investigated. 
3.2. Chapter aims 
The work in this chapter addressed the research question: can the hydrolysis of 
PNT be minimized in order to achieve an acceptable chemical stability of a ready-to-
use aqueous based PNT formulation? This required a chemical stability study of PNT 
in aqueous-based solutions as a function of pH, buffer type, buffer strength, and 
temperature using a stability-indicating assay for PNT and BP, but the entire 
degradation pathways of PNT were not part of this investigation. Solubility and 
stability of PNT was also determined in the presence of cosoivents (PG), ~-
cyclodextrin (~-CD), hydroxypropyl-~-cyclodextrin (HP-~-CD) and iodide (I} Some 
estimations of shelf-life stability of PNT in suspensions were also performed. 
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3.3. Materials and methods 
3.3.1. Materials 
PNT, BP and solvents were the same as described in Chapter 2. ~-CD and HP-
~-CD and potassium iodide (KI) were purchased from Sigma-Aldrich, MO, USA. All 
other chemicals and solvents were of analytical grade (BDH Chemicals Ltd., England, 
or Ajax Finechem, New Zealand). 
3.3.2. Methods 
3.3.2.1. Instrumentation and chromatographic conditions 
Instrumentation and chromatographic conditions were the same as described in 
Chapter 2 (Section 2.3.2.2). 
3.3.2.2. Determination of apparent pKa by UV absorbance spectroscopy 
The pKa (8.4 or 8.5) of PNT is cited in various reports (Mamyzin injection 
technical monograph; Rasmussen, 1959; Ziv and Rasmussen, 1975; Ziv and Sulman, 
1975). None of these reports, however, provides details of methodology used for the 
determination of pKa of PNT. Given its instability, it is difficult to determine the pKa 
because of significant degradation during the required measurements and therefore the 
published results may be unreliable. Since pKa is an important parameter in the 
stability and pharmacokinetics of PNT, an effort was made to confirm the previous 
reports on pKa of PNT. 
Absorbance spectra of freshly ( <1-2 min) prepared PNT aqueous solutions over 
the pH range 3.8 - 10.2 were measured using a Shimadzu UVNIS Spectrophotometer 
(UV 1601/PC, Japan) to determine the absorption maxima of the ionised and non-
ionised species. An analytical wavelength of 250 nm was selected to determine the 
pKa based on the method described by Albert and Serjeant (1971 ). Briefly, a series of 
buffers of low ionic strength(µ= 0.01) was prepared as described by (Perrin, 1963). 
Then buffer (2.95 ml) was mixed with 50 µl of fresh PNT stock solution in methanol 
(7 mg mr1) to give a final drug strength of 116 µg mr1 (2.6 x 104 M), and a final 
methanol concentration of 1.6%. The absorbance was measured at 23 °C at known 
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times for up to 4 min after mixing of the buffer and stock solution. The absorbance at 
time zero (Ao) was obtained by extrapolation of the linear least squares regression line 
of absorbance versus time to time zero. Eq. 3-1 was fitted by nonlinear least squares 
regression to estimate Au, Ai and pKa using PRISM software (GraphPad 5.0). 
A 
- All + A. X lO(pK.-pH) 
0 - l 
1 + lO(pK.-pH) Eq. 3-1 
where Ao is the absorbance of the solution at time zero obtained by 
extrapolation, Au is the absorbance of unionised species and Ai the absorbance of the 
ionised species. Duplicate experiments were conducted and the mean values were 
used for calculation of pKa. 
3.3.2.3. Solubility studies of PNT 
Cosolvent systems 
In order to predict the chemical stability of PNT in suspensions in cosolvent 
systems, the solubilities of PNT in cosolvent PG (5, 20, 40, 60% v/v) - citrate buffer 
(50 mM, pH 4.5) systems were determined at 30 °C. In addition, solubility of PNT in 
cosolvent PG (5% v/v) -citrate buffers (50 mM, pH 4.5) was determined at 5 °C and 
20 °C. Excess PNT (80 mg mr1) was added to the solvent (4 ml) in screw capped 
glass tubes and the tubes were shaken (100 opm) at 5 °C or 20 °C or 30 °C in a 
shaking water-bath for 2 h during which time PNT showed negligible degradation. 
Samples were centrifuged at 3000 rpm (Eppendorf centrifuge (Model 5810 R, 
Germany) for 10 min, and supematants were then filtered (0.22 µm, Millipore, USA) 
using a warm (30 °C) syringe to avoid precipitation, diluted with quenching solution, 






/J-CD, HP- /J-CD and iodide 
Similar to cosolvents, the solubilities of PNT HI in P-CD (0-60 mM), HP- P-
CD (10-100 mM), KI (16-96 mM)- acetate buffer (50 mM, pH 4.5, µ = 0.15) systems 
were determined at 30 °C following a procedure similar to that for PNT solubility in 
cosolvent systems (Section 3.3.2.3). The concentration of r present from PNT HI is 
16mM. 
3.3.2.4. Chemical stability studies of PNT 
Degradation kinetics 
The kinetic studies were carried out as follows: buffer (9.5 ml) in a 25 ml 
stoppered Erlenmeyer flask was brought to water-bath temperature (30 ± 0.1 °C) and 
then 0.5 ml of stock solution of PNT (10 mg mr1 in PG) was added with mixing. At 
appropriate times, samples (0.5 ml) of the reaction mixture were taken and added to 
4.5 ml of quenching solution (at O °C, slushy-ice bath) and analysed by HPLC within 
24 h. Chemical stability was studied over 3-4 half-lives of PNT. All the PNT samples 
were protected from light during the study and experiments were performed in 
duplicate. 
pH-rate profile 
Buffer solutions (50 mM) of phosphate (pH 2.0 - 3.0 and 6.5 - 8.0), acetate (pH 
4.0 - 6.0) and borate (pH 9.0 - 9.3) were adjusted to constant ionic strength(µ= 0.15) 
with sodium chloride. The pH of the reaction mixtures was measured (Sartorius basic 
pH meter PB-11, Germany) at the beginning and end of data collection and no change 
in pH was observed. 
Buffer 
PNT (500 µg mr1) solutions in acetate (4.52 and 6.01), phosphate (pH 3.01, pH 
6.01, 7.15 and 8.04) and citrate buffers (pH 4.52) were prepared and compared at two 
buffer concentration (50 mM and 150 mM) with constant ionic strength (µ = 0.5) 
adjusted with sodium chloride at 30 ± 0.1 °C to investigate the catalytic effect of 
buffer on the degradation of PNT. 
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fl-CD, HP- fl-CD and iodide 
Similar to cosolvents, the solubilities of PNT HI in ~-CD (0-60 mM), HP- ~-
CD (10-100 mM), KI (16-96 mM)- acetate buffer (50 mM, pH 4.5, µ = 0.15) systems 
were determined at 30 °C following a procedure similar to that for PNT solubility in 
cosolvent systems (Section 3.3.2.3). The concentration of r present from PNT HI is 
16mM. 
3.3.2.4. Chemical stability studies of PNT 
Degradation kinetics 
The kinetic studies were carried out as follows: buffer (9.5 ml) in a 25 ml 
stoppered Erlenmeyer flask was brought to water-bath temperature (30 ± 0.1 °C) and 
then 0.5 ml of stock solution of PNT (10 mg mr1 in PG) was added with mixing. At 
appropriate times, samples (0.5 ml) of the reaction mixture were taken and added to 
4.5 ml of quenching solution (at O °C, slushy-ice bath) and analysed by HPLC within 
24 h. Chemical stability was studied over 3-4 half-lives of PNT. All the PNT samples 
were protected from light during the study and experiments were performed in 
duplicate. 
pH-rate profile 
Buffer solutions (50 mM) of phosphate (pH 2.0 - 3.0 and 6.5 - 8.0), acetate (pH 
4.0 - 6.0) and borate (pH 9.0 - 9.3) were adjusted to constant ionic strength(µ= 0.15) 
with sodium chloride. The pH of the reaction mixtures was measured (Sartorius basic 
pH meter PB-11, Germany) at the beginning and end of data collection and no change 
in pH was observed. 
Buffer 
PNT (500 µg mr1) solutions in acetate (4.52 and 6.01), phosphate (pH 3.01, pH 
6.01, 7.15 and 8.04) and citrate buffers (pH 4.52) were prepared and compared at two 
buffer concentration (50 mM and 150 mM) with constant ionic strength (µ = 0.5) 
adjusted with sodium chloride at 30 ± 0.1 °C to investigate the catalytic effect of 




PNT (500 µg mr1) in buffers (50 mM) solutions of phosphate (pH 3.01) and 
borate (pH 9.01) buffer with varying ionic strength (µ = 0.05, 0.15 and 0.5) were 
investigated for the salt effect on the stability of PNT at 30 ± 0.1 °C. The modified 
Debye-Huckel equation (Eq. 3-2) recommended for solutions with higher values of 
ionic strength (µ = 0.5 ) was used (Carstensen, 1970): 
logkb =a+2QZ Z jµ 
a s • • A B • (1 + jµ) 
Eq. 3-2 
where kobs is the observed rate constant, a is the log of the rate constant at zero 
ionic strength, Q is a constant for the solvent at a given temperature (2Q = 1.026 at 
30 °C) (Carstensen, 1970) and ZA and ZB are the charges on reactants A and B 
respectively. A plot of log kobs versus -Vµ / (1 + -Vµ) was used to evaluate the effect of 
µ on the degradation rate of PNT. 
Temperature 
Solutions of PNT (500 µg mr1) were prepared in phosphate (pH 3.01 and 8.04) 
and acetate (pH 6.01) buffers (50 mM) and ionic strength (0.15). Degradation was 
observed at 30 ± 0.1 °C, 40 ± 0.1 °C and 50 ± 0.1 °C. The observed pseudo-first-order 
degradation rate constant (kobs) for each buffer/temperature condition was determined 
by nonlinear least squares regression. The energy of activation (Ea) for PNT 
degradation in each buffer was determined by nonlinear least squares regression using 
Eq. 3-3. 
-Ea 
kobs = A.e RT Eq. 3-3 
where R is the Universal Gas Constant (J K-1 mole-1) and T is the absolute 
temperature (K) and A the frequency factor (h-1). 
Cosolvent systems 
In preliminary studies with cosolvents reported in Chapter 2, PG:buffer (pH 4.5, 
1 M) (50:50 v/v) was found to be most promising for the stability of PNT (Jain et al., 
2009). Further studies on the stability of PNT (500 µg ml-1) were carried out in 
various PG:citrate buffer (50 mM) cosolvent systems (20:80, 40:60, and 60:40 v/v) at 
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pH 3.01, 4.52 and 6.01 at 30 ± 0.1 °C following a procedure similar to that for 
degradation kinetics studies (Section 3.3.2.4). 
/3- CD, HP-/3-CD and iodide solutions 
Supematants obtained from the solubility studies (Section 3.3.2.3) for ~-CD (16 
- 60 mM), HP- ~-CD (10-100 mM), KI (16-96 mM) were filtered (0.22 µm Millipore, 
USA) into 10 ml Erlenmeyer flasks and placed in a shaking water-bath (30 ± 0.1 °C) 
and PNT stability was determined following a procedure similar to that for 
degradation kinetics studies (Section 3 .3 .2.4 ). PNT stability was also determined in 
0.45-1.8 mM HP-~-CD at three different pH buffers (phosphate pH 3, acetate 4.5 and 
borate pH 9, 50 mM, µ = 0.15) at 30 °C following a procedure similar to that for 
degradation kinetics studies (Section 3.3.2.4). 
3.4. Results 
3.4.1. Ionisation constant (pKa) for PNT 
Determination of pKa is a challenge for rapidly degrading molecules like PNT. 
In this study, absorbances of the PNT solutions changed over 4 minutes, changes 
being more rapid at higher pH values. Based on these changes it is estimated that 5% 
degradation occurred at pH 8 indicating that extrapolation to time zero was necessary 
for the accurate determination of pKa. The pKa of PNT determined using Eq. 3-1 was 
8.40 ± 0.13 (mean± SD) consistent with earlier reports (Mamyzin injection technical 
monograph; Rasmussen, 1959; Ziv and Sulman, 1975; Ziv and Rasmussen, 1975). 
3.4.2. Solubility of PNT in cosolvent systems, cyclodextrins and iodide 
PG increased the solubility of PNT up to 3 times at a temperature of 3 0 °C 
(Table 3-1 ), the log solubility being linearly related to the volume fraction of PG in 
the PG:citrate buffer solvent systems (Figure 3-1 ). 
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Figure 3-1. Effect of PG content on the solubility of PNT in PG: citrate buffer (pH 4.5) 
mixed solvents at 30 °C. Data points are means (n = 2). 
The dielectric constants of the mixtures were calculated from the relation cmix = 
c:wfw + cpo/pa (Desai and Park, 2004), where s and fare the dielectric constant and 
volume fraction respectively, and the subscripts mix, w and PG refer to the mixed 
solvent, water (buffer) and PG, respectively. The relationship between log solubility 
and dielectric constant of the PG solutions is also linear as expected (Figure 3-2); 
however, it would be of interest see if this relationship holds for other solvents. 
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Figure 3-2. Effect of dielectric constant of PG: citrate buffer (pH 4.5) mixed solvents on 
the solubility of PNT at 30 °C. Data points are means (n = 2) 
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Table 3-1. Solubility of PNT in presence of cosolvent (PG), cyclodextrins (P-CD, HP-P-CD) and iodide (r) at 30 °C. Data are means (n=2) 
PG% Solubility of PNT P-CD Solubility of PNT HP-P-CD Solubility of r (mM) in Solubility of PNT 
(v/v) (mg mr1) (mM) (mg mr1) (mM) PNT (mg mr1) solution (mg mr1) 
5 8.9 0 8.9 0 8.9 16 8.9 
20 11.6 2 10.1 10 11.5 32 5.9 
40 18.8 4 10.8 20 13.3 48 4.6 
60 28.2 8 12.0 30 15.4 64 3.9 
--- --- 12 12.1 40 16.8 80 3.1 
--- --- 16 12.1 50 18.1 96 3.0 
--- --- 20 12.0 80 22.9 --- ---
--- --- 24 11.4 100 26.0 --- ---
--- --- 30 11.1 --- --- --- ---
--- --- 40 10.7 --- --- --- ---
--- --- 50 10.7 --- --- --- ---
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There was a small increase in solubility of PNT in presence of B-CD, however 
PNT solubility increases 3 times with increase in HP-B-CD concentrations (Table 3-
1 ). Phase solubility diagrams were constructed by calculating molar concentrations of 
PNT from the data (Table 3-1) obtained from the solubility studies versus B-CD 
(Figure 3-3) and HP- B-CD (Figure 3-4) and the complexation constants (Ku) were 
determined using Eq. 3-4 (Higuchiand Connors, 1965) 
K = Slope J-1 · Intercept (l - Slope) Eq. 3-4 
Phase solubility diagrams for B-CD showed a Bs type curve with an initial 
increase in PNT solubility followed by a plateau indicating a complex of limited 
solubility. The complexation constant determined from the initial linear portion of the 
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Figure 3-3. Phase solubility diagram for PNT in presence of (}-CD at 30 °C. Data points 
are means (n = 2) 
On the other hand an A1 type curve was observed in presence of HP-B-CD with 
a linear increase in solubility over the concentration range. The complexation constant 
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Figure 3-4. Phase solubility diagram for PNT in presence of HP-P-CD at 30 °C. Data 
points are means (n = 2) 
In contrast, the solubility of PNT decreased 3 times with an increase in r. When 
the data (Table 3-1) were plotted as the molar concentration of PNT (Mol wt 561) in 
solution versus the reciprocal of the iodide-ion concentration (Eq. 1-7), a linear curve 
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Figure 3-5. PNT solubility in presence of common ion r at 30 °C. Data points are means 




3.4.3. Chemical stability of PNT 
Degradation kinetics 
In addition to the PNT peak, BP and other degradation peaks were observed in 
the chromatograms but the other degradation peaks were not identified. Various 
kinetic models (first-order and zero-order) were fitted to the PNT-time data from each 
kinetic experiment by nonlinear regression using PRISM (Graph pad version 5.0) 
software and the best-fit model selected based on the Akaike's information criterion 
(AIC). On this basis the first-order model gave the best fit (Figure 3-6) indicating 
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Figure 3-6. Observed pseudo-first-order degradation kinetics of PNT and best-fit line in 
various buffer solutions (50 mM, µ = 0.15; PG= 5%) of different pH at 30 ± 0.1 °C. (v) 
pH 4.52 (+) pH 5.51 (.i.) pH 6.02 (•) pH 7.03 (•) pH 9.31. Data points are means (n = 2) 
Figure 3-7 and 3-8 show the degradation of PNT and subsequent formation of 
BP over time in acidic and alkaline pH at 30 °C respectively. It is apparent that: the 
sum of molar concentrations of PNT and BP is not constant, the amount of BP formed 
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Figure 3-7. Concentration versus time profiles of PNT and BP in buffer solutions (50 
mM, µ= 0.15; PG= 5%) at 30 ± 0.1 °C. Keys: PNT at(+) pH 3.01, (A) pH 4.02. BP at (0) 
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Figure 3-8. Concentration versus time profiles of PNT and its degradation product BP in 
buffer solutions (50 mM, µ= 0.15; PG= 5%) at 30 ± 0.1 °C. Keys: PNT at (..t..) pH 7.52, 
(+) pH 9.01, and BP at (M pH 7.52 and (0) pH 9.01. Data points are means (n = 2). 
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These facts and the presence of other degradation peaks indicate that PNT does 
not just degrade to BP and that the BP produced, also degrades (Scheme III), and the 
contributions of the degradation pathways are dependent on the pH of the solution. 
L






products Scheme III 
where kobs is the observed rate constant which is the sum of kPNTBP and kPNTDeg· 
Since only PNT and BP were quantified, it is possible the kPNTDeg represents several 
parallel degradation pathways of PNT. At each pH, data for PNT and BP were 
regressed simultaneously on time (Eq. 3-5 and 3-6) in order to estimate kPNTBP, kPNTDeg 
and kBPDeg· 
p = P, e (-(kPNTBP + kp,\"f'Deg )*t) 
0 
B = Boe-kBPDeg*t + kPNTBPPO [e-(kPNTBP +kPNI'Deg)*t -e-kBPD,g*t] 
( k BP Deg - k PNTBP - k PNTDeg ) 
Eq. 3-5 
Eq. 3-6 
where B and P represent BP and PNT concentrations at time (t), Bo and Po are 
the initial concentration of BP and PNT respectively. At pH 2, 3 and 4 where no or 
very little BP was found (Figure 3-7), the model (Eq. 3-6) was collapsed to fit for 
kPNTDeg only. At pH 7.5, 8, 9 (Figure 3-8) and 9.3 where PNT degraded mainly to BP, 
the model was fitted to calculate kPNTBP and kBPDeg, At intermediate pH (4.5 - 7.0) 
degradation of PNT was described by all reactions according to Scheme III. The best-
fit model was selected based on AIC. Table 3-2 shows the rate constants involved in 
various degradation reactions of PNT according to Scheme III. 
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Table 3-2. Rate constants for various reactions in the degradation of PNT in buffer solutions (50 mM, µ = 0.15; PG= 5%) of different pH at 30 °C. 
Data are best-fit estimates ± SE from the fit. 
pH kPNTBP (10-3 h-1) kPNTDeg (10-3 h-1) kBPDeg (10-3 h-1) R2 
2.03 a 868 ± 3 a 0.99 
3.01 a 127 ± 3 a 0.99 
4.01 a 22.8 ± 0.7 a 0.99 
4.52 4.8 ± 3.4 11.9 ± 3.4 53.2 ± 4.5 0.99 
5.01 12.5 ± 1.2 9.5 ± 1.3 15.8 ± 2.6 0.99 
5.51 37± 2 5.8 ±2.5 13.9 ± 2.1 0.98 
6.02 85 ± 3 4.1 ± 3.0 11.3 ± 2.7 0.99 
6.51 223 ± 10 207 ± 12 5.6± 3.0 0.98 
7.03 693 ± 59 202 ± 74 98 ± 53 0.95 
7.52 1173 ± 240 a 2207 ± 453 0.95 
8.04 1120 ± 290 a 1833 ± 430 0.98 
9.01 6328 ± 650 a 14780 ± 1600 0.91 
9.31 9800 ± 850 a 30280 ± 4000 0.93 
a = This degradation pathway not fitted at this pH 
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pH-rate profile 
The overall fitted pH- rate profile (not corrected for buffer catalytic effects) 
generated from the sum of the rate constants (kPNTBP + kPNTDeg) agreed closely with the 
experimental data (Figure 3-9) with a V- shaped curve in the pH range of 2 - 7.0 and 
an inflection in the pH range 7.5-9.3 which was consistent with the pKa of PNT of 8.4. 
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Figure 3-9. Overall pH rate profile of PNT in various buffer solutions (0.05 M, µ = 0.15; 
PG = 5%) at 30 ± 0.1 °C. Data points are means (n = 2). The solid line is the calculated 
line using k = kPNTBP + kPNTDeg in the pH range 2 - 9.3. 
Buffer and ionic strength effects 
The chemical stability of PNT was found to be subject to general acid-base 
catalysis by phosphate buffer (Figure 3-10). The rate constants (kPNTBP + kPNTDeg = 
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Figure 3-10. Effect of buffer concentration on the pseudo-first-order rate constants of 
the degradation of PNT at fixed pH values (30 ± 0.1 °C, µ = 0.5) ( •) Phosphate pH 3.01 
(•) Phosphate pH 7.15 (4.) Phosphate pH 8.04 (+) Phosphate pH 6.01 (V) Acetate pH 
6.01 (o)Acetate pH 4.52, (0) Citrate pH 4.52 (symbols for Acetate pH 4.5 and Citrate pH 
4.52 are overlapped in the Figure). Data points are means (n = 2). 
Phosphate buffers (pH 6 - 8) had a catalytic effect on the rate of degradation of 
PNT. Phosphate buffers at pH 6.0 had higher rate constants than acetate at pH 6.0, 
however only a slight catalysis was observed in phosphate (pH 3.0) citrate (pH 4.5) 
and acetate buffer (pH 4.5 and 6.0) on the rate of degradation of PNT. These results 
suggest that although the pH rate profile (Figure 3-9) was not corrected for buffer 
concentration, the lines in Figure 3-10 are flat and extrapolating them back to zero 
buffer concentration indicates that it would make little difference in the estimated 
observed rate constants in the absence of buffer. 
For ionic strength effects a widely applied (Carstensen, 1970; Tu et al., 1990; 
Wang and Yeh, 1993; Okamoto et al., 1997) approach as described in Eq. 3-2 was 
used. Figure 3-11 shows the salt effect on the degradation of PNT in pH 3.01 and 9.01 


















Figure 3-11. Salt effect on degradation of PNT at pH(•) pH 3.01 and (11) pH 9.01 at 30 ± 
0.1 °C. Data points are means (n = 2). 
Increasing the ionic strength caused a small but significant (p::::; 0.05) increase 
in degradation rate at pH 3.01. The slope of the regression line was not significantly 
different (p ~ 0.05) from the theoretical slope of+ 1.026 expected for the hydronium 
ion catalysed degradation of the protonated cationic form of PNT. At pH 9.01, where 
the predominant reaction is likely to be the hydroxyl ion catalysed hydrolysis of the 
non-ionised form of PNT, the salt effect was negligible as expected. 
Temperature effects 
The temperature dependence of PNT degradation at phosphate (pH 3.01 and 
8.04) and acetate (6.01) buffer solutions (50 mM, µ= 0.15) was studied in the 
temperature range 30 - 50 °C. Arrhenius plots (Figure 3-12) were linear (R2 ~ 0.99) 
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Figure 3-12. Arrhenius plots, showing effect of temperature on the reaction rates of 
hydrolysis of PNT at various pH. (A) pH 3.01 (•) pH 6.01 (•) 8.04. Data points are 
means (n = 2). 
Solvent effects and stability in solution 
The chemical stability of PNT in different cosolvent systems followed pseudo-
first-order kinetics (R2 2: 0.99). The stability of PNT in solution in the cosolvent 
systems is shown in Table 3-3. The degradation rate constant of PNT in the PG:citrate 
buffer system decreased as the content of PG increased (Table 3-3) with the half-life 
(t112) for PNT at pH 4.5 in 60:40 PG:citrate buffer cosolvent system being 105 h ( 4.4 




Table 3-3. Stability of PNT in PG: citrate buffer (50 mM) solvent systems at different 
pH and 30 °C. Data for kobs are± SE. 
pH3.01 pH 4.52 pH 6.01 
PG~!:~fer kobs (10-3 h-1) t112 (h) kobs (10-3 h-1) t112 (h) kobs (10-3 h-1) t112 (h) 
5:95 a a 16.0 ± 0.3 43 a a 
20:80 170 ± 6 4 10.2 ± 0.4 68 51 ± 1 14 
40:60 110± 5 6 9.4±0.1 74 46± 1 15 
60:40 81 ± 1 9 6.6 ± 0.4 105 43 ± 1 16 
a = PNT stability in this cosolvent system was not determined at this pH 
Stability of PNT in presence of /J-CD, HP-f]-CD and iodide 
The chemical stability of PNT in presence of P-CD, HP-P-CD and r, followed 
pseudo-first-order kinetics. There was no significant change in the degradation rate of 
PNT in the presence of P-CD, HP-P-CD (Table 3-4). However the degradation of 
PNT increased as the content of r increased (Table 3-4) with the half-life (t112) for 
PNT at pH 4.5 in presence of 96 mM r being 26 h (1.1 days) compared with 43 h (1.8 
days) in pH 4.5 buffer alone. 
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Table 3-4. Stability of PNT in presence of cyclodextrins and iodide in solutions at 30 °C (pH 4.5) 
P-CD (mM) kobs {10-3 h-1} ± SE HP-P-CD kobs {10-3 h-1} ± SE Total r kobs {10-3 h-1} ± SE 
(mM) in solution (mM) 
0 15.8 ± 0.8 0 15.8 ± 0.8 16 15.8 ± 0.8 
16 16.5 ± 0.7 10 19.4 ± 0.8 32 17.2 ± 0.5 
20 16.5 ± 0.4 20 18.1 ± 0.5 48 18.9 ± 0.7 
24 18.3 ± 0.9 30 19.0 ± 0.6 64 22.7 ± 0.3 
30 19.6 ± 0.5 40 16.5 ± 0.8 80 25.5 ± 0.6 
40 17.4±0.4 50 17.0±0.5 96 27.2 ± 1.2 
50 16.3 ± 0.6 80 15.9 ± 0.5 
100 
15.4 ± 0.5 
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The influence of pH on the degradation of PNT in aqueous HP- ~-CD 
buffer solutions, investigated at pH 3, 4.5 and 9 (Figure 3-13) shows that there 
is very little change in pseudo-first-order rate constants of PNT with increase in 
HP-~-CD at each pH. 
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Figure 3-13. Effect of pH and different concentrations of HP-J}-CD on the stability of 
PNT in solutions at 30 °C. Data points are means (n = 2) and the lines are best-fit 
regression lines. 
3.5. Discussion 
The results allow assessment of the potential of developing a novel ready-to-use 
aqueous based PNT formulation. The degradation of PNT in aqueous solutions 
followed pseudo-first-order kinetics over the pH range 2 - 9.3 and a V- shaped pH rate 
profile was observed. The impact of the investigated buffer concentration and ionic 
strength on PNT stability was small but at pH 6 the type of buffer salt had some 
influence with solutions in acetate being about twice as stable as those in phosphate at 
the higher buffer concentration (Figure 3-10). However the major effects on stability 
were pH, cosolvent (PG), common ion and temperature; so the following discussion 
focuses on these factors. Initially, the PNT degradation kinetics will be discussed to 
emphasise the importance of using the developed stability-indicating HPLC assay for 
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PNT (Chapter 2) (Jain et al., 2009) for investigating the chemical stability of the 
prodrug itself. 
In the acidic region (pH 2.0 - 4.0) degradation of PNT was not accompanied by 
an equivalent detectable formation of BP, in fact BP concentrations were very low 
(Figure 3-7). This indicates that PNT may be hydrolysing to products other than BP 
(e.g. cleavage of the ~-lactam ring of PNT) or may be hydrolysing to BP which then 
rapidly, sequentially, hydrolyses, or degradation may be a combination of these 
pathways. The literature reports degradation rates of BP at pH 4 for various 
temperatures (Lu et al., 2008) from which a degradation rate of BP 143 x 10-3 h-1 for 
30 DC was calculated. Taking this rate constant into consideration and assuming that 
PNT only degrades to BP then calculations suggests that BP concentrations should 
have been 0.012 mM; however no BP was observed in this study at pH 4. This 
suggests that at low pH (pH 2 - 4) PNT degradation to BP is minimal and it mainly 
degrades by alternative pathways. 
In the intermediate region (pH 4.0 - 7.5) degradation of PNT involves all the 
reactions according to Scheme III so that PNT is degraded to BP and other 
degradation products. The BP so formed was estimated to have a t112 of 6.2 days at pH 
6.5 which is somewhat shorter than the 38 days reported for BP at pH 6.75 at 30 DC ( 
Connors et al., 1986a). However, the present study was aimed at assessing the 
stability of PNT, not BP, and therefore experimental conditions were not optimised 
for BP stability analysis. In order to determine the stability of the BP with more 
precision, the experiments would need to be conducted for a longer time period. 
In the alkaline region (pH 7.5 - 9.3) a high concentration of BP was detected 
indicating that the major reaction involves cleavage of the ester group probably due to 
hydroxide ion attack (Figure 3-8). The ionic strength results support a reaction 
between OH- and an uncharged species (i.e. neutral PNT). BP also subsequently 
degraded. The reported degradation rate (kDbs) of BP at pH 9.0 is 8.6 x 10-3 h-1 (25 DC) 
and 30.4 x 10-3 h-1 (35 DC) respectively (Lu et al., 2008) which are much slower than 
that estimated here at 30 DC. 
The results from this study suggests that PNT, both in protonated (PH+) and 
nonprotonated form (P), can be degraded to BP ( ester hydrolysis) or other degradation 
products W-lactam ring opening) as shown in Scheme III which can further degrade 
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following multiple pathways. The partitioning of the observed rate constants between 
ester hydrolysis and ~-lactam ring opening suggested that PNT does degrade with 
alternative degradation pathways, in particular at low pH. In addition, these studies 
suggest that since BP degrades during the kinetic study, the stability assessments of 
the early literature which were based on spectrophotometric or biological assays of 
BP underestimated the degradation of PNT. Dinsmore (1952) used change in partition 
coefficient or change in solubility together with a spectrophotometric assay to 
estimate stability at 25 °C. At pH 3 - 4 (100 mM buffer) they reported about 10 % 
degradation over a period of 2 - 2.5 h; however, the present study indicates 18 % 
degradation of PNT over a period of 2 - 3 hand degradation of BP. Hallas-Moller, et 
al., (1952) reported 39% degradation of PNT in 22 hat pH 5 and 37 °C whereas the 
present study estimates 68% degradation in this time. Consequently, the development 
of a ready-to-use aqueous based PNT formulation must be assessed on the prodrug 
itself. 
The lower chemical stability of PNT in the alkaline region (pH 7.5 - 9.3) and 
the shape of the pH-rate profile are consistent with specific hydroxyl ion catalysis of 
the ester. The pH-rate profile exhibited an inflection point in this pH region, that is, 
around the pKa of PNT of 8.4. Inflections are frequently observed near the pKa of 
substrate, when the reactivity of protonated and nonprotonated forms are sufficiently 
different. Similar profiles have been reported for ~-lactam antibiotics and reflect 
changes in the mechanisms of degradation with changes in pH (Yamana and Tsuji, 
1976; Tsuji et al., 1981; Berge et al., 1983). The pH rate profile for the pH range 2 -
4 shows that the deviation from theoretical slope of -1 is insignificant (p 2: 0.05) and 
consistent with specific acid catalysis of the conjugate acid form of PNT in this pH 
range and this was supported by the positive ionic strength effect at pH 3. The slope 
of+ 1 for the pH range 5 - 7.5 suggests specific hydroxyl ion catalysis of the conjugate 
acid form of PNT in this pH range. The maximum PNT stability was found at pH 
around 4.5. 
The addition of PG improved the stability of PNT, this is possibly because 
decreasing the polarity of the reaction medium favours the uncharged species, and 
thereby stabilizes a solute against any reaction that produces charged products or 
proceeds through a charged transition state (Zhao and Yalkowsky, 2001). 
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Cyclodextrins have been used in imparting stability to chemically unstable 
drugs in aqueous solutions. Loftsson (1989) showed a 19-fold increase in the aqueous 
stability of chlorarnbucil and about 5-fold increase in that of melphalan by forming an 
inclusion complex with 2-HP-P-CD at neutral pH and 40 °C and 60 °C respectively, 
and suggested that both drugs degrade at much slower rate within the 2- HP-P-CD 
cavity than outside in the aqueous solution. Backensfeld et al., (1990) showed the 
effect of various cyclodextrins on the stability of indomethacin. There was a 3-6 fold 
increase in stability of indomethacin in aqueous solutions of P-CD and HP-P-CD. 
In this study, the presence of P-CD, HP-P-CD did not significantly influence the 
stability of PNT in solution (Table 3-4). The percentages of PNT complexed with 
different concentrations of P-CD and HP-P-CD were :S 10 % for both P-CD and HP-P-
CD because of the relatively low complexation constants (K1:1). Thus even if the PNT 
in the complexes is stable, there is insufficient PNT complexed to make a difference 
in the overall stability. Also, the degradation rate of PNT was not influenced with 
increase in the concentration of HP-P-CD at different pH (Figure 3-13). Similar 
results have been reported elsewhere for chlorambucil (Ehrsson et al., 1980) and 
melphalan (Stout and Riley, 1985). 
The common ion effect has been utilised to decrease the solubility of drugs and 
hence increase the drug stability in an aqueous environment (Serajuddin et al., 1987; 
Serajuddin 2007; Zaiu1ou et al., 2007). Serajuddin et al., (1987) showed the effect of 
common ion on the solubility of the sodium salt of an acidic drug in aqueous media. 
The solubility of acidic drug decreased in presence of sodium chloride. As 
anticipated, in this study the common ion r decreased the solubility of PNT. If PNT in 
the solid state is stable, and only that in solution degrades, this result would suggest 
that iodide might be useful in stabilising a PNT product by increasing the fraction of 
PNT in suspension and reducing the fraction in solution. However, the iodide 
promoted the degradation of PNT in solution (Table 3-4) and this would counteract 
the advantage of the lowered solubility. 
The above discussion of the chemical stability of PNT was focused only on 
PNT solutions. To further assess the potential development of a ready-to-use aqueous 
based PNT suspension formulation, chemical stabilities of PNT in suspensions 
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assummg only PNT in solution degrades whereas that in solid is stable. For a 
suspension the shelf-life (t90) is: 
fgo = 0.1 X Co 
ko 
Eq. 3-7 
where C0 is the initial PNT concentration in the suspension and k0 is the 
apparent zero-order rate constant. The zero-order rate constant is calculated from the 
solubility data using Eq. 3-8 (Martin and Bushmante, 1993): 
k O = k obJPNTJs Eq. 3-8 
where kobs is the apparent first-order rate constant; [PNT]s is the solubility of 
PNT in the relevant cosolvent system, ~-CD, HP-~-CD or common ion r (Table 3-1). 
It is to be noted that the solubility of PNT in the cosolvents may have not reached 
equilibrium within 2 h of the analysis; however, this was a compromise between 
approach to equilibrium and limiting degradation of PNT. 
In presence of cosolvent PG, the shelf-life was estimated for aqueous based 
PNT suspensions containing up to 50% drug content and up to 60% cosolvent content 
for a temperature range 5 °C to 30 °C and pH 4.5. The required first-order rate 
constants kobs for pH 4.5 at temperatures 5 °C and 20 °C were estimated by applying 
the following procedure and assumptions: A polynomial was fitted to the V-shape pH-
rate profile for 30 °C. The same polynomial, except for the intercept term, was fitted 
to the limited pH-rate data (pH 3.01, 6.01 and 8.04) for 40 °C and for 50 °C. The 
change in the intercept, corresponding to a vertical dislocation seems an acceptable 
assumption as Connors, et al., (1986a) have reported a similar trend of retaining the 
shape of pH-rate profiles at different temperatures with a dislocation in vertical 
direction for other drugs e.g. BP and indomethacin (Connors et al., 1986a, b). 
Consequently, rate constants kobs for 40 °C and 50 °Cat pH 4.5 were determined and 
activation energy and intercept from the Arrhenius equation (Eq. 3-3) were calculated. 
Finally, rate constants for 5 °C and 20 °C were extrapolated from the Arrhenius plot 
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Figure 3-14. Estimated shelf-life for PNT suspensions with different% PG and 
temperatures at pH 4.5. 
Figure 3-14 shows the shelf-life over PNT concentration in suspensions for pH 
4.5 depending on cosolvent PG content and temperature. With increasing PNT 
concentration in PG colsovent mixtures the shelf-life increases linearly from about 0.3 
days (5% PG) and 0.7 days (60% PG) in solution to about 14 days (5% PG) and 11 
days (60% PG) in a 50% PNT suspension. Although PG improves the stability of 
PNT in solution, its addition to a suspension formulation does not result in enhanced 
stability, at least at pH 4.5, of the formulation since PG increases the solubility of 
PNT (Table 3-1). Consequently, the zero-order rate constants increase and thus a 
decrease in the overall stability of PNT in suspension results. The overall impact of 
PG cosolvent content at 30 °C on the stability of PNT suspension is insufficient for 
product stability if ICH guidelines (ICH, 2003) would be applied for intermediate 
conditions (30 °C, 65% RH). On the other hand the shelf-life increases with 
decreasing temperature and increasing PNT concentration in suspension (5% PG). A 
best case scenario was calculated for a 50% PNT suspension in acetate/ citrate buffer 
(pH 4.5, 50 mM) containing 5% PG for a temperature of 5 °C. A shelf-life (t90) of 
about 164 days or 5.5 months could be achieved theoretically which is still too short 
for achieving an acceptable shelf-life of one year for this kind of product. 
In the presence of HP-~-CD, no significant change in the half-life of PNT was 
observed in solution, however with increasing concentration of HP-~-CD, the 
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solubility of PNT increased linearly and resulted in a decrease in estimated shelf-life 
in suspension (Table 3-5). There was little influence of P-CD on the solution and 
suspension stability (Table 3-5) of PNT. The effect of iodide was observed 
predominantly on the solubility of PNT and as expected from Eq. 3-1 the solubility 
decreases with increase in concentration of iodide. 
Table 3-5. Calculated shelf-lives (t90) of PNT in suspensions in the presence of P-CD, HP-
P-CD and common ion r (pH 4.5, 30 °C). 
t90 (days) in HP-1}-CD t90 (days) in 
r(mM) 
t90 (days) in P-CD (mM) 
(333 mg mr1) (mM) (333 mg mr1) 
in 




0 10.3 0 10.3 16 10.3 
16 7.3 10 6.5 32 14.3 
20 7.3 20 6.0 48 16.4 
24 6.9 30 5.0 64 16.2 
30 6.7 40 5.3 80 17.4 
40 7.8 50 4.7 96 18.0 
50 8.4 80 4.0 
100 3.6 
Similar to cosolvents, the shelf-life was estimated for an aqueous based PNT 
suspension product containing up to 50% drug content at 30 °C and pH 4.5 in 
presence of r (96 mM). Increase in iodide resulted in an increase in the shelf-life 
stability of PNT in suspension (Figure 3-15). The estimated shelf-life was increased 
from 10 days (without any additional r other than that due to PNT HI) to 18 days for 
a 33 % suspension and from 15 days to 26 days for a 50 % suspension (which would 
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Figure 3-15. Estimated shelf-life for PNT suspensions with different concentration of r 
at pH 4.5, 30 °C. 
However, the overall impact of iodide content at 30 °Con the stability of PNT 
suspension is insufficient for product stability ifICH guidelines (ICH, 2003) would be 
applied for intermediate storage conditions (30 °C) and this increase in stability is not 
sufficient to prepare a suitable ready-to-use formulation of PNT. 
3.6. Conclusions 
Treating bovine mastitis with PNT is a common practice but the current 
formulation requires a reconstitution step which is inconvenient on a farm. There is a 
need for a chemically stable ready-to-use formulation. Applying the stability-
indicating HPLC assay for PNT in aqueous solutions gave important insights into 
PNT degradation pathways depending on the pH. Although this was not the focus of 
this study, important results about the chemical stability and its consequences for 
formulation development were obtained, such as, it is essential to analyse the prodrug 
itself, otherwise PNT chemical degradation can be significantly underestimated. It 
was demonstrated that PNT does not only degrade to BP but also follows other 
degradation pathways depending on pH but the other pathways were not investigated 





Although the chemical stability of PNT in solution significantly depends on the 
pH, on buffer type, buffer concentration, ionic strength and cosolvent, shelf-life of an 
optimistic 50% PNT aqueous suspension does not exceed 14 and 26 days for PG and 
r respectively at 30 °C even at pH 4.5. The biggest impact on improved chemical 
stability of aqueous-based PNT suspensions would be achieved for pH 4.5 by 
reducing the temperature to 5 °C. This would lead to a calculated shelf-life of 5.5 
months for a 50% PNT suspension in PG (5%) but with the disadvantage of keeping 
the ready-to-use product refrigerated on a farm. Clearly, this is insufficient and 
inconvenient to introduce such a ready-to-use PNT suspension into the market. 
Consequently, it seems appropriate to avoid aqueous vehicles or aqueous/ cosolvent 
vehicles and therefore the next chapter aimed at removing the aqueous component and 
investigating the stability of PNT in oily systems. 
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Chapter 4. Chemical stability studies 





Oily vehicles are potentially useful in the formulation of drugs which are 
susceptible to hydrolysis. Since, the degradation of PNT in aqueous vehicles is now 
better understood (Chapter 3) (Jain et al., 2011), it is a useful drug to probe 
mechanisms of degradation of water-sensitive drugs in oily vehicles. However, unlike 
the case for aqueous media in which the variables which affect stability are well 
established (i.e. pH, buffer composition, ionic strength, etc.) (Chapter 3) the factors 
such as drug solubility in the oil, moisture content of the oil and chemical composition 
of the oil itself, which might potentially affect the chemical stability of drugs in oil 
have not been carefully and systematically studied and reported. 
Oily vehicles such as vegetable oils ( e.g. sesame, soybean, arachis, and 
sunflower oils), mineral oils (liquid paraffin), synthetic medium chain triglycerides 
(Miglyol®) and ethyl oleate have been used in parenteral formulations as i.m. 
injections (Zuidema et al., 1994; Knepp et al., 1998). Theoretically, oily vehicles 
should protect a drug from aqueous chemical degradation; however, oily vehicles 
sometimes themselves result in drug instability. Due to their composition and 
chemical nature, some oils are prone to hydrolytic and oxidative degradation in the 
presence of light, heat and moisture resulting in formation of peroxides and 
degradation products (Zuidema et al., 1994; Cable, 2009; Sheski, 2009) which can 
affect the stability of drugs formulated in these vehicles. 
Also, oils do contain low levels of moisture (0.01 - 0.1 % ) (Sheski, 2009; 
Cable, 2009; Gupta and Singh, 2009; Sheng, 2009) which may affect the stability of 
drugs such as PNT, which are susceptible to hydrolysis, when formulated in these 
vehicles. Therefore it is necessary to investigate the effect of moisture, already present 
in these oils or taken up from the environment during manufacture or storage, on the 
stability of drugs. 
To date there are no reports on the chemical stability of PNT in oily vehicles 
and very few reports on the stability of other drugs in oily solutions or suspensions. 
One such study on an ophthalmic solution of diclofenac in different oils reports 2: 
90% stability in sunflower, arachis, safflower, sesame and soybean oil under 
accelerated (40 °C, 70 % RH, 6 months) and room temperature storage (12 months) 






mustard and olive oils was also reported. Guyon (1992) reported about 6% 
degradation occurred for cloxacillin in an oily suspension formulation after 3 years 
storage at room temperature. 
The oils light liquid paraffin (LP), Miglyol 812 (MIG), ethyl oleate (EO) and 
sunflower oil (SO) used in this study were selected based on composition, viscosity, 
moisture content and their i.m application. These oils are generally regarded as safe 
(GRAS) and included in Food and Drug Administration (FDA) inactive ingredients 
guide. These oils have different chemical composition, viscosity and moisture content 
(Table 4-1). 
Table 4-1. Chemical composition, moisture content and viscosity of different oils 









Mixture of saturated 
hydrocarbons (C14-C1s) 
Mixture of triglycerides of 
saturated fatty acids (C6-Cs), 
mainly of caprylic acid (50-
80%) and of capric acid (20-
50% 2 
Oleic acid (60%)(C20), ethyl 
ester, 
Mixture of triglycerides (Cw 
C1s) of linoleic acid ( 48-
74% ), oleic acid (14-40%), 
palmitic acid ( 4-9% ), stearic 

























4.2. Chapter aims 
The aim of this study was to determine the chemical stability of PNT in 
different oils and to investigate some of the mechanisms of degradation in these oils. 
Consequently, additional studies of (1) PNT stability in the solid state under different 
humidity conditions (2) the solubility of PNT in different oils and (3) the chemical 
stability of PNT in solutions and suspensions prepared in oils of different 
compositions and moisture contents were carried out. 
4.3. Materials and methods 
4.3.1. Materials 
PNT (particle size: D90 :S 25 µm, LA 950, Horiba particle size analyser, USA) 
and BP were the same as described in Chapter 2. Sunflower oil (Ph Eur grade) was 
purchased from Sigma-Aldrich (USA), ethyl oleate (Ph Eur grade) was purchased 
from Sigma-Aldrich (UK), Miglyol® 812 (medium chain triglyceride, MCT) (Ph. Eur 
grade) and light liquid paraffin (BP grade) were obtained from Midwest 
Pharmaceutical Ltd (New Zealand). Milli-Q water (Millipore Corporation, Bedford, 
MA, USA) was used for mobile phase and sample preparations. All other chemicals 
and solvents were analytical grade (BDH Chemicals Ltd, England and Ajax Finechem 
New Zealand). 
4.3.2. Methods 
4.3.2.1. HPLC instrumentation and chromatographic conditions 
HPLC instrumentation and chromatographic conditions were the same as 
described in Chapter 2 (Section 2.3.2.2). Calibration curves were constructed for each 
sampling day and PNT and BP concentrations were calculated. 
Interference of the oils with the HPLC assay of PNT 
The interference of the oils with the HPLC assay of PNT was determined by 
following procedure. Two sets of screw capped glass tubes were used. One set 











consisted of PNT (200 µg mr1) in quenching solution (5 ml) plus 0.1 ml of LP or 
MIG or EO or SO. Tubes were vortexed (vortex reagent mixer, Sentra ST19, 
Australia) (5 min), sonicated in an ultrasonic water-bath (Sonorex RK 100 H, 
Germany) (5 min) and end-over-end rotated for 30 min, followed by centrifugation in 
an Eppendorf centrifuge (Model 5810 R, Germany) for 2500 rpm for 10 min. 
Duplicate samples (0.25 ml) were withdrawn using a 1 ml syringe fitted with a needle 
from the bottom aqueous layer and appropriately diluted with quenching solution for 
the analysis of PNT by HPLC. 
4.3.2.2. Volumetric Karl-Fischer (KF) titration 
The moisture contents of pure oils, PNT suspensions in oils and PNT powder 
were determined by volumetric KF titration method using a Metrohm 736 GP Titrino 
Apparatus (Metrohm, Switzerland) with detection limit of 0.01 % moisture content. 
The KF titration was performed by automatic titration and by means of a two-step 
chemical reaction where iodine reacts with water in the presence of sulphur dioxide 
(Eq. 4-1 ). The parameter measured in the KF method is the amount of iodine reduced 
in the second reaction step (Thomasow, 1972; Reh et al., 2004). 
CH pH+ S0 2 + RN B [RNH ]S0 3CH 3 +Hp+ 12 + [RNH ]S0 3CH 3 + 2RN ~ 
[RNH ]SO 4CH 3 + 2[RNH ]I Eq. 4-1 
where RN (primary amine) represent Karl-Fischer reagent. Following 
calibration with water, about 0.5 g or 1 g (accurately weighed) of pure oil or PNT oil 
suspension or PNT powder was analysed for moisture content at room temperature 
(23 °C) with CombiTitrant 5 (Merck, Germany) as reagent and Apura solvent oils and 
fats (Merck, Germany) for EO, SO and MIG and Combisolvent oil solvent (Merck, 
Germany) for LP as the solvents. The analysis was performed in triplicate and the 
results averaged. In the preliminary studies, pure oils were stored in large open 
petridishes in thin layer and the moisture contents were determined before and after 
storage (14 days) at 96.5% relative humidity (RH) at 30 °C. 
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4.3.2.3. Stability of PNT in oily suspensions 
LP, MIG, EO and SO were dried in a vacuum oven (at 400 mbar) at 50 °C for 7 
days and moisture content was measured by KF titration method. Suspensions of PNT 
( of known moisture content) in each of the oils were prepared in duplicate by adding 
300 mg g·1 of PNT in oil (5g) in crimp capped glass vials. These suspensions were 
then mixed thoroughly by sonication in an ultrasonic water-bath for 5 min and 
vortexed for 5 min and mounted vertically in a shaking water bath (100 opm), that 
kept the solids dispersed throughout the oil, in the dark at 30 ± 0.1 °C according to 
ICH, (2003) for intermediate storage conditions. At appropriate times, 0.1 g of the 
continuously mixed oily suspension was taken using a warm pipette, and added to 4.9 
g of quenching solution (at O °C, slushy-ice bath). These diluted samples were 
sonicated (5 min), vortexed (5 min) and end-over-end rotated (50 rpm) for 30 min 
followed by centrifugation at 2500 rpm for 5 min. Duplicate samples (0.1 ml) were 
withdrawn using a syringe fitted with a needle from the bottom aqueous layer and 
appropriately diluted with quenching solution for the analysis of PNT by HPLC. 
4.3.2.4. Effect of moisture on the stability of PNT in solid state 
A PNT powder sample (200 mg) was placed in thin layer in each of several 
open glass petridishes in closed humidity chambers (25%, 53%, 75% and 96.5% RH) 
containing saturated salt solutions (Rockland, 1960) at 30 °C. The height and surface 
area of the powder bed was 0.15 cm and 27 cm2 respectively. At various times (0, 4, 7 
and 30 days) duplicate samples of PNT from each RH chamber were taken for 
analysis of moisture content (Karl Fischer) and PNT. For PNT analysis, stock 
solutions were prepared (1 mg mr1) in quenching solution. Working solutions of 50 
µg mr1 were prepared in quenching solutions from the stock solution and measured 
for concentration of PNT by the HPLC assay. The PNT content before storage (at 
time 0) was also determined as control. Moisture contents of powders were measured 
using KF titration method at each time point. 
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4.3.2.5. Determination of solubility of PNT in oils 
The solubility of PNT in LP, MIG, EO and SO was determined at 30 °C by 
adding an excess of PNT (~15 mg mr1) to 4 ml of each oil in screw capped glass 
tubes in duplicate. To achieve uniform mixing, glass tubes were subjected to end-
over-end rotation (50 rpm) at 30 °C. After 24 h, samples were centrifuged at 2500 rpm 
for 30 min. The supematants were collected using a warm (30 °C) syringe to avoid 
precipitation and filtered using warm (30 °C) filters (0.45 µm Nylon filters, Millipore, 
USA). An aliquot (0.1 g) of the filtrate was then diluted with 4.9 g quenching solution 
(at O °C, slushy-ice bath). These diluted samples were treated as described above for 
the analysis PNT and BP by HPLC. All the PNT samples were protected from light 
during the study and experiments were performed in duplicate. 
4.3.2.6. Stability of PNT in oily solutions 
Supematants obtained from the solubility studies (Section 4.3.2.5, after 24 h) 
were filtered using warm filters (0.45 µm Nylon filters, Millipore, USA) and placed in 
10 ml crimp capped vials in a shaking water bath (30 ± 0.1 °C, 100 opm) to study the 
stability of PNT in solution. At appropriate times, samples (0.1 g) were taken and 
added to 4.9 g of quenching solution (at O °C, slushy-ice bath). These diluted samples 
were treated as described above for the analysis of PNT and BP by HPLC. All the 
PNT samples were protected from light during the study and experiments were 
performed in duplicate. 
4.3.2. 7. Stability of PNT in suspension in EO of differing moisture contents 
The stability of PNT was determined in suspensions (300 mg t 1) prepared in (a) 
EO dried in a vacuum oven (at 400 mbar) at 50 °C for 7 days (moisture content :S 0.03 
%) and (b) EO kept at RH 96.5% at 30 °C for 7 days (moisture content = 0.7%). 
Moisture content was measured using KF titration. These suspensions were then 
mixed thoroughly by sonication in an ultrasonic water-bath for 5 min and vortexed for 
5 min and mounted vertically in a shaking water bath (100 opm), that kept the solids 
dispersed throughout the oil, in the dark at 30 ± 0.1 °C according to ICH (2003) for 
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intermediate storage conditions. At appropriate times, 0.1 g of the continuously mixed 
oily suspension was taken using a warm pipette, and added to 4.9 g of quenching 
solution (at O °C, slushy-ice bath). These diluted samples were treated as described 
above for the analysis PNT and BP by HPLC. All the PNT samples were protected 
from light during the study and experiments were performed in duplicate. 
4.4. Results 
The oils did not interfere with the HPLC analysis of PNT and the percentage 
recoveries(± SD) of PNT in presence of LP, MIG, EO and SO were 99.8 ± 2.1, 101.2 
± 1.3, 99.57 ± 2.0 and 100.2 ± 0.79 respectively. 
4.4.1. Stability of PNT in oily suspensions 
PNT stability (% drug remaining) in oily suspensions after 105 days at 30 °C 
was in the order LP (96.2%) > MIG (95.4%) > EO (94.1 %) > SO (86%) (Figure 4-1). 
The degradation profile of PNT showed some similarity in LP, MIG and EO with 
degradation occurring over the first few days then remaining stable thereafter. In SO 
however, an initial 5% loss in 24 h was followed by a linear decline in content of PNT 
over time. There were no degradation peaks in any of the chromatograms for the LP, 
MIG and EO samples; however, the SO samples (after 60 days) showed peaks 
corresponding to BP. The concentrations of BP were determined by dividing molar 
concentration of BP at the time of analysis by molar concentration of PNT at time (t = 
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Figure 4-1. Stability of PNT in various oily suspensions at 30 °C. Data points are means 
(n=2) 
A weak correlation (r = 0.62) (Figure 4-2) was observed between the percentage 
of PNT remaining and solubility of PNT in oil (see Section 4.4.3 below). From Eq. 3-
8 (Chapter 3), if it is the drug in solution that is degrading, zero order kinetics might 
be expected. However, the degradation of PNT in oil suspensions did not follow zero 
or first order kinetics. 
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Figure 4-2. Correlation between PNT remaining (%) in oil suspensions and PNT 
solubility in oils. Data points are means (n =2) 
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Moisture contents of the oily PNT suspensions in LP, MIG, EO and SO were 
0.01 %, 0.03%, 0.03% and 0.01 % respectively. There is no (r = 0.047, p 2'.: 0.05) 
correlation between percentage of PNT degradation at 7 days (i.e. the initial fall) and 
moisture content of the oil suspensions (Figure 4-3). 
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Figure 4-3. Correlation between PNT degraded (%) at 7 days and moisture content of 
the oil suspensions. Data points are means (n =2). 
Also there is no correlation between percentage of PNT degradation at 105 days 
(r = 0.18, p 2'.: 0.05) and moisture content of the oil suspensions. A plot between the 
slope of the curves (7-105 days) and moisture content of the oil suspensions also 
showed no correlation (r = 0.45, p 2'.: 0.05). Thus, it is clear that neither the initial 
losses nor any continued decline nor the values at 105 days of PNT degradation in the 
case of LP, MIG, EO and SO were entirely predicted by the moisture contents of the 
oil suspensions. Moisture may be involved but presence of the potential confounding 
effect of oil cannot be neglected. 
4.4.2. The stability of PNT in solid state 
The aim of this study was to investigate if degradation in the solid state is 
sufficient to explain degradation of PNT solid in the oily suspension. The degradation 
of PNT in solid state was ::S 1 % under all humidity conditions of storage. There were 
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no new peaks in the HPLC chromatograms over the 30 day study period. The 
moisture content in PNT samples in solid state reached equilibrium after 2 days at RH 
25 % and after 4 days at RH 53%, 75% and 96.5%. The equilibrium moisture contents 
in PNT samples after 30 days at RH 25%, 53%, 75% and 96.5% were 0.07%, 0.24%, 
0.4% and 2.4% (w/w) respectively. Although there was a small loss of PNT over the 
first seven days, this loss did not correlate with the moisture content, nor did it 
continue between 7 and 30 days (Figure 4-4). 
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Figure 4-4. Stability of PNT in solid state in presence of different humidity environments 
at 30 °C. Data points are means (n=2). 
4.4.3. Solubility of PNT in different oils 
The solubility (at 24 h) of PNT in different oils was in order LP< MIG< EO < 
SO and the values were 0.043, 0.148, and 1.17 mg mr1 for LP, MIG, EO and SO 
respectively, much lower than the aqueous solubility of 8.9 mg mr1 (Chapter 3). 
There were no new peaks in the HPLC chromatograms suggesting that there was no 
( or very little) degradation in the samples over the 24 h period. 
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4.4.4. Stability of PNT in oily solutions 
The degradation of PNT in solution in LP, MIG, EO and SO was fast with less 
than 10% of PNT remaining after 7 days in EO and SO and 15 days in LP and MIG 
(Figure 4-5) at 30 °C. 
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Figure 4-5. Concentration versus time profiles of PNT and BP at 30 °C in oil solutions 
(a) LP (b) MIG (c) EO (d) SO. 
The sum of the molar concentrations of PNT and BP was not constant (Figure 
4-5). This means that PNT might be degrading by several routes, not just BP or BP 
itself is degrading in the oil. 
Various kinetic models (first-order and zero-order) were fitted to the PNT-time 
data from each kinetic experiment in oils by nonlinear regression using PRISM 
(Graph pad version 5.0) software and the best-fit model selected based on the 
Akaike's information criterion (AIC). On this basis the first-order model gave the best 
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Moisture contents of the oily PNT solutions in LP, MIG, EO and SO were 
0.01%, 0.06%, 0.056% and 0.058% respectively. There is a weak but non-significant 
correlation (r = 0.35, p 2: 0.05) between pseudo-first-order degradation rate constants 
(kobs) for PNT in oil solutions and moisture contents of the oil solutions (Figure 4-6). 
The slope (mean± SE) 2.2 ± 2.2 and intercept 0.16 ± 0.11 (mean± SE) were not 
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Figure 4-6. Correlation between pseudo-first-order degradation rate constants for PNT 
in oil solutions and moisture contents of the oil solutions. Data points are means (n =2). 
4.4.5. Stability of PNT in EO suspensions of varying moisture contents 
In order to determine the potential effect of moisture content, with the potential 
confounding effect of oil removed, the stability of PNT suspensions in EO with 
different moisture contents was investigated. EO was selected for this study as it 
absorbed 0.7% moisture compared with only 0.01%, 0.18% and 0.1% for LP, MIG, 
and SO respectively at 96.5% RH (30 °C). The degradation of PNT was significantly 
(p :'.S 0.05) lower in EO suspensions containing 0.03% moisture than at 0.7 % moisture 
content. More than 20% degradation was observed in the suspensions in EO 
containing 0. 7% moisture along with formation of BP (Figure 4-7) and other 
degradation products. However the sum of the molar concentration of PNT and BP 
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was not constant suggesting that PNT might be degradaing via pathways other than 
hydrolysis to BP. 
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Figure 4-7. Stability of PNT suspensions prepared in EO containing different moisture 
contents at 30 °C. Data points are means (n=2). 
4.5. Discussion 
In the oil suspensions the stability of PNT was in the order LP > MIG > EO > 
SO. There was no correlation between PNT stability in suspensions and solubility 
(Figure 4-2) of PNT. However PNT did degrade more in SO and EO where it has a 
higher solubility compared to LP and MIG with lower PNT solubility. 
In different oily PNT suspensions, the molar concentration of PNT was 3 0-100 
times more than the molar concentration of moisture content of the suspensions 
(Table 4-2). BP was not found in PNT suspensions in LP, MIG and EO and the 
degradation was :S 5% (Figure 4-1 ). As 1 mole of moisture/water can degrade 1 mole 
of PNT (hydrolysis reaction) and assuming that all the moisture/water is available for 
degradation only once, then theoretical calculations based on Table 4-2 suggests that 




Table 4-2. Concentration of PNT and moisture content in various oily solutions and 
suspensions 
Solutions Suspensions 
Oils Moisture PNT Oils Moisture PNT 
(% moisture) (mM) (mM) (% moisture) (mM) (mM) 
LP (0.01) 5.5 0.08 LP (0.01) 5.5 534 
MIG (0.06) 31 0.47 MIG (0.03) 16.6 534 
EO (0.06) 31 1.4 EO (0.03) 16.6 534 
so (0.06) 31 3.0 so (0.01) 5.5 534 
---- ---- ---- EO (0.7) 388 534 
PNT degradation in oil suspensions was in the range 1-3% in LP and MIG at 7 
days (initial fall) (Figure 4-8) suggesting some effect of moisture on PNT degradation, 
however higher (4-6 %) then the theoretical degradation was observed for EO and SO 
(Figure 4-8). Thus higher PNT degradation compared to theoretical and absence of BP 
suggests that degradation of PNT cannot be solely attributed to moisture content for 
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Figure 4-8. Comparison between PNT degradation at 7 days and theoretical degradation 
of PNT due to hydrolysis. 
To further examine the effect of moisture on the degradation of PNT in oil 
suspensions, EO, was selected as the worst case scenario as it absorbed 0.7% 
moisture (at 96.5% RH, 30 °C) compared with LP, MIG and SO (Section 4.4.5). In 
the EO suspensions (0. 7% moisture) the molar concentration of PNT (Table 4-2) was 
only ~ 1-1.5 times more than that of moisture content of the suspensions; higher 
degradation (% degraded :S20%) in comparison to EO suspensions (% degraded :S 
5%) with low moisture content (0.03%) was observed suggesting the influence of 
moisture on the degradation of PNT suspensions in EO. The degradation of PNT was 
not associated with the corresponding formation of BP. This again suggest that either 
PNT degraded by several routes, not just to BP or the BP itself is degrading in the oil. 
Also, being an ester, EO itself can be hydrolysed and its hydrolysis will consume 
some of the moisture which will not be available for the hydrolysis of PNT, hence less 
BP. This suggests that along with moisture, other mechanisms of degradation may be 
involved. 
In comparison with the oil suspensions where about 5% degradation occurred 
over 30 days (Figure 4-1) only 1 % occurred in the solid state (Figure 4-4) independent 
of the humidity of storage. This suggests that solid state degradation is not 




PNT solubility in the oily solutions was in the order LP > MIG > EO > SO. 
However it should be noted that due to instability of PNT, the solubility of PNT in 
oils was determined by allowing only 24 h for equilibration, which may not be enough 
as equilibrium may take longer than 24 h. This means that there may have been more 
PNT in solution in the oily suspensions than the solubility data (based on 24h) 
suggested. This could be the reason why there is a poor correlation between stability 
of the oily suspensions and the solubility in the oils. Also in future, it would be 
interesting to investigate the solubility of the free base of PNT in these oils. 
In oily solutions, PNT degradation followed pseudo-first-order kinetics. The 
molar concentration of moisture in the oily solutions was 15-125 times higher than the 
molar concentration of PNT (Table 4-2). A second-order reaction (Eq. 4-2) between 
water and PNT is given by 





where k is the second-order rate constant, [H20] and [PNT] are the 
concentrations of water/moisture and PNT respectively. However in the presence of 
excess water (Table 4-2) (i.e. [H20] - constant) then 
- dPNT = k' obs [PNT] 
dt 
Eq. 4-3 
where k'obs is the observed pseudo first-order rate constant which is equal to 
k.[H20]. A plot between k'obs and water/moisture (Figure 4-6) shows a positive slope 
as expected but the slope is not significantly different form zero. A larger experiment 
using more moisture levels would be required to determine if there is a true effect of 
moisture on the stability of PNT in EO. However, even then the results might be 
confounded by other components in the oil which could be affecting stability. 
Other than solubility and moisture content another mechanism of degradation of 
PNT in oils could be related to the chemical stability of the oils themselves. Both LP 
and EO undergo oxidation when exposed to heat and light (Sheng, 2009). Huang et 
al., (1981) have shown that in SO, the formation of peroxides increase over time (28 
days) even in dark at 35 °C. The peroxides result in the formation of free radicals, 




al., 2009), it was found that H202 has catalytic effect on PNT degradation. The SO 
used in this study did not contain antioxidants, whereas both EO and LP had BHA as 
antioxidant (Table 4-1) which might have prevented oxidative degradation reaction in 
PNT suspensions in EO and LP. This however requires further investigation by 
measuring the peroxide content of the oils initially and those formed during the 
storage, and determining their influence on the degradation of PNT. 
The results from this study suggest that chemical stability of PNT for over 3 
months (30 °C) could be achieved by formulating PNT suspensions in LP, MIG and 
EO containing low levels (0.01-0.03%) of moisture. 
4.6. Conclusions 
PNT solubility was low (:SO.I%) in oily vehicles and it was more stable in 
suspensions compared with solutions prepared in oily vehicles. In comparison to the 
current marketed aqueous suspension (Mamyzin or Penethaject) (Chapter 1), the 
stability of PNT was greatly enhanced in oily suspensions with around 95% PNT 
remaining after 3 months (30 °C) in LP, MIG and EO. PNT remained stable in the 
solid state over the 30 days study period under different humidity conditions. PNT 
was more stable in suspension or solid state compared to solution state. Degradation 
of PNT in oils cannot be solely attributed to the presence of moisture and other factors 
such as composition of oils may be involved. There is a need to minimise the moisture 
content of oils to prevent degradation of PNT in oils. Addition of antioxidants may be 
necessary to avoid degradation due to catalytic effects of the oxidative degradation 
products of the oils. In comparison to PNT suspensions in SO, the degradation of PNT 
can be minimized during the storage-life by formulating PNT suspensions in LP, MIG 
and EO and these oily vehicles are potential candidates for developing novel RTU 
oily suspension formulations of PNT. 
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Chapter 5. STELLA modeling for 
PNT intramuscular injections 
A 
5.1. Introduction 
There are few animal studies where PNT was injected i.m. in cows and the 
concentration of BP was measured in the milk. In one study ( Friton et al., 2003) PNT 
in aqueous suspension formulation (5 g) (Mamyzin) was used, and in another 
(Edwards, 1965) an oily suspension formulation of PNT was injected intramuscularly. 
Due to this very limited data on PNT in animal studies, and given the 
difficulties of analysing such a rapidly hydrolysing drug, a simulation model has been 
developed in order to gain some insight into the pharmacokinetics of PNT and BP in 
milk. The drug properties (pKa, chemical half-life as a function of pH) determined in 
the work reported in previous chapters, along with pharmacokinetic parameters 
(volume of distribution and clearance), have been used in the simulation model to 
make the predictions. Such a simulation model could be useful in designing 
formulations (aqueous or oily suspensions) with different absorption rates in future. A 
Simulation model could also be utilized in determining the dose and dosing frequency 
required to achieve preferred concentration versus time profiles of PNT and BP in 
milk where majority of S. uberis resides. Model predictions also offer the advantage 
of saving time and effort involved in conducting expensive animal studies. 
5.1.1. Program selection - STELLA simulation software 
Simulation models are created using a variety of general programming 
languages or dedicated simulation software. In the past, writing absorption and 
distribution models required knowledge of programming languages (Boyd and Boyd, 
1987). However, as the knowledge base increases, the models will be frequently 
altered, so a program which allows easy alteration is essential. Further, as the 
understanding of the system expands, it is essential that one should be able to convert 
or link various simple models to produce more complex systems (Grass and Lee, 
1993). Simulation models such as STELLA offers the advantage of being user 
friendly and do not require knowledge of programming languages. STELLA has been 
utilised for generating a variety of pharmaceutically related simulation models such as 
models of ocular pharmacokinetics (Grass and Lee, 1993; Ranta et al., 2003), 
performance of sustained release dosage forms (Ramsay et al., 1991; Grass et al., 
1994), and oral absorption (Mikulecky, 1990; Shono et al., 2009), including prodrug 
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performance (Grass and Morehead, 1989). However, there are no reports in the 
literature on the use of such simulation models to predict concentration of drug in 
milk after i.m injection in cattle in general or for PNT in particular. 
STELLA TM (Structural Thinking Experimental Leaming Laboratory with 
Animation), is a simulation software, utilised as both an educational and predictive 
tool. In pharmacokinetics, this simulation program requires knowledge of the factors 
such as degradation half-life (tI12) in milk and plasma, volume of distribution (Vd), 
clearance (CL) of drugs, which control the rate of transfer of the drug between various 
body compartments. A graphical representation of the system is created by the 
programme by utilizing a graphical interface, which enables the user to construct and 
run simulation models. The program uses symbols for the various elements of the 
model (Figure 5-1). 
D 0 
(a) (b) (c) (d) 
Figure 5-1. Four symbols used to construct STELLA models. (a) stocks (b) flow control 
and flow path (c) information transfer (connector) (d) parameter value (converter) 
These symbols are arranged to construct a flow diagram of the system or 
process to be modeled. Each symbol represents a factor in the model and may be 
programmed as a numerical constant, as a logic statement or a linear or non-linear 
relationship between two parameters. The model uses built-in logic, Boolean and time 
functions, such as if ... then ... else, delay, pulse, that allows a set of rules to be 
developed which the program uses to control the model. These control statements can 
be placed in 'converters' and, using input links, it is possible to develop complex rule 
sets to control flow through the model. Once the model is complete, it can be 'run' by 
feeding a total run time and a time increment (dt). The program then by using either 
Euler's or a Runge-Kutta method calculates the value of every parameter in the model 
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at each successive time increment. The results are represented graphically and in 
tabular form. 
5.2. Chapter aims 
The first aim of this chapter was to construct a STELLA model for PNT 
formulations for i.m administration in cows. The second aim was to compare the 
concentration versus time data of BP, the hydrolytic product of PNT in milk from 
simulations with the data from literature for an aqueous PNT suspension (Mamyzin) 
(Friton et al., 2003). The third aim was divided into three parts (1) sensitivity analysis 
of the model for pharmacokinetic parameters: ka (absorption rate from i.m injection 
site), PA (product of permeability and cell surface area), V d and CL (2), additional 
outcomes and (3) applications of the model. Sensitivity analysis showed the influence 
of pharmacokinetic parameters on the predicted milk concentrations and allowed 
some insights into the absorption rate of PNT from the i.m. injection site for the 
design of formulations in future. Additional outcomes provided information on the 
concentrations of antibiotics (PNT and BP) in alveolar and cistemal compartments. 
Finally, the model was applied to determine the effects of dose, milk volumes and 
milk pH (healthy versus mastitic cows) on the concentrations of PNT and BP in milk. 
5.3. Methods 
Simulations were conducted using STELLA software (ISEE Systems, Inc. NH, 
USA) version 8.1. 
5.3.1. A STELLA model of bovine i.m. injection of PNT 
In this study, a compartmental simulation model (Figure 5-2) was constructed 
for aqueous PNT suspensions, to generate the milk concentration-time profiles for BP 
after i.m administration of PNT formulation in cattle. As common MCOs such as S. 
uberis resides predominantly in the milk, the concentration of BP was determined 
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The model (Figure 5-2) was constructed in various segments and then linked in 
a stepwise manner: Step (1) Absorption of PNT from injection site (2) Elimination of 
PNT and BP from the body and hydrolysis of PNT to BP in the body (3) Transfer of 
PNT and BP from the body to alveolar milk, transfer to cistemal milk and elimination 
by hydrolysis of PNT and BP from milk (alveolar and cistemal) and milking of PNT 
and BP from milk (4) Milk production, flow of milk from alveolar to cistemal 
compartments and milking out of milk from cistemal and alveolar compartments. The 
body is considered as a single kinetic compartment. In the diagrams the mass in the 
body is labeled as 'PNT in plasma'. In the diagrams and the discussion which follows, 
this stock (compartment) refers to the whole body except the injection site and the 
udder. These steps are described in the following paragraphs. Various assumptions 
that were made in the design of the model are described in the Appendix (Section 
A.I). 
Step I: Absorption of PNT from injection site 
In this step, PNT suspension was administered at the i.m injection site. Figure 5-
3 is the diagram of this step of the model. The absorption of PNT from the injection 
site was assumed to follow either first-order kinetics or zero-order kinetics. For first 
order kinetics: 
Absorption rate PNT = ka x Mass of PNT at injection site Eq. 5-1 
where ka (first order) (h-1) is the first order absorption rate constant for delivery of 
PNT to plasma and it will be influenced by the release rate from aqueous or oil 
suspension and the rate of diffusion through the interstitial tissue between the 
formulation and plasma. Similarly for zero-order kinetics with rate constant ka (zero order) 
(µg. h-1), the absorption rate is given by the input function in the model as: IF (PNT at 
injection site> 0) THEN ka ELSE 0. 






















Step 2: Elimination of PNT and BP from body and hydrolysis of PNT to BP in the 
body 
This step (Step 2, Figure 5- 4) of the model considers the hydrolysis of PNT to 
BP and elimination of PNT and BP from the plasma. 
Half life of PNT in plasma 
Hydrolysis rat 
Clearance BP 
PNT eliminated BP eliminated 
Figure 5-4. Step 2 of the model used to simulate i.m injection of PNT in cattle. 
Since there are no reports in the literature on the pharmacokinetic parameters 
Vd and CL for PNT, initially values of Vd and CL used in the model were within the 
range for various weakly basic drugs (Table 5-1 ). This was based on the fact that 
these drugs are weak bases with similar pKa to PNT and some of them that are used in 
the treatment of mastitis have high milk/plasma ratio similar to that of PNT. This 
assumption was considered reasonable for initial predictions of milk concentration of 
BP after hydrolysis from PNT, as it has been suggested that drug molecules with 
similar physicochemical properties may follow similar pharmacokinetic behaviour in 
vivo (Yu, 2010). However various Vd and CL values were used to test the sensitivity 
(sensitivity analysis) of the model to this assumption (Section 5.4.3.). 
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Table 5-1. Pharmacokinetic parameters for a range of weakly basic drugs 
pKa Vd (L.kg-1) CL (L.h-1.kg-1) 
Protein binding 
Milk / plasma ratio References 
(%) 
(Rasmussen, 1959; 
PNT 8.4 a a 42b 2-6 
Ziv and Sulrnan, 
1972; Friton et al., 
2003) 
(Ziv and Sulrnan, 
Tylosin 7.7 1.1±0.4 0.5 ± 0.2 33-44 4.5 1972; Wang et al., 
2003; Lewicki, 2006) 
(Ziv and Sulrnan, 
Erythromycin 8.8 0.8 ± 0.2 0.2 ± 0.03 18-20 8.5 1972; Baggot and 
Gingerich, 197 6) 
(Ziv and Sulrnan, 
Spiramycin 8.2 14.9 ± 4.0 1.2 ± 0.3 38 4.6 1972; Sanders et al., 
1992) 
Terbutaline IO.I 0.3 ± 0.3 2.6 ± 1.0 24-28 a 
(Wang et al., 2003; 
Boileau et al., 2007) 
Detomidine 7.2 0.7± 0.2 0.6 ± 0.1 75-85 a (Salonen et al., 1989) 
Tilmicosin 7.4 and 8.5 25 ± 3.6 0.6 ± 0.1 a a (Modric et al., 1998) 
a = not reported in the literature, b = calculated using PreADMET (Bioinformatics & Molecular Design Research Center (BMDRC) Seoul, 
South Korea) 
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The concentration of PNT in plasma (Cp PNT) is calculated by 
C PNT = PNT in plasma 
p Vd 
Eq. 5-2 
The elimination rate for PNT is calculated from the clearance using equation 
Elimination rate PNT = CL x Cp PNT Eq. 5-3 
In addition to clearance of PNT by usual mechanisms ( e.g. hepatic, renal) which 
for PNT are assumed similar to other weakly basic drugs, and because PNT is a 
rapidly hydrolysed prodrug, this hydrolysis is inserted as a separate clearance route. 
Thus in plasma, PNT hydrolyses to BP as: 
Hydrolysis rate PNT in plasma= PNT in plasma* khydrolysis PNTp Eq. 5-4 
where khydroiysis PNT P is the hydrolysis rate constant for PNT in plasma (pH 7.4, 
37 °C). It was assumed that the degradation in plasma is the same as degradation in 
buffer of the same pH and at the same temperature (i.e. enzyme catalysed hydrolysis 
is neglected); so the rate constant value used here is determined from the kinetic 
studies of PNT in buffers (Chapter 3). BP concentration is calculated as 
Cp BP = BP in plasma 
Vd 
Eq. 5-5 
The values for the pharmacokinetic parameters Vd (0.27 L.kg-1) and CL (0.59 L. 
h-1.kg-1) for BP are from literature (Bengtsson et al., 1997). The elimination rate of BP 
is calculated as: 
Elimination rate BP = CL x Cp BP Eq. 5-6 
Step 3: Transfer of PNT and BP from plasma to milk 
In this step the model is expanded to include alveolar milk compartments 
(Figure 5-5) to which the transfer of both PNT and BP is governed by partitioning of 
lipophilic, unionised, unbound PNT and BP from plasma (pH 7.4) to milk (pH 
6.8)(Rasmussen, 1959; Miller et al., 1967a; Miller et al., 1967b; Rasmussen, 1971; 
Fleishaker, 2003). Active transport into milk has been ignored although there has been 
a report that some active transport does occur, but this has not been quantified 
(Schadewinkel-Scherkl et al., 1993). When information on the kinetic parameters for 
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active transport of PNT and BP become available, this complexity might be 
incorporated into the model. The flow from plasma to alveolar milk is shown as 
reversible, since movement of drug can take place reversibly between plasma and 
alveolar milk compartments (Knight et al., 1994). The fraction unionised (fu) of PNT 
and BP was calculated by Henderson-Hasselbach equation for PNT (pKa 8.4- Chapter 
3) and BP (pKa 2.8) 
f UPNTp = 1- [1/(1 + 1 o<pHp-pK.) )l 
f UPNTm = 1- [1/(1 + 1 o<pHm-pK.) )] 
fuBPp = 1-[1/(l + 1 o<pK.-pHp))] 





where fuPNTp and fuBPp are the fractions unionised PNT and BP in plasma 
(pHp 7.4) and fuPNTm and fuBPm the fractions unionised in milk (pHm 6.8) 
respectively. The pH of healthy milk is in the range 6.5-6.8 (Giguere et al., 2007) 
whereas the pH of mastitic milk is 6.9-7.2 ( Giguere et al., 2007). Simulations were 
carried out to test the importance of the value and to understand what effect mastitis 
might have of the concentrations of the antibiotics in milk (Section 5.4.3). 
As both BP (30%) (Ziv and Sulman, 1972) and PNT (42 %) (Predicted using 
PreADMET (Bioinformatics & Molecular Design Research Center (BMDRC) Seoul, 
South Korea) are not highly protein bound the protein bindings were considered as 
inclusive in the clearance. 
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Figure 5-5. Step 3 (including Step 1 and 2) of the model used to simulate i.m administration of PNT in cattle. 
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The transfer of PNT ( or BP) from plasma to milk (p to m PNT or BP) is also 
influenced by permeation (PA value) or clearance (L h-1) of PNT or BP from plasma 
to milk. Assuming Fickian diffusion, PA is the product of permeability (P) and 
surface area (A) of the mammary epithelial cells: 
Flux =-P.A (Concentration across the membrane) Eq. 5-11 
where P is the permeability coefficient (m h-1) and A is the surface area (m2) 
across which diffusion occurs from the mammary capillaries through the alveolar 
epithelial cells into the milk. Pis equal to the diffusion coefficient (D, m2 h-1) divided 
by the diffusional distance (m). Since there are no reports on PA values for PNT or 
BP, a P value of 1 x 10-5 cm sec-1 or 3.6 x 10-4 m h-1 was used for calculation of 
permeability across membrane. These values were within the range of P values (0.015 
x 10-5 to 8.3 x 1 o-5) determined by Caco - 2 cell based permeation studies for various 
drugs reported in the literature (Corti et al., 2006; Wessling et al., 2007). There are 6 x 
1012 alveolar cells in bovine udder (Weber et al., 1955) and the diameter of each cell 
ranges from 10-15µm (Akagi et al., 2002). Assuming that the cells are arranged as a 
monolayer on the bovine mammary alveolar epithelium in the form of flattened 
circular disc, the total surface area (nr2) for all the cells was calculated (Table 5-2). 
The P value calculated was in the range 0.169-0.381 m3 h-1 or 169-381 L h-1. 




Surface area Caco-2 cell 
of cell 
of circular 
(A) of 6 trillion permeability (P) m 
PxA 
disc (m3 h-1) (r2) (m2) cells (m2) h-1 
shaped 
cell (m2) 
2.5x10-11 7.8x10-ll 471 3.6x 10-4 0.169 
5.6xl0-11 l.7x10-11 1060 3.6 X 10-4 0.381 
Another way of determining the PA value could be from the knowledge of 
blood flow to the udder in cows. Davis and Collier (1985) reported that the udder of a 
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Jersey cow (350 kg body weight) at peak lactation is perfused by 15.6% (7 L min-1 = 
420 L h-1) of cardiac output (45 L min-1) giving a daily milk yield of 16 kg. Thus the 
clearance (PA) of drug from plasma to milk cannot exceed 420 L h-1. For a 600 kg 
cow the PA could not exceed 720 L h-1• The sensitivity of the model to the PA value 
was assessed (Section 5.4.3). Since PNT and BP have approximately the same 
molecular weights, and therefore are likely to have similar diffusion coefficients for 
the unionised diffusing molecules, the PA value for PNT and BP were assumed to be 
the same. Thus, applying Fick's equation, the transfer of PNT and BP from plasma to 
alveolar milk is: 
TransferratePNT= PA PNTx[(CpPNTxfuPNTp)-(CmPNTxfuPNTm)] Eq. 5-12 
TransferrateBP= PA BPx [(CpBPxfuBPp)-(Cm BPx fuBPm)] Eq. 5-13 
Once in alveolar milk, PNT or BP can be hydrolysed, transferred to the cistemal 
milk compartment and milked out. In cistemal milk, PNT and BP can be hydrolysed 
and milked out. 
PNT is assumed to hydrolyse to BP (t112 = 0.52 h, buffer pH 6.8, 37 °C - again 
enzyme catalysed hydrolysis is neglected) by first-order kinetics in both alveolar and 
cistemal milk: 
Hydrolysis rate PNT = PNT in alveolar milk* khydrolysis PNT m Eq. 5-14 
Hydrolysis rate PNT = PNT in cistemal milk* khydrolysis PNT m Eq. 5-15 
where khydroiysis PNT mis the hydrolysis rate constant for PNT in milk pH 6.8 (37 
°C). The rate constant values used here were determined from the kinetic studies of 
PNT in buffers (Chapter 3). 
The hydrolysis of BP (t112 = 322 h, buffer pH 6.5, 37 °C- again enzyme 
catalysed hydrolysis is neglected) (Lu et al., 2008) in the alveolar and cistemal milk is 
assumed to follow first-order kinetics: 
Hydrolysis rate BP = BP in alveolar milk* khydrolysis BP m 
Hydrolysis rate BP= BP in cistemal milk* khydrolysis PNT m 
Eq. 5-16 
Eq. 5-17 
The transfer of PNT and BP from alveolar to cistemal milk is governed by the 
flow of milk from the alveolar compartment to the cistemal compartment. Thus: 
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Transfer ratea1veolar to cisterna1 milk = Cm PNT alveolar milk * alveolar to cistemal milk flow 
Eq. 5-18 
Transfer ratea1veolar to cisterna1 milk = Cm BP alveolar milk * alveolar to cistemal milk flow 
Eq. 5-19 
Knight et al., (1994) suggested that a fraction of alveolar milk is left behind 
after normal milking whereas the cistemal milk is completely milked out. The milking 
out of PNT and BP from the alveolar milk is shown as a PULSE in the model for, 
12:12 h, 8:16 h or 24h depending on the frequency of milking. For 12:12 h milking of 
PNT and BP from alveolar milk and cistemal milk: 
Milking PNTaivcolar milk = PULSE (fraction of alveolar milk milked out* PNT in alveolar milk,12, 12) 
Eq. 5-20 
Milking BP alveolar milk = PULSE (fraction of alveolar milk milked out* PNT in alveolar milk, 12, 12) 
Eq. 5-21 
Milking PNTcisternalmilk = PULSE (PNT in cistemal milk, 12, 12) 
Milking BPcistemaimiik = PULSE (PNT in cistemal milk, 12, 12) 
Eq. 5-22 
Eq. 5-23 
The concentrations of PNT and BP in the alveolar or cistemal milks are 
calculated from 
Cm PNT or BP = PNT or BP in alveolar or cistemal milk 
Volume of alveolar or cistemal milk 
Eq. 5-24 
where the volumes of milk (L) in the alveolar and cistemal compartments are 
determined by the production of milk in the alveolar region of the udder, the flow of 
milk from the alveolar region to the cistemal region, and the milking out of milk 
(once or twice daily) from the udder. This is discussed in Step 4 below. 
Step 4: Milk production and flow of milk, PNT and BP from alveolar to cisternal 
compartments 
Milk is secreted continuously by the alveolar cells in the udder into the alveolar 











udder periodically (once or twice a day) depending on the milking. If only fore-milk 
(the first milk) is collected and analysed, this milk (a fraction of the cistemal milk) 
has a different concentration of drug from total milk (Stockler et al., 2009). It was 
therefore considered useful to incorporate into the model separate compartments for 
alveolar and cistemal milk. The milk that remains within the secretory alveoli and 
small ducts is alveolar milk, and that which descends into the larger ducts and cistern 




Figure 5-6. Schematic of the mammary gland showing teat and gland cisterns, milk 
ducts, and glandular tissue (A). Glandular tissue is made up of many small microscopic 
sacs called alveoli that are lined by milk-producing epithelial cells (B). There are 
millions of alveoli within each mammary gland. Adapted with permission (Schroeder, 
2010). 
This distribution process of milk in the udder has been reported in goats (Peaker 
and Blatchford, 1988) and in cows (Knight et al., 1994 ). Based on experimental data, 
Knight et al., (1994) explained the distribution process by a mathematical model. 
According to them, the milk flow (shown as milk production in the model Figure 5-7) 
into the alveolar compartment is defined as: 


















where Va is the volume of milk in alveolar compartment, bo and b1 are 
parameters representing secretion and inhibition of milk secretion respectively. The 
flow of milk from alveolar compartment to cisternal compartment is defined as: 
dVJdt=a 1Va -a 2Vc Eq. 5-26 
where V c is the volume of milk in the cisternal compartment, a1 is alveolar to 
cistern flow and a2 is cisternal resistance. In the model, an initial value of 0.1 L was 
given for V c and Va to initiate the flow of milk. The initial values are required to 
calculate the concentration of PNT and BP in milk to avoid a division by zero. The 
model for step 4 is shown in Figure 5-7. 
e milked out 
Cone BP cisternal milk 
Cm PNT alveolar milk 
Milk production 
0 
Cm BP alveolar milk 
Figure 5-7. Diagram of Step 4 of the model used to simulate i.m administration of PNT 
in cattle. 
The values for flow parameters a1 (0.005±0.01 h-
1),a2 (0.03±0.02 h-
1),bo 
(1.71±0.24 L h-1) and b1 (0.19±0.04 h-
1
) (Knight et al., 1994) were used directly in the 
model. Simulations were performed on the milk secretion parameter bo (shown as 
milk production in the model) and described in Section 5.4.3. 
The concentrations of PNT and BP in alveolar, cistemal and total milk were 
calculated by 
C PNT BP 
_ (Fraction of alveolar milk milked out* PNT or BP in alveolar milk) 
one or 1 1 .1k-



















PNT or BP in cisternal milk 
Cone PNT or BP cisternal milk= Volume of cisternal milk 
Eq. 5-28 
C PNT BP 
_ (Fraction of alveolar milk milked out* PNT or BP in alveolar milk) + PNT or BP incistemal milk 
one or 1 .1k-
101a m, (Fraction of alveolar milk milked out* Volume of alveolar milk)+ Volume of cistemal milk 
Eq. 5-29 
The components of the model, absorption from the i.m site to plasma, 
hydrolysis/clearance from plasma, partitioning into milk, milk/production and milking 
are linked in the complete model (Figure 5.8). Since lg of PNT (Mol. wt. 561) 
hydrolyses to 0.6g of BP (Mol. wt. 334) a factor of 0.6 is used in calculating the 
concentration of BP. The concentration of PNT and BP in alveolar milk, cisternal 
milk and total milk are shown by converters in the right side of the model. 
The parameter values used were based on the kinetic studies described m 
Chapter 3 or literature values. Where values were not available, estimates were made 
based on values for similar molecules (e.g. clearance for weakly basic drugs) or on 
physiological calculations ( e.g. PA) and then sensitivity analyses were conducted to 
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Cone BP in total milk 
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Cone BP in total milk 
Figure 5-8. A STELLA model for i.m injection of PNT in cattle 
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5.3.2. Preliminary simulation of the milk concentrations versus time profiles for 
various absorption rate constants 
Initially simulations were performed for various physiologically reasonable 
absorption rate constants within the range of typical first order absorption rate 
constants (Table 5-3) from the literature after i.m injection of drugs from aqueous 
vehicles. Also the value of Vd (1.1 L ki1) and CL (0.47 L kg-1 h-1) of Tylosin 
(Lewicki, 2006) were used for PNT (Table 5-4). This was based on the fact that both 
antibiotics are weak bases with similar pKa 7.73 and 8.5 respectively and both have 




Table 5-3. Typical absorption rates from the i.m injection site. 
Absorption 
rate 
Base Method Species Drugs (clearance References 






(Hazra et al., 
studies prednisolone 2007) 
Insulin I131 0.47 
Radioactivity Human Nal 2.1 









Camel Orbifloxacin 1.35 et al., 2009) 





Aqueous ES* 0.010 
suspension 
AcMS* 0.244 (Hirano, 





*p aminobenzene (PAAB), p-hydroxyazobenzene (PHAB), o-aminoazotoluene (OAAT), l-




Table 5-4. Initial parameter values used for simulations 
Model parameters BP PNT 
Vd L kg-I 0.27 
1.1 
CL L h-I kg-I 0.59 
0.47 
t112 (h) plasma/buffer pH 7.4, 37 NA* 0.22 oc 
t112 (h) milk/buffer pH 6.8, 37 °C 322 0.52 
PA or CL from plasma to milk 
(L h-I) 169 169 
pKa 2.8 8.4 
ka(first order) (h-l) 
NA 0.05-1.5 
* hydrolysis of BP in plasma is assumed to be included within the clearance value 
from the literature. 
5.3.3. Simulation of the milk concentrations versus time profiles using STELLA 
simulation model 
The simulations were carried out for an aqueous PNT suspension formulation 
(Mamyzin) for a cow weight of 600 kg (Friton et al., 2003) using initial parameter 
values for PA, CL and V d (Table 5-5). These values were obtained from preliminary 





Table 5-5. Parameter values used for simulations to match the milk concentration versus 
time profile of BP with the literature data for Mamyzin 
Model parameters* BP PNT 
-
Vd L kg-1 0.27 
3.3 
--
CL L h-1 kg-1 0.59 
2.3 
PA or CL from plasma to milk 
(L h-1) 169 169 
ka(first order) {h-1) NA 0.65 
ka(zero order) {µg. h-1) NA 1200000 
*t112 plasma, milk and pKa were same as shown in Table 5-4 
Together with these values ka values were then adjusted to best match simulated 
concentrations of BP in the total milk with those from literature data (Friton et al., 
2003) for a dose of 5 g PNT aqueous suspension. The best fit (first or zero order) 
model was selected by mean square error (MSE) of the difference between the 
predicted and experimental values: 
MSE = I:(Experimental value - Predicted value )2 
n 
where n is the number of observations. 
Eq. 5-26 
For aqueous formulations (Mamyzin), the literature was not clear about the 
milking frequency; therefore the simulations were done for standard 12:12 h milking 
using both first and zero order absorption kinetics from the injection site. 
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5.3.4. Sensitivity analyses of the model, additional outcomes and applications of 
the model 
Sensitivity analyses were done by varying the following parameters: zero or 
first absorption rate constants, PA, V d and CL for PNT and milk production. The 
parameters were varied one at a time while holding others fixed. The aim of the 
sensitivity analyses for the absorption rate constants was to provide some insights for 
formulation of i.m. injections of PNT. The aim of the sensitivity analyses for PA, Vd, 
and CL was to determine which parameters have greatest influence on the predicted 
milk concentrations with a view to making recommendations on which should be 
investigated in future research. 
As additional outcomes, the concentrations of antibiotics (PNT and BP) in 
alveolar and cistemal compartments were also considered to provide some insights 
into the design of animal trials and which milk should be analysed in these trials. 
Simulations were also performed on milk volumes to understand how milk 
production might influence inhibitory concentrations of antibiotic in milk. This has 
implications for the doses of PNT used in practice and the design of formulations. 












5.4.1. Preliminary simulations for various absorption rates using STELLA 
All parameters were fixed (Table 5-4) except first order absorption rates (Table 
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Figure 5-9. Concentration versus time profiles for BP in total milk. Data for milk 
concentration for Mamyzin (o) (Friton et al., 2003) were compared with STELLA model 
(solid lines) for various physiologically reasonable absorption rates after i.m injection of 
an aqueous suspension of 5 g dose of PNT 
Figure 5-9 suggests that the concentrations of BP in milk vary with change in ka 
(first order), however they were not in agreement with the Mamyzin data when the V d 
and CL for Tylosin were used. Therefore further simulations were performed (Section 
5.4.2) using the values of CL and Vd within the range shown in Table 5-1 and 
physiologically reasonable ka and PA values to match the BP concentrations with 
Mamyzin data. 
5.4.2. Simulation of the milk profiles using STELLA 
The parameters (PA, CL and V d) (Table 5-5) were fixed and the simulations 
were performed for various first order and zero order absorption rates from the i.m 

















literature data for Mamyzin, for first-order and zero-order absorption rates. The 



























--STELLA first order 12:12 h 
milking 600 kg cow ka 0.65 
h-1 
--STELLA zero order 12:12 h 
milking 600 kg cow ka 
1200000 ug h-1 
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Time (h) 
Figure 5-10. Concentration versus time profile for BP in total milk. Data for milk 
concentration for Mamyzin (o) were compared with STELLA model (solid line) after 
i.m injection of an aqueous suspension formulation of 5 g dose of PNT. 
The best fit values obtained from the simulation for first-order and zero-order 
rate constants were 0.65 h-1 and 1200000 µg h-1 respectively. MSE values for first 
order and zero order ka were 0.001 and 0.013 respectively. The simulations for milk 
concentration time profile of BP based on MSE value suggests that first-order 
absorption may be occurring for the Mamyzin formulation. 
A first absorption rate model was used in subsequent sensitivity analyses for 
other parameters. Table 5-6 shows the values of Cmax, tmax and AUCo-24 from model 
simulation compared to that with Mamyzin data and suggests a close agreement 


















Table 5-6. Pharmacokinetic parameters of BP in milk following i.m injection of PNT 
Data for Mamyzin (Friton et al., 2003) are means ± SD 
Cmax tmax 
(µg mr1) (h) 
Mamyzin 0.4 ± 0.1 4.7 ± 2.6 
STELLA 0.4 4.0 
t112e1 
(h) 




5.1 ± 1.0 
5.5 
5.4.3. Sensitivity analyses of the model, additional outcomes and applications of 
the model 
Varying the first order absorption rate constants for a total dose of PNT ( 5 g) on 
the absorption of drug from the aqueous suspensions (Figure 5-11) shows that, the 
Cmax of BP increases in the milk and the tmax decreases with an increase in the 
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Figure 5-11. Concentration versus time profile for BP in total milk. Data for milk 
concentration for Mamyzin (o) were compared with STELLA model (solid lines) with 
varying first order rate constants (ka (first order))• 
Sensitivity for PA, CL and V d were carried out using a ka (first order) of 0.65 h-1. 
Figure 5-12 and Table 5-7 shows the results of these simulations. The sensitivity 
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analysis suggested that a 9 times increase in PA resulted in a 2 times increase in Cmax 
and AUCo-24 of BP in total milk. A 6 times increase in Vd resulted in 4 times decrease 
in Cmax and AUCo-24 BP in milk and a 5 times increase in CL resulted in 0.8 times 
decrease in Cmax and AUCo-24 of BP in total milk. 
Table 5-7. AUC0_24 obtained from sensitivity analysis on various parameters for 
Mamyzin - ka(first order) was set at 0.65 (h-1) for PA, V d and CL. 
PA AUCo-24 Vd AUCo-24 CL AUCo-24 
(L h-1) (µg.h mr1) (L kg-1) (µg.h mr1) (L h -1kg-1) (µg.h mr1) 
80 3.8 0.82 14.0 0.55 6.5 
169 5.5 1.65 9.2 1.1 6.1 
381 7.2 3.3 5.5 1.6 5.9 
500 7.5 4.5 4.2 2.3 5.5 
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Figure 5-12. Concentration versus time profiles for BP in total milk. Data for milk concentration for Mamyzin (o) were compared with STELLA 














Additional outcomes from the model 
In addition to the sensitivity analysis, the model is also useful in providing 
information on the relative milk volumes in the alveolar and cistemal compartments. 
The model also delivers new information on the concentration of PNT, BP and total 
antibiotic (PNT + BP) in the alveolar, cistemal and total milk. This information would 
be useful in the design of animal trials and which milk should be analysed in these 
trials . 
The milk volumes (alveolar and cistemal milk) are shown in Figure 5-13. The 
volume of alveolar milk increases rapidly compared to that of cistemal milk and the 
volume of alveolar milk is always higher than that of cistemal milk. This is in 
accordance with Knight et al., (1994) as expected, given that his equations were 
incorporated into the model. The drop in the curve for alveolar and cistemal milk at 





















--Total vo lume 
mil ked out 
Figure 5-13. Milk volumes in alveolar and cisternal compartment and total volume 
milked out. 
The concentration of BP, PNT and total antibiotic (BP and PNT) in the alveolar, 
cistemal and total milk is shown in Figure 5-14a-c. Figure 5-14a suggested that the 
concentration of BP in alveolar and total milk were similar whereas in the cistemal 
milk were higher after milking. This means that total milk is more representative of 
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the antibiotic concentrations in milk and total milk should be sampled as opposed to 
cistemal milk for analysis. PNT concentrations (Figure 5-14b) increases initially in 
total milk for up to 3 h with no PNT remaining in the milk after 8 h. Figure 5-14c 
shows the concentration of total antibiotic (PNT + BP) and suggests that along with 
BP, PNT is also present in milk at least in samples for up to 8 h. 
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Figure 5-14. Data for milk concentration for Mamyzin (o) were compared with STELLA model (solid line). Concentration of (a) BP (b) PNT (C) 

















Applications of the model 
The model is not only useful in the prediction of absorption rates and 
concentration of PNT, BP and total antibiotic in alveolar, cistemal and total milk but 
also has range of other applications. Some of them includes the determination of the 
(1) effect of different doses on milk concentration of BP (2) effect of change in milk 
pH in mastitis (3) effect of change in milk production in cows . 
Changing the dose of PNT from 5 g to 15 g, while keeping the kafirstorder (0.65 h. 
1
) the same resulted in an increase in Cmax and tmax for BP in milk (Figure 5-15). 
Although the concentration of BP in milk is elevated above MIC90 (S. uberis 0.015-
0.06 ug mr1) (Salmon et al. , 1998; Guerin-Faublee et al., 2002) for 24 h , the 
concentration drops after first milking even at a higher dose of PNT and remains 
below MIC after subsequent milkings. However, at a higher PNT dose (15 g) and 
slower first absorption rate (0.05 h·1), the concentration of BP in milk remains well 
above the MIC90 for up to 48 h. This is important for a time-dependent antibiotic. 
Thus by controlling the rate of absorption from the injection site desired 
concentrations of BP can be achieved in the milk. This also suggests that drug release 
from the i.m. injection site continues after the first milking, thus allowing drug to 
build up again in milk. 
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Figure 5-15. Effect of dose and absorption rate on the predicted concentration versus 











The milk secretion (shown as milk production in the model) parameter values 
for b0 (Knight et al. , 1994) were changed while keeping other parameters the same as 
shown in Table 5-5 for first-order absorption, and the effect on BP concentrations 
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--Milk secretion 
parameter bO = 1.71 
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Figure 5-16. Effect of milk production on the concentration of BP in total milk. 
Increasing milk production from 8 L daf1 (bo = 0.8 L h-1) to 36 L daf1 (bo = 3.5 
L h-1) resulted in 1.5 times decrease in concentration of BP in total milk suggesting 
the influence of milk volumes on the concentrations of BP in total milk. This means 
that alteration in dose may be required for cows producing different milk volumes in 
different stages of lactation to maintain BP concentrations above MIC in the milk. 
In mastitis the pH of milk changes from 6.5-6.8 to 6.9-7.2 (Giguere et al., 2007). 
Since change in milk pH influences the partitioning of PNT from plasma to milk, 
model simulations were carried out for normal (pH 6.5) and mastitic milk (7.2), 
keeping other parameters as shown in Table 5-5 for first-order absorption. Figure 5-17 
suggests that the concentrations of BP after i.m injection of PNT reduce to half in 
mastitic milk compared to that in normal milk. Thus the dose of PNT required for 
maintaining the therapeutic levels of BP for the duration of therapy may be higher 

































Figure 5-17. Effect of total milk pH on the concentrations of BP in total milk at pH 6.5 
(normal) and pH 7.2 (mastitic milk). 
5.5. Discussion 
A STELLA simulation model was constructed for PNT formulations to generate 
the milk concentration time profile of BP after hydrolysis from PNT. 
For drugs like PNT, which are chemically unstable at physiological conditions, 
it is difficult to measure the drug concentrations in plasma and milk and therefore no 
pharmacokinetic parameters are reported in the literature for PNT. However by 
selecting molecules which have similar physicochemical properties and assuming that 
PNT will have similar pharmacokinetic behaviour, some initial model predictions 
could be performed. 
Model simulations suggested that absorption rate constants are critical in 
influencing the concentration of BP in milk. Increase in absorption rate increases the 
Cmax and tmax of BP in milk and the levels fall rapidly after milking (Figure 5-9), 
however at slower absorption rates, the concentration of BP rise again even after 
milking (Figure 5-9). The concentration versus time profile of BP after i.m. injection 
of Mamyzin (Friton et al., 2003) suggests that the absorption of PNT/BP is almost 
over before the first milking (12 h). However, the milk production continues resulting 
in a decrease in concentration of BP. Milking also results in clearance of BP from the 
milk (Figure 5-10). 
133 
7 
PA values are important as they govern the transfer of drugs from plasma to 
milk compartments. There are no reports in the literature for PA values for PNT or 
BP. The PA values were estimated based on the calculations using (Table 5-2) and 
suggested a range of PA values from 169 L h-1 to 720 L h-1. However, the P values 
can vary from 0.015 x 10-5 to 8.3 x 10-5 (Corti et al., 2006; Wessling et al., 2007). The 
number of alveolar cells and consequently the surface area may also vary depending 
on the size of udder and weight of cows (Weber et al., 1955). Sensitivity analysis 
(Figure 5-12a) of the PA values suggested that changes in PA values influences the 
concentration of BP in milk and there is a need to determine P values using in vitro 
permeation studies such as Caco-2 cell and PAMPA (Parallel Artificial Membrane 
Permeation Assay) for more accurate predictions of PNT or BP concentrations in 
milk. 
The values of the parameters used in this study ( such as V d and CL) for PNT 
were within the range of V d and CL for drugs which are weak bases and have similar 
pKa (Table 5-2). The results from sensitivity analysis (Figure 5-12b) suggest that Vd, 
is critical in influencing the concentration of BP in milk and it will be useful to 
evaluate it experimentally by conducting animal studies, if possible. On the other 
hand, the model suggests that CL did not greatly influence the concentration of BP in 
milk (Figure 5-12c). 
Separate compartments for alveolar or cistemal milk are incorporated in the 
model (Figure 5-7). This was thought necessary since it is important to understand 
what milk has been analysed when interpreting the literature. Stockler et al., (2009) 
suggested that pharmacokinetic data based on drug concentrations in foremilk 
( cistemal milk) may be misleading and total milk is more representative than 
foremilk. Model simulations in this study suggest that alveolar/or total milk is more 
representative of the drug concentration in vivo, since the cistemal milk was found to 
have higher concentration of BP compared to that in the total or alveolar milk (Figure 
5-14a). This is due to differences in the milk volumes (Knight et al., 1994) in the 
alveolar and cistemal compartments (Figure 5-13). Since common MCOs (S. uberis) 
reside in alveolar, milk the concentration of antibiotics in the alveolar or total milk are 
needed for the therapeutic effect and therefore the model supports the literature 
findings that total milk should be analysed in the animal trials. 
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Model simulations also provided insight in designing of PNT formulations with 
once only treatment compared to the current once-a-day treatment. Figure 5-15 
suggests that increasing the dose from 5g to 15g at an absorption rate of 0.65 h-1 might 
not necessarily result in therapeutic concentrations for longer than 24 h. On the other 
hand, an increase in dose at a slow absorption rate (0.05 h-1), could maintain the 
therapeutic concentrations for up to 48 h. This means that manipulation of absorption 
rate by modifying the drug formulations could result in desired concentration versus 
time profiles in milk and may be helpful in reducing the dosing frequency. The model 
might also be useful in investigating and designing controlled release formulations of 
PNT that follow zero-order absorption kinetics from the injection site for achieving 
desired concentrations of BP in milk. 
Simulations for the milk production (Figure 5-16) give the insight that cows that 
are producing more milk than the average may require higher doses of antibiotics for 
effective treatment since the concentration of antibiotics decreases with an increase in 
the total volume of milk produced by the cow. 
Mastitis causes a change in the pH of milk, and the simulations (Figure 5-17) 
show that this leads to decreased milk concentrations of BP. Thus the dose of PNT 
required for maintaining the therapeutic levels of BP for the duration of therapy may 
be higher than that predicted from studies in healthy cows. Thus the model provides 
insight in deciding, if there is a need to alter the dose or the design of formulation, 
considering the impact of milk pH on achieving therapeutic concentrations in healthy 
cows and cows with mastitis. 
Finally, the model can be utilised not only for PNT and BP but also for a large 
number of drug formulations injected i.m in cattle for predicting concentration of 
drugs in milk. This would require information on the PK parameters of the drugs such 
as pKa, chemical half-life as a function of pH, clearance, Vd and PA values. These 
parameters can then be inserted into the model for the predictions. 
5.6. Conclusions 
A STELLA simulation model was constructed for PNT formulations. The 
simulations for first-order absorption rate model showed that the milk concentration 





Sensitivity analysis suggested that ka, PA and V d are critical parameters for model 
predictions. The parameters ka and V d should be evaluated experimentally by 
conducting animal studies and P values needs be investigated by Caco-2 cell or 
PAMPA based permeation studies. Importance should be given in reporting of milk 
yield and milking frequency as the model suggests that they influence the antibiotic 
levels in milk. This model may be useful in providing insights into design of 
formulations and animal studies, before proceeding to expensive animal studies. 
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Chapter 6. Formulation development 
and animal study of PNT oily 
• suspensions 
6.1. Introduction 
In Chapters 3 and 4, the stability of PNT in aqueous and oily vehicles was 
investigated using a stability-indicating HPLC assay. It was concluded that long-term 
chemical stability of PNT in aqueous suspension is difficult to achieve due to 
hydrolysis of PNT in aqueous media. However PNT was stable in oily suspensions in 
LP, MIG and EO with a storage-life of over 3 months under intermediate storage 
conditions (30 °C) Out of the three oils, EO was selected for formulation development 
in this study due to its low viscosity (3.9 cP) (Howard and Hadgraft, 1983) and fastest 
disappearance rate (t112 = 10 days) (Schultz et al., 1998) from the i.m. injection site. 
The physicochemical factors influencing the properties of oily suspensions are 
quite different from those in aqueous suspensions. In oily suspensions there is an 
absence of the electrical effects and the formation of boundary layers which prevent 
the flocculation of the particles in aqueous suspensions (Falkiewicz, 1988). This has 
implications for the caking of sediments on storage of oily suspensions. In the present 
investigation, PNT in EO suspensions were examined to assess the influence of 
several formulation variables (added surfactant, particle size and rheology) on the 
physical stability of these suspensions. 
There are few animal studies where PNT was injected i.m. in cows and the 
concentration of BP was measured in the milk (Chapter 5). Results for the aqueous 
suspension of PNT (Mamyzin) (Friton et al., 2003) showed therapeutic concentrations 
of BP above the MIC90 (S. Uberis 0.015-0.06 mg L-
1
) for 24 hand below the MRL 
(0.004 mg L-1) for BP after 48 h resulting in a short withholding time for milk. 
However, BP concentrations from oily suspensions (5g) (Edwards, 1965) remained 
well over the MIC90 and MRL even after 24 h with a long withholding period for 
milk. 
In this study two PNT oily formulations (1) Formulation A- PNT suspension in 
EO and (2) Formulation B - PNT suspension in EO containing Polysorbate 80 were 
tested in an animal study and the concentrations of BP were measured in milk. 
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6.2. Chapter aims 
The first aim of this chapter was to develop a stable PNT oily suspension in EO. 
Chapter 4 provided the basis for a chemically stable oily suspension. In this Chapter, 
physical stability of PNT in EO was addressed. The second aim of this Chapter was to 
carry out an animal study in the target species (cow) comparing the concentrations of 
BP in milk after i.m. injection of the developed PNT oily formulations and a marketed 
PNT aqueous suspension (Penethaject™- Bomac Laboratories Limited, Auckland). 
6.3. Materials and methods 
6.3.1. Materials 
PNT and EO were the same as described in Chapter 2 and 4. Polysorbate 80 (Ph 
Eur grade) was purchased from Sigma-Aldrich, MO, USA. All other chemicals and 
solvents were analytical grade (BDH Chemicals Ltd, England and Ajax Finechem 
New Zealand). Penethaject (PNT dry powder for reconstitution) for the animal study 
was supplied by Bomac Laboratories Limited, Auckland. 
6.3.2. Methods 
6.3.2.1. Preparation of PNT suspension formulation in EO 
Two PNT suspension formulations in EO were prepared with and without 
Polysorbate 80 (Table 6-1 ). 




PNT 35 35 
Polysorbate 80 0 0.15 
EO 65 64.85 
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The formulations were prepared by dispersing PNT in EO or in a mixture of EO 
and Polysorbate 80 using an Ultra-Turrax T25 mixer (Staufen, Germany) at 9500 rpm 
for 1 min. The formulations were stored in aluminum capped amber coloured glass 
vials at 20 °C. 
6.3.2.2. Chemical stability of PNT in Formulation A and B 
Chemical stability of PNT suspensions in EO (Formulation A) has been 
discussed (Chapter 4, Section 4.4.1). To investigate the effect of the addition of 
Polysorbate 80 on the chemical stability of PNT in EO suspensions (Formulation B) 
the procedure as described in Chapter 4, Section 4.3.2.3 was applied. The samples 
were stored for 95 days at 30 °C (65% RH) (ICH, 2003) and analysed by HPLC. 
6.3.2.3. Physical stability of PNT in Formulations A and B 
6.3.2.3.1. Sedimentation volume and re-dispersion 
The sedimentation volumes of Formulation A and B were determined by 
keeping 10 ml of each formulation in a stoppered measuring cylinder stored 
undisturbed at 20 °C in duplicate. The separation of clear liquid was noted at various 
times up to 75 days. The sedimentation volume was calculated using Equation 6-1. 
Sedimentation volume= Vu 
Vo 
Eq. 6-1 
where Vu is the volume of sediment and V O is the original height of the 
suspension (Sinko, 2010). After 75 days, the suspensions were shaken by hand for 1 
min to redistribute the sediment and the presence of cake, if any, was recorded. 
6.3.2.3.2. Rheological measurements of formulations 
The viscosities of duplicate samples of Formulations A and B were measured 
using a HAAKE Rheostress 1 rotary viscometer fitted with concentric cylinder 
sensors and a temperature controlled water-jacket set at 20 °C. The measuring cup 
(outer cylinder: ZlO DIN 53019) was filled with the suspension and the inner cylinder 
(ZlO DIN 530) was placed on the top such that the suspension was in the small gap 
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between inner and outer cylinders. The suspension was allowed to remain undisturbed 
for 2 min to allow thermal equilibration. The inner cylinder was set in motion 
(rotated) at different shear rates (1 s-1, 10 s-1 and 100 s-1) for 300 s. Through the 
movement of inner cylinder the sample was sheared and the viscosity was calculated 
using the software (HAAKE Rheowin 3.61). 
6.3.2.3.3. Syringeability 
Formulations were pushed by hand through a 1 ml or 5 ml syringe fitted with 20 
G or 16 G (25 mm) hypodermic needles and time required for the formulation to pass 
out through the needle was recorded. 
6.3.2.3.4. Particle size measurements 
Each formulation was uniformly mixed by shaking then an aliquot (0.05 ml) 
was taken and mixed with EO (15 ml) as a diluent in the quartz sample container for 
particle size measurement by laser diffraction analysis (Horiba Instruments, Irvine, 
CA). The relative refractive index was set at 1.44 (for EO)(Cable, 2009). The cell 
recirculation speed of 2 was used during the analysis. Samples were prepared in 
duplicate and analysis results were the mean of at least 10 measurements. 
6.3.3. Pilot animal study 
The study was conducted in February-March 2011. Cows (7 animals) were 
maintained at the farm situated in the practice region of Agricultural Farm Services, 
Massey University, Palmerston North, New Zealand. They were managed under New 
Zealand pastoral conditions that are consistent with good farming practice 
requirements. Cows were held at pasture and grazed as a single herd. Water was 
available to them ad libitum. Seven cows were entered in the pilot study. The study 
was approved by AgResearch animal ethics committee, New Zealand (Approval 
number: 12250 and 12280). 
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6.3.3.1. Inclusion criteria 
The following inclusion criteria were applied: the breed was common dairy 
cattle, female, 2-8 year old, healthy condition with four functional quarters. 
6.3.3.2. Exclusion criteria 
A cow was excluded from the study if (1) it did not meet above inclusion 
criteria, (2) it was producing less than 10 L of milk per day (3) it had been treated 
with antimicrobials within 30 days of commencement of the study, ( 4) it had a 
somatic cell count (SCC) above 250,000 cells mr1 in milk at the latest herd test, (5) it 
was found positive on inhibitory substances at the latest herd test. 
6.3.3.3. Randomization and treatment of cows 
Random allocation into groups was be done by the principal investigator using 
block assignment on milk yields. Cows were ranked according to ascending milk 
production data (minimum 4-day average preceding day -4, inclusive) and divided 
into three groups (Table 6-2). The range was between 10 L and 30 L of milk per cow 
per day. Cows in the treatment group (Table 6-2) received one-off treatment of an oily 
formulation of PNT hydriodide (5g) (Formulation A or B) intramuscularly in the 
anterior half of the neck using a 20-ml syringe with 16 G (25 mm) needle. Cows in 
the positive control group received an aqueous suspension of Penethaject (Bomac 
laboratories limited, New Zealand). Each 15g vial containing PNT hydriodide dry 
powder was reconstituted by mixing with diluent and the bottle split into 3 equal 
doses of 5g. The administration of Penethaject was in accordance with label 
instructions and standard operating procedures issued to the investigators and the 
farmers by the manufacturer. 
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Table 6-2. Various formulations used in the animal study 
Group Treatment Number of cows 
1. Formulation A (OTPNTRTU-20) 1 
2. Formulation B (OTPNTRTU-24) 3 
3. Penethaject (positive control) 3 
Total 7 
6.3.3.4. Milk sampling, storage, transfer and disposition 
Cows were milked twice daily (8 h and 24 h) according to standard milking 
practice in dairy farming in New Zealand through Tm-test in-line milk sampling units 
attached to the main milking line. The milk collected in the sampling flask was 
representative of pooled milk from the four quarters from the entire milking of each 
individual cow. A minimum of 160 ml from a sampling flask was sub-sampled. The 
milk specimens were collected 4 days prior to treatment, on the day of treatment ( day 
0) before the antibiotic was administered, and up to 7 days after the last treatment. 
The collected sub-sample milk volume was sub-divided into aliquots for the analysis 
of inhibitory substances (10 ml), SCC, fat and protein (20 ml). Before sample 
collection, the teat ends were cleaned with cotton swabs moistened with methylated 
spirit, and the first 2-3 streams of milk were discarded. All milking equipment was 
thoroughly washed between cows or sampling time points using the in-line washing 
system. The fresh milk for SCC, fat and protein analysis were maintained between 2-8 
~C and sent for analysis to SAITL Dairy Laboratories, Hamilton, New Zealand, within 
84 hours of collection. Specimen sets for inhibitory substance analysis were 
dispatched frozen (-18 °C) to SAITL Dairy Laboratories, Hamilton, New Zealand. 
6.3.3.5. Analytical procedures 
Milk analyses were carried out by SAITL Dairy Laboratories for each cow from 
pooled milk collected from each quarter. 
For inhibitory substances testing: The milk samples from each cow were 
screened for residual inhibitory substance (BP) based on a screening test for inhibitory 





Briefly, the Copan milk test uses individual tubes filled with an agar medium pre-
seeded with spores of Bacillus stearothermophilus var. calidolactis with glucose 
(fermentable sugar) and bromocresol purple (pH indicator). Aliquots of 100µ1 of milk 
sample are placed on the surface of the agar medium and then incubated at 64 °C in a 
water-bath for 3 h. The milk quickly diffuses throughout the agar medium and if there 
are no antimicrobial substances in the milk sample or the concentration is lower than 
the limit of detection, the Bacillus spores germinate, grow and metabolize the sugar. 
The acid produced from the fermentation of glucose changes the colour of the 
indicator in the medium to a yellow colour. Alternatively, if the antimicrobial 
substances are present in the milk sample then germination and growth of the Bacillus 
spores is inhibited. This means there is no fermentation of glucose, no acid production 
and therefore the indicator in the medium remains purple in colour. The detection 
limit for BP by Copan milk test is 1-2 µg L-1. 
6.3.3.6. Statistical analysis 
The Student's t-test was used to compare the concentrations and kinetic 
parameters (AUCo-48, and t112e1) in milk for formulations and Penethaject. The values 
were considered statistically significant at p :'.S 0.05. 
6.4. Results 
6.4.1. Chemical stability of PNT in Formulation B 
Similar to the result for PNT suspensions prepared in EO (Chapter 4), PNT was 
chemically stable in Formulation B under intermediate storage conditions of (30 °C, 
65% RH) with > 95% remaining at 5 months (Figure 6-1) suggesting that addition of 
Polysorbate 80 did not influence the chemical stability of PNT in EO suspensions. 
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Figure 6-1. Stability of PNT in Formulation Bat 30 °C. Data points are means (n=2). 
6.4.2. Physical stability of PNT in Formulation A and B 
6.4.2.J. Sedimentation volume and re-dispersion 
The sedimentation volumes decreased rapidly over the first 6 days and 
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Figure 6-2. Changes in the sedimentation volumes for formulations A and B over time. 
Data points are means (n=2) 
The sedimentation volume profile for Formulations A was different from that of 
Formulation B. At 6 days Formulation A exhibited a small sedimentation volume, 
indicative of a tighter packing of particles and thus a greater potential to cake upon 
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standing. Also Formulation A continued to compact slowly during the study period 
(next 70 days). Formulation B containing flocculating agent (polysorbate 80) 
exhibited a lager sedimentation volume at 6 days in comparison to Formulation A and 
the decline was minimized afterwards up to 75 days (20 °C) of the study. Since the 
suspension produces sediment on storage it must be readily re-dispersible so as to 
ensure the uniformity of the dose. Formulation B showed good re-dispersibility on 
mild shaking. In Formulation A, a visible cake was seen at the bottom of the vials and 
required vigorous shaking and then vortexing (5-10 min) to re-disperse the 
suspensions. It was concluded that polysorbate 80 enhanced the physical stability of 
Formulation B by mildly flocculating the PNT. 
6.4.2.2. Rheological and particle size measurements 
For the rheological measurements, different shear rates were applied to simulate 
the shear stress during storage (1 s-1 on standing), mild shaking of the suspension 
before injecting (10 s-1) and shear stress during injection (100 s-1). The viscosities (cP) 
of Formulations A and Bat 20 °Cat varying shear rates are shown in Table 6-3. 
Table 6-3. Viscosities for Formulations A and B at various shear stresses. Data are 
means± SD (n=2). 
Viscosity ( cP) at 20 °C 
Shear rate (sec-1) Formulation A Formulation B 
1 153 ± 9 396 ± 12 
10 35 ± 0.5 87 ±2 
100 10 ± 0.1 25 ± 1 
The viscosities of Formulation B were significantly higher (p :'.S 0.05) than those 
of Formulation A at all shear rates. A plot of shear rate versus shear stress at 20 °C 
(Figure 6-3) tentatively suggests that both Formulations A and B were either plastic or 
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Figure 6-3. Pseudoplastic flow behaviour of PNT oily formulations. Data points are 
means (n=2). 
The mean particle sizes for Formulations A and B were 14.7 ± 0.19 µm (D90 
24.7 ± 0.9 µm) and 13.7 ± 0.16 µm (D90 23.6 ± 2.8 µm) respectively. This suggests 
that there was only a minor difference between the particle sizes of the two 
formulations. 
6.4.2.3. Syringeability 
Both Formulations A and B could be easily pushed through a hypodermic 






6.4.2.4. Pilot animal study 
There were no injection site reactions observed in the cows and all the 
formulations were well tolerated. The results for milk components (SCC, proteins and 
fats) were in the normal ranges (data not shown). Figure 6-4 shows the data from 
animal study for up to 48 hand Table 6-4 shows the complete results up to 104 h. 
The results from animal study suggests that Formulation B achieved similar 
milk concentrations of BP (p ~ 0.05) to that achieved from the marketed aqueous 
formulation of PNT (Penethaject) after i.m. injection of an equivalent dose (5g) at 8 h 
and remained above MIC90 of BP for up to 24 hand the concentrations were below 
the MRL of BP after 48 h. 
The AUC0_48 (mean ± SD) for Penethaject and Formulation B in this low 
powered pilot study were not significantly different (p ~ 0.05) with values of 3.56 ± 
0.17 mg. h L-1 and 4.90 ± 1.4 mg. h L-1 respectively. Also the elimination half-lives 
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Figure 6-4. Concentrations of BP in milk after i.m. injection of 5g of Formulation A, B 
and positive control Penethaject in cows. Data points are means ± SD (n=3) for 
Formulation B and Penethaject and n=l for Formulation A. 
Milk concentrations of BP after administration of Formulation A were lower 
than for Formulation Band Penethaject at 8 h although this result is based on a single 
cow in this pilot study. The calculated AUCo-48 and t112e1 for the single cow were 2.03 
mg. h L-1 and 5.5 h respectively. Although this suggests that Polysorbate 80 did not 
influence the drug release from the formulations, the effect of Polysorbate 80 could 
only be confirmed by a larger study with Formulation A. 
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Table 6-4Milk concentrations in cows for the treatment group (Formulations A and B) and positive control group (Penethaject) 
Milk concentrations BP (mg L-1) 
Cow ID 
Treatment 
Sh 24h 32 h 48 h 56 h 72 h 80 h 96 h 104 h 
group 
363 Formulation A 0.12 0.036 0.012 0.002 <0.003 <0.003 <0.003 <0.003 <0.003 
35 Formulation B 0.54 0.02 0.002 <0.003 <0.003 <0.003 <0.003 <0.003 <0.003 
177 
Formulation B 0.21 0.06 0.006 <0.003 0.029 <0.003 <0.003 <0.003 <0.003 
227 
Formulation B 0.30 0.06 0.012 <0.003 <0.003 <0.003 <0.003 <0.003 <0.003 
Positive 
Sh 24 h 32 h 48 h 56 h 72 h 80 h 96 h 104 h 
control group 
47 Penethaject 0.24 0.05 0.008 <0.003 <0.003 <0.003 <0.003 <0.003 <0.003 
67 
Penethaject 0.24 0.04 0.006 <0.003 <0.003 <0.003 <0.003 <0.003 <0.003 
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In this study two PNT oily suspension formulations (Formulations A and B) 
were prepared in EO and analysed for physicochemical stability. They were injected 
i.m. in cows in a pilot animal study and the concentrations of BP (active), the 
hydrolytic product of PNT, were analysed in milk. 
In Chapter 4, oily suspension formulations of PNT in LP, MIG and EO showed 
enhanced chemical stability under intermediate storage conditions (ICH, 2003) for 
over 3 months (30 °C), in comparison to just 2 days (15-20 °C) for the present 
marketed aqueous suspension of PNT (Penethaject or Mamyzin). Apart from chemical 
stability, disappearance of oils from the injection site is another important criterion for 
selection of oils for i.m. formulations. The half-lives for disappearance from the i.m 
site of low viscosity EO (3.9 cP) moderately viscous peanut oil (35.2 cP) (Howard 
and Hadgraft, 1983) and sesame oil (35 cP) were reported as 10, 23, and 30 days 
respectively (Schultz et al., 1998), and the highly viscous castor oil (286 cP) is 
reported to remain at the injection site indefinitely (Madan, 1985). Thus, EO was 
chosen as vehicle for the development of Formulations A and B due to its low 
viscosity and faster disappearance from the i.m. injections site. 
In this study a non-ionic surfactant Polysorbate 80, commonly used as a 
wetting/flocculating agent was incorporated in Formulation B. It has been reported to 
form a bridge between oil and drug particles to provide better dispersion of drug 
particles as well as increasing the viscosity of the system (Pena et al., 1995). It has 
also been shown to enhance drug release from oily suspensions (0th and Moes, 1985). 
Polysorbate 80 is listed in the FDA list of inactive ingredients and used in the range 
0.04% - 12% depending on solution, suspension formulation and route of 
administration. Polysorbate 80 (0.5% - 4% w/w) is also known to increase the 
solubility of drugs in aqueous and oily systems (Amin and Bryan, 1973; Chow and 
Sims, 1981; Comaire et al., 2000). 
Since in Chapter 4, PNT was found to degrade in solution state an increase in 
solubility due to Polysorbate 80 was not desirable. Also polysorbate 80 may contain 
low levels of peroxides (Ha et al., 2002) which could influence the chemical stability 
of PNT. Therefore in this study a low concentration of 0.15 % (w/w) was used. At this 




PNT remammg determined in Chapter 4 (Formulation A) and in this study 
(Formulation B) were statistically not different (p 2: 0.05). Also the physical stability 
of Formulation B was improved without compromising the chemical stability of PNT. 
During the preliminary studies, Formulation A was found to form sediment at 
the bottom of the vials which was difficult to re-disperse. Addition of Polysorbate 80 
in Formulation B prevented caking by acting as a flocculating agent and the 
formulation was easy to re-disperse with mild shaking. There were minor differences 
in the particle size of the two formulations suggesting that the mild flocculation in B 
was easily overcome under the conditions used in the particle sizing measurements. 
In the absence of Polysorbate 80, PNT suspension in EO had a low viscosity 
and possibly a pseudoplastic rheology. On the other hand, in the presence of 
Polysorbate 80 there was an increase in viscosity of the suspension with a greater 
degree of pseudoplasticity (Figure 6-3); however more investigations are required to 
confirm this. Since only one concentration of polysorbate 80 was used, it is difficult to 
speculate on the formation and strength of a PNT-polysorbate 80-EO network. It is 
postulated that Polysorbate 80 is acting as a bridge between the EO and PNT causing 
weak flocculation and thereby enabling better redispersion of PNT sediment. Similar 
results were reported in the literature for rbSt (recombinant bovine somatotropin) 
suspensions in Miglyol containing Polysorbate 80 (Pena et al., 1995). However this 
has to be investigated further in PNT suspensions in EO with various concentrations 
of Polysorbate 80. 
The pilot animal study was conducted in cows to understand the effect of PNT 
Formulations A and B on the concentration of BP, the hydrolytic product of PNT in 
milk. Different from aqueous formulations, oily formulations often result in a slow or 
prolonged release of drugs (Zuidema et al., 1988). There are a few reports on the i.m 
injection of PNT in aqueous or oily vehicles. The AUC0_24 (5.1 ± 1 mg. h L-
1
) and t112e1 
(4.59 ± 1 h-1) reported for BP in milk for Mamyzin ( Friton et al., 2003) were similar 
to that obtained from this study for Penethaject (aqueous suspension) and oily 
suspension Formulations A and B after i.m injection (5g) of PNT. 
Another study by Edwards (1965) with i.m injection of PNT in oily suspension 
of an equivalent dose of 5g reported significantly higher concentrations of BP (p :S 
0.05) in milk and the calculated AUC0_24 from their mean data (n=2) was higher 
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(11.36 mg. h L-1) than that obtained in the present study. However, it is difficult to 
compare the data from (Edwards, 1965), as they did not provide information on the 
type of oil used and frequency of milking which can influence the concentration of BP 
in milk (Chapter 5). In practice, cows are milked 1-2 times a day even when the cow 
is suffering from mastitis. However, if cows are milked once a day, it would allow BP 
to remain in the milk until the next milking. BP is a time dependent antibiotic and as 
long as BP concentration remains above the MIC, milking once or twice daily will not 
affect the efficacy of BP in the treatment of mastitis. 
This pilot animal study was of low power, given that only three animals were 
used for Formulation B and Penethaject, so the fact that no statistically significant 
differences between these formulations were found, must be interpreted cautiously at 
this stage. However, the data are encouraging and support further and larger animal 
trials. Results from this study tentatively suggest that similar to i.m. injection of 
Penethaject, i.m. injections of Formulations A and B can maintain the therapeutic 
activity (above MIC) of BP for 24 h and with short withholding period in milk. 
Further, Formulation B has the potential of being a physically and chemically stable 
RTU oily formulation of PNT, which in comparison to the marketed aqueous 
formulation offers the advantage of significantly longer storage-life of over 5 months 
under intermediate storage conditions and eliminates the inconvenience of 
reconstitution and storage in refrigerated conditions prior to use. 
6.6. Conclusions 
The chemical stability of PNT suspension formulations in EO was not 
influenced by the presence of Polysorbate 80 at least at 0.15% w/w, and PNT was 
chemically stable under intermediate storage conditions (30 °C, 65% RH) for over 5 
months. There was no difference in the particle size of the two formulations. The 
presence of Polysorbate 80 in Formulation B prevented caking and the formulation 
was easy to re-disperse with mild shaking. Both Formulations A and B achieved 
concentrations above MIC in milk for 24 h comparable to that of the marketed 
aqueous suspension of PNT. Formulation B was found to have the potential to be a 
physically and chemically stable RTU formulation of PNT. A larger animal study is 
warranted. 
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Chapter 7. Summary and future 
considerations 
+ 
Bovine mastitis is an infectious disease caused by bacteria infecting the udder of 
dairy cows. It is a major economic cost to the dairy industry because of decreased 
milk production, the need to discard infected milk and the labour costs for the 
treatment (Zhao and Lacasse, 2008). The major MCOs are S. aureus, S. uberis, S. 
agalactiae and S. dysgalactiae. A large number of antibiotics (Chapter 1) are 
currently used for the treatment of mastitis via parenteral or intramammary routes 
(Ziv, 1980b; Serieys et al., 2005). The preferred antibiotics for i.m. injections are 
those that are chemically weak base and sufficiently lipid soluble to readily diffuse 
through the alveolar membrane (Rasmussen, 1959; Ziv, 1980b)(Chapter 1). 
PNT is a lipophilic weak base with advantageous physicochemical properties 
over other ~ - lactam antibiotics in that is gives a higher milk to plasma ratio of 2-6 
(Ziv, 1980a; Friton et al., 2003) compared to BP (0.2), amoxicillin (0.26) or ampicillin 
(0.26) (Ziv, 1980a). It provides an effective treatment for mastitis caused by penicillin 
sensitive MCOs and provides therapeutic levels of bactericidal BP, the hydrolytic 
product of PNT, to all quarters following i.m. injections. 
Due to the chemical instability of PNT in aqueous environments, PNT is 
available currently as dry powder which has to be reconstituted with buffers prior to 
use (Mamyzin, Penethaject). The storage-life of the reconstituted product is short (2 
days at 15-20 °C) and any unused product has to be discarded. From the veterinarians 
perspective the reconstitution step is inconvenient in the field and therefore a ready-
to-use PNT product with long shelf-life (~lyear) is sought as a preferred formulation 
type if available. 
There are several old reports in the literature about the chemical stability of 
PNT in aqueous vehicles (Jensen et al., 1951; Dinsmore and Bailey, 1952; Hallas-
Moller et al., 1952). Since there was no stability indicating assay for PNT, researchers 
assessed the chemical stability of PNT on the basis of spectroscopic analysis of BP 
(Jensen et al., 1951; Dinsmore and Bailey, 1952; Hallas-Moller et al., 1952). A 
stability indicating assay of PNT capable of separating PNT from BP and other 
degradation products was developed and validated in Chapter 2 (Jain et al., 2009). 
This HPLC method is a valuable addition to the scarce scientific literature on the 
analysis of PNT. It is not only useful to investigate chemical stability of PNT but also 
for analysis of PNT in formulations. The work on PNT stability in stress conditions 
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(Chapter 2) (Jain et al., 2009) suggested that PNT can not only degrade to BP but also 
can follow alternative degradation pathways in different pH conditions. The study of 
the entire degradation pathway of PNT was not part of this investigation; however, 
this can be determined in future by developing a LC-MS assay for PNT to understand 
degradation pathways of PNT and to identify the degradation products in 
formulations. 
A thorough investigation of the chemical stability of PNT in aqueous vehicles 
was conducted in Chapter 3. PNT degrades in aqueous solutions by several pathways 
over the pH range 2.0 - 9.3 with a V-shaped pH-rate profile and a minimum around 
pH 4.5 (30 °C) (Jain et al., 2011). The impact of the investigated buffer concentration 
and ionic strength on PNT stability was small but at pH 6 the type of buffer salt had 
some influence with solutions in acetate being about twice as stable as those in 
phosphate at the higher buffer concentration. Once the stability of PNT in various pH, 
buffers, ionic strength and temperature was better understood, various formulation 
strategies were applied to stabilise PNT in aqueous vehicles. Cosolvents (PG) were 
used for increasing the stability of PNT in solution. Cyclodextrins (P-CD or HP-P-
CD) were used to form a complex with PNT that will protect the labile ester linkage 
in solution. Common ion (iodide) was added to decrease the solubility of PNT and 
thereby possibly increase the stability of suspensions. 
The stability of PNT solutions in mixed solvents was greater than in aqueous 
solutions. In PG:citrate buffer (60:40, v/v, pH 4.5, 30 °C) the half-life of PNT was 4.3 
days compared with 1.8 days in aqueous buffer. In aqueous solutions, there was no 
significant change in the stability of PNT in the presence of P-CD, HP-P-CD at pH 4.5 
(30 °C). 
P-CD and HP-P-CD were used with the aim of protecting the labile ester linkage 
of PNT; however both cyclodextrins did not form a stable complex with PNT. SBE-P-
CD a parenteral excipient approved by FDA, may offer a better option than P-CD and 
HP P-CD for a PNT injectable. SBE-P-CD is negatively charged and hence may have 
a greater binding potential for positively charged drugs such as PNT at low pH (Zia, 
et al., 2001). Thus a strong complex between SBE-P-CD and PNT might protect the 
labile ester linkage of PNT and the stability of PNT could be improved. On the other 
hand, if this complex also increases the solubility of PNT then it could result in 
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decrease in chemical stability of PNT suspensions. However this has to be 
investigated in future for PNT complexes with SBE-~-CD by studies similar to those 
performed in Chapter 3. 
The degradation rate of PNT in solution increased as the content of iodide 
increased, the half-life (t112) for PNT at pH 4.5 (30 °C) in presence of 96 mM iodide 
being 26 h (1.1 days) compared with 43 h (1.8 days) in pH 4.5 buffer alone. This 
increase in degradation rate largely cancelled out the gain in stability of PNT 
suspensions caused by the reduced solubility of PNT in the presence of excess iodide. 
The shelf-life of PNT in suspension was estimated from the solubility studies 
and the degradation rates of PNT in solutions. The estimated shelf-life (t90) of an 
optimistic 50% PNT aqueous suspension does not exceed 14 and 26 days for PG and 
iodide respectively at 30 °C even at pH 4.5. Thus the results from Chapter 3 suggest 
that the enhancement of chemical stability of PNT using cosolvents, cyclodextrins and 
iodide is not sufficient to bring a ready-to-use formulation to the market. Therefore a 
non-aqueous approach was considered. 
The chemical stability of PNT in different oils was determined and some of the 
mechanisms of degradation in these oils were investigated (Chapter 4). This included 
studies of, PNT stability in the solid state under different humidity conditions, the 
solubility of PNT in different oils and the chemical stability of PNT in solutions and 
suspensions prepared in oils of different compositions and moisture contents. The oils 
LP, MIG, EO and SO used in this study were selected based on composition, 
viscosity, moisture content and their i.m application. 
In comparison to aqueous suspensions, the stability of PNT was greatly 
enhanced in oily suspensions (moisture content 0.01 % - 0.03%) with 2: 95% PNT 
remaining after 3 months (30 °C) in LP, MIG and EO and 2: 86 % in SO. There was 
no correlation between PNT degradation in suspensions and solubility in oils. 
In different oily PNT suspensions, no correlation was found between PNT 
stability in oil suspensions (low moisture content) and moisture content of the oils. In 
order to determine the potential effect moisture content, with the potential 
confounding effect of oil-type removed, the stability of PNT suspensions in EO with 
different moisture contents was investigated. EO suspensions with high moisture 
content (0.7%) showed more than 20% degradation compared to -5% in EO 
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suspensions with low moisture content (0.03%), suggesting moisture does influence 
the degradation of PNT in EO suspensions. However, the molar degradation of PNT 
was not associated with corresponding molar formation of BP. This means that either 
PNT degraded by several routes, not just to BP, or the BP itself is degrading in the oil. 
This also means that moisture may be involved but the presence of other mechanisms 
of degradation cannot be neglected. 
PNT degradation was fast (7-15 days) in oily solutions compared to oily 
suspensions (30 °C). Although the molar concentration of moisture content in the oily 
solutions was 15-125 times higher than the molar concentration of PNT (Table 4-2), 
there was no significant correlation observed between PNT stability in solution and 
moisture content of the oils. A larger experiment using more moisture levels would be 
required to determine if there is a true effect of moisture on the stability of PNT in 
solutions. However, even then the results might be confounded by other components 
in the oil which could be affecting stability. 
Degradation in SO suspensions was higher compared to LP, MIG and EO (after 
105 days, 30 °C). It has been reported that the formation of peroxides increase over 
time (28 days) even in dark at 35 °C in SO (Huang (1981). The peroxides result in the 
formation of free radicals, which can act as catalysts. Thus the mechanism of 
degradation of PNT in SO suspensions could be mediated by the formation of 
peroxides which may have catalysed the degradation of PNT. However this has to be 
confirmed by measuring the peroxide content in the oily formulation before and after 
storage to investigate their effect on the stability of PNT. Also, studies in peroxide-
free SO and in the presence of antioxidants would be of value. 
The results from Chapter 4 concluded that the stability of PNT can be 
significantly improved over aqueous suspensions during the storage-life by 
formulating PNT suspensions in LP, MIG and EO and these oily vehicles are potential 
candidates for developing novel RTU oily suspension formulations of PNT. 
A STELLA simulation model was constructed to predict the concentration of 
BP in milk after i.m injection of PNT formulations in cows (Chapter 5). The model 
provided insights into the absorption rate of PNT from the i.m. injection site. 
Sensitivity analysis suggested that absorption rate constant (ka), clearance from 
plasma to milk (PA) and volume of distribution (V d) are critical parameters for model 
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predictions. The parameter P (permeability) needs to be investigated by permeation 
studies such as Caco-2 cell or PAMPA, and V d should be evaluated experimentally 
by conducting animal studies. 
The model also provided some understanding of the concentration of PNT, BP 
and total antibiotic in different milk fractions (alveolar, cistemal and total milk). This 
will be useful in the design of animal trials and which milk should be analysed in 
these trials. The model also showed applications in determining the effect of dose, 
milk pH and milk volumes on the concentration of BP in milk. For example, mastitis 
causes a change in the pH of milk, and the simulations show that this leads to 
decreased milk concentrations of BP. Thus the dose of PNT required for maintaining 
the therapeutic levels of BP for the duration of therapy may be higher than that 
predicted from studies in healthy cows. 
Although the model has been written for PNT, with minimal modification in the 
pharmacokinetic parameters such as pKa, chemical half-life as a function of pH, 
clearance, V d and PA, it could be utilised for predicting concentration of other drugs 
in milk. PNT is a rapidly hydrolysed prodrug, thus hydrolysis in plasma is inserted as 
a separate clearance route in the model. This hydrolysis route may not be required for 
other drugs that are chemically stable in plasma. Also the model neglected esterase 
(e.g. acylesterase) catalysed hydrolysis in plasma and milk. It has been reported that 
the level of esterases in mastitic milk is greater than in healthy milk (Forster et al., 
1961; Prasad and Newbould, 1968). This neglect of esterases catalysed hydrolysis in 
the model may have implications on the predictions of concentrations of PNT and BP 
in milk. 
Based on the stability studies (Chapter 3 and particularly Chapter 4) two oily 
PNT suspension formulations (Formulation A and B) were prepared in EO for animal 
testing (Chapter 6). EO was chosen because of its low viscosity and faster 
disappearance rate from the injection site (Howard and Hadgraft, 1983; Schultz et al., 
1998). During preliminary studies, Formulation A was found to form sediment at the 
bottom of the vials which was difficult to re-disperse. Addition of a low concentration 
of Polysorbate 80 (Formulation B) prevented caking and the suspensions were easy to 
re-disperse. PNT in Formulation B showed good physical and chemical stability. 
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In the pilot animal study, the developed physically and chemically stable RTU 
oily formulation of PNT (Formulation B) achieved concentration of BP above MIC90 
(S. uberis) for 24 hand below the MRL after 48 h, comparable to marketed aqueous 
suspension. Based on the animal study results, this oily formulation of PNT, is 
suitable for 24 h dosing. This pilot animal study was of low power, given that only 
three animals were used for Formulation B and Penethaject. However, the data are 
encouraging and support further and larger animal trials. In future, the results from a 
larger trial on Formulation B could be used in the simulation model (Chapter 5) for 
predicting the absorption rate from the injection site, concentration of antibiotic in 
different milk compartments and effect of dose and milk frequency. 
To further improve the convenience, new innovative formulations of PNT need 
to be developed, which will reduce the number of administrations from 3-4 daily 
injections to a once only treatment. To achieve this, a controlled release formulation 
of PNT needs to be developed using oily vehicles (for chemical stability) to control 
PNT absorption from the i.m. injection site to maintain the milk levels of BP above 
MIC for longer than 24 h. This will reduce the frequency of dosing and may increase 
the efficacy. 
As animal studies are time consuming and costly, development and validation of 
an in vitro drug release model from oil formulations will be useful. The data from in 
vitro studies could be incorporated in the STELLA model for predictions of 
absorption rates. This would allow screening of formulations prior to animal studies 
and thus would accelerate the development of novel formulations and minimise costs 
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The following were considered in the design of the model (Section 5.3.1): 
(1) The V d and CL for PNT were assumed to be similar to those for a range of 
weakly basic drugs (Table 5-1). These parameters including PA values, have 
little effect on the peak time or shape of the milk concentration profile but do 
affect the numerical values of the concentrations of BP in milk. 
(2) It was assumed that there is no degradation of PNT at the injection site. 
With these assumptions, the simulations were conducted using Euler's method 
with a dt value of 0.002 h. The various steps involved in a first order absorption 
model for 12:12 h milking were 
Alveolar_milk_ volume(t) = Alveolar_milk_ volume(t - dt) + (Milk_production -
Alveolar_to_cistemal_milk_flow- Milked_out_alveolar_milk_volume) * dt 
INIT Alveolar milk volume= 0.1 - -
INFLOWS: 
Milk_production = 1.71- 0.19* Alveolar_milk_ volume 
OUTFLOWS: 
Alveolar_to_cistemal_milk_flow = (0.05* Alveolar_milk_ volume -
0.03 *Cistemal_ milk_ volume) 
Milked out alveolar milk volume = - - - -
PULSE(fraction _of_ alveolar_ milk_ milked_ out* Alveolar_ milk_ volume, 12,12) 
BP _eliminated(t) = BP _eliminated(t - dt) + (Elimination_rate_BP) * dt 
INIT BP eliminated = 0 
INFLOWS: 
Elimination_rate_BP = Clearance_BP*Cp_BP 
BP _eliminated_from_cistemal_milk(t) = BP _eliminated_from_cistemal_milk(t - dt) + 
(Hydrolysis_rate_BP _in_cistemal_milk) * dt 
INIT BP eliminated from cistemal milk = 0 - - - -
INFLOWS: 
Hydrolysis_rate_BP _in_cistemal_milk = 
BP _in_ cistemal_ milk*k _hydrolysis_ of_BP _in_ milk 
BP _eliminated_from_alveolar_milk(t) = BP _eliminated_from_alveolar_milk(t - dt) 
+ (Hydrolysis _rate_ of_BP _in_ milk) * dt 
INIT BP eliminated from alveolar milk= 0 - - - -
INFLOWS: 
Hydrolysis_rate_of_BP _in_milk = 
BP _in_alveolar_milk*k_hydrolysis_of_BP _in_milk 
BP _in_alveolar_milk(t) = BP _in_alveolar_milk(t - dt) + 
(Hydrolysis_rate_of_PNT_in_milk + Plasma_to_milk_BP -
Hydrolysis_rate_of_BP _in_milk - Milking_BP _alveolar_milk -














Hydrolysis_rate_of_BP _in_milk = 
BP _in_ alveolar_ milk*k _hydrolysis_ of_BP _in_ milk 
Milking_ BP_ alveolar_ milk= 
PULSE(fraction_of_alveolar_milk_milked_out*BP _in_alveolar_milk,12,12) 
alv to cis BP = Cm BP alveolar milk* Alveolar to cistemal milk flow --- -- - -- - -
BP _in_cistemal_milk(t) = BP _in_cistemal_milk(t - dt) + (alveolar_to_cistemal_BP + 
Hydrolysis_rate_of_PNT_in_cis_milk - Milking_BP _cistemal_milk -
Hydrolysis_rate_BP _in_cistemal_milk) * dt 
INIT BP in cistemal milk = 0 
- - -
INFLOWS: 
alv to cis BP = Cm BP alveolar milk* Alveolar to cistemal milk flow --- -- - -- - -
Hydrolysis_rate_of_PNT_in_cis_milk = 
(k _hydrolysis_ of_ PNT _in_ milk*PNT _in_ cistemal _milk) 
OUTFLOWS: 
Milking_BP _cistemal_milk = PULSE(BP _in_cistemal_milk,12,12) 
Hydrolysis_rate_BP _in_cistemal_milk = 
BP _in_cistemal_milk*k_hydrolysis_of_BP _in_milk 
BP _in_plasma(t) = BP _in_plasma(t - dt) + (Hydrolysis_rate_in_plasma -
Elimination_rate_BP - Plasma_to_milk_BP) * dt 
INIT BP _in_plasma = 0 
INFLOWS: 
Hydrolysis_ rate _in _plasma = (PNT _in _plasma *k_ hydrol _ PNT _in _plasma) 
OUTFLOWS: 
Elimination_rate_BP = Clearance_BP*Cp_BP 
Plasma_to_milk_BP = PA_BP*(Cp_BP*fuBPplasma-
Cm_BP _alveolar_milk*fuBPmilk) 
Cistemal_milk_volume(t) = Cistemal_milk_volume(t- dt) + 
(Alveolar_to_cistemal_milk_flow- Milked_out_cistemal_milk_volume) * dt 
INIT Cistemal milk volume = 0.1 
- -
INFLOWS: 
Alveolar_to_cistemal_milk_flow = (0.05* Alveolar_milk_volume -
0.03 *Cistemal_ milk_ volume) 
OUTFLOWS: 
Milked_out_cistemal_milk_ volume= PULSE(Cistemal_milk_ volume,12,12) 
Final_volume_milked_out(t) = Final_ volume_milked_out(t - dt) + 
(Milked_ out_ cistemal_ milk_ volume+ Milked_ out_alveolar _milk_ volume) * dt 
INIT Final volume milked out = 0 - - -
INFLOWS: 
Milked_ out_ cistemal_ milk_ volume = PULSE(Cistemal _milk_ volume, 12, 12) 









Milked out BP from alveolar milk(t) = Milked out BP from alveolar milk(t - dt) - -- - - - -- - -
+ (Milking_BP _alveolar_milk) * dt 
INIT Milked out BP from alveolar milk = 0 - - - - -
INFLOWS: 
Milking_ BP_ alveolar_ milk = 
PULSE(fraction_of_alveolar_milk_milked_out*BP _in_alveolar_milk,12,12) 
Milked_out_pnt_from_alveolar_milk(t) = Milked_out_pnt_from_alveolar_milk(t - dt) 
+ (Milking_PNT_alveolar_milk) * dt 
INIT Milked_out_pnt_from_alveolar_milk = 0 
INFLOWS: 
Milking_PNT _alveolar_ milk = 
PULSE(fraction_of_alveolar_milk_milked_out*PNT_in_alveolar_milk,12,12) 
Milk_out_BP _from_cistemal_milk(t) = Milk_out_BP _from_cistemal_milk(t - dt) + 
(Milking_BP _cistemal_milk) * dt 
INIT Milk out BP from cistemal milk = 0 - - - -
INFLOWS: 
Milking_BP _cistemal_milk = PULSE(BP _in_cistemal_milk,12,12) 
PNT_at_injection_site(t) = PNT_at_injection_site(t - dt) + (Dosing - Absorption_rate) 
* dt 




Absorption_rate = PNT_at_injection_site*ka 
PNT_eliminated(t) = PNT_eliminated(t - dt) + (Elimination_rate_PNT) * dt 
INIT PNT eliminated = 0 
INFLOWS: 
Elimination _rate_ PNT = Clearance_ PNT*Cplasma _ PNT 
PNT_in_alveolar_milk(t) = PNT_in_alveolar_milk(t - dt) + (Plasma_to_milk_pnt -
Hydrolysis_rate_of_PNT_in_milk - Milking_PNT_alveolar_milk -
Alveolar_to_cistemal_PNT) * dt 
INIT PNT in alveolar milk= 0 - - -
INFLOWS: 





Milking_PNT _alveolar_ milk = 
PULSE(fraction_of_alveolar_milk_milked_out*PNT_in_alveolar_milk,12,12) 
Alveolar to cistemal PNT = - - -
Cm PNT alveolar milk* Alveolar to cistemal milk flow - - - -- - -
PNT_in_cistemal_milk(t) = PNT_in_cistemal_milk(t - dt) + 
(Alveolar_to_cistemal_PNT - Hydrolysis_rate_of_PNT_in_cis_milk -
Milking_ PNT _from_ cistemal_ milk) * dt 
INIT PNT in cistemal milk = 0 - - -
INFLOWS: 
Alveolar to cistemal PNT = - - -






Milking_PNT _from_ cistemal_ milk = PULSE(PNT _in_ cistemal _ milk, 12, 12) 
PNT_in_plasma(t) = PNT_in_plasma(t - dt) + (Absorption_rate -
Hydrolysis_rate_in_plasma - Plasma_to_milk_pnt - Elimination_rate_PNT) * dt 
INIT PNT_in_plasma = 0 
INFLOWS: 
Absorption_rate = PNT_at_injection_site*ka 
OUTFLOWS: 
Hydrolysis _rate _in _plasma = (PNT _in _plasma *k _ hydrol_PNT _ in _plasma) 
Plasma_ to _milk _pnt = PA_ BP*( (Cplasma _PNT*fuPNTplasma)-
(Cm _PNT _alveolar_ milk*fuPNTmilk)) 
Elimination_rate_PNT = Clearance_PNT*Cplasma_PNT 
PNT_milked_out_from_cis_milk(t) = PNT_milked_out_from_cis_milk(t - dt) + 
(Milking_ PNT _from_ cistemal _milk) * dt 
INIT PNT milked out from cis milk = 0 - - - - -
INFLOWS: 
Milking_ PNT _from_ cistemal _ milk = PULSE(PNT _in_ cistemal_ milk, 12, 12) 
Clearance BP= 354 
Clearance PNT = 1380 
Cm_ BP_ alveolar_ milk= (BP _in_ alveolar_ milk/ Alveolar_ milk_ volume) 
Cm PNT alveolar milk = PNT in alveolar milk/ Alveolar milk volume - - - -- - - -
Cone BP alveolar milk = - - -
(fraction_of_alveolar_milk_milked_out*BP _in_alveolar_milk)/(fraction_of_alveolar_ 
milk_ milked_ out* Alveolar_ milk_ volume )*(0.6)/Converter _L _to_ ml 
Conc_BP _cistemal_milk = ((BP _in_cistemal_milk)/(Cistemal_milk_volume)*(0.6) 
/(Converter_ L _to_ ml)) 
Cone BP in total milk = - - - -
(((fraction_of_alveolar_milk_milked_out*BP _in_alveolar_milk)+(BP _in_cistemal_m 
ilk))/((fraction _ of _alveolar_ milk_ milked_ out* Alveolar_ milk_ volume )+(Cistemal_mi 
lk_ volume))*0.6)/Converter_L_to_ml 
Conc_PNTBP _alveolar_milk = (Conc_BP _alveolar_milk+Conc_PNT_alveolar_milk) 
Cone PNTBP cistemal milk = - - -
(Cone_ BP_ cistemal_ milk+Conc _PNT _ cistemal_ milk) 
Conc_PNTBP _total_milk = (Conc_BP _in_total_milk+Conc_PNT_total_milk) 
Cone PNT alveolar milk = - - -
(fraction_of_alveolar_milk_milked_out*PNT_in_alveolar_milk)/(fraction_of_alveola 
r_ milk_ milked_ out* Alveolar_ milk_ volume )/Converter_ L _to_ ml 
Cone PNT cistemal milk = - - -
(PNT _in_ cistemal _ milk/Ci sternal_ milk_ volume )/Converter_ L _to_ ml 
Cone PNT total milk = - - -
((fraction_ of_ alveolar_ milk_ milked_ out*PNT _in_ alveolar_ milk)+(PNT _in_ cistemal 
_milk))/( (fraction_ of_ alveolar_ milk_ milked_ out* Alveolar_ milk_ volume )+(Cistemal 
_milk_ volume) )/Converter_ L _ to _ml 
Converter L to ml = 1000 
- - -
Cplasma_PNT = (PNT_in_plasma/Vd_PNT) 
Cp_BP = (BP _in_plasma/Vd_BP) 
fraction of alveolar milk milked out = 0.9 - - -
178 
fuBPmilk = 1-(1/(1 + 101\2.8-pHBPmilk))) 
fuBPplasma = 1-(1/(1 + 10"'(2.8-pHBPplasma))) 
fuPNTmilk = 1-(1/(1 + lQl'(pHmilk-8.4))) 
fuPNTplasma = 1-(1/(1 + lOA(pHplasma-8.4))) 
Half life of BP in milk= 322 - - - - -
Half life of PNT in milk= 0.52 - - - - -
Half_life_of_PNT_in_plasma = 0.216 
ka = 0.65 
k_hydrolysis_of_BP _in_milk = 0.693/Half_life_of_BP _in_milk 
k_hydrolysis_of_PNT_in_milk = 0.693/Half_life_of_PNT_in_tnilk 
k_hydrol_PNT_in_plasma = 0.693/Half_life_of_PNT_in_plasma 
PA BP= 169 
pHBPmilk = 6.8 
pHBPplasma = 7.4 
pHmilk= 6.8 
pHplasma = 7.4 
Vd BP= 162 
Vd PNT = 1980 
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